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ABSTRACT
Nascent Peptides That Induce Translational Arrest

Christopher J. Woolstenhulme
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Although the ribosome is a very general catalyst, it cannot synthesize all protein
sequences equally well. Certain proteins are capable of stalling the ribosome during their own
synthesis. Stalling events are used by both prokaryotic and eukaryotic cells to regulate gene
expression. Characterization of natural stalling peptides shows that only a few strategically
placed amino acids are needed to inactivate the ribosome. These motifs share little sequence
similarity suggesting that there are more stalling motifs yet to be discovered.
Here we use two genetic selections in E. coli to discover novel stalling peptides and detail
their subsequent characterization. Kinetic studies show that some of these nascent peptides
dramatically inhibit rates of peptide release by release factors. We find that residues upstream of
the minimal stalling motif can either enhance or suppress this effect. In other stalling motifs,
such as polyproline sequences, peptidyl transfer to a subset of aminoacyl-tRNAs is inhibited.
Translation factor EF-P alleviates pausing of the polyproline motifs, but has little or no effect on
other stalling sequences. The EF-P ortholog eIF5A also alleviates pausing of polyproline
sequences in yeast.
Our studies show that short peptides sequences are capable of stalling the ribosome
during elongation and termination through different mechanisms. These sequences are
underrepresented in bacterial proteomes and show evidence of stalling on endogenous E. coli
proteins.
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Chapter 1. Introduction

Overview of Translation
The Ribosome
The ribosome is a large macromolecular complex that is responsible for protein synthesis
in eukaryotic, archaeal and bacterial cells. It consists of two subunits whose names are derived
from analytical sedimentation studies performed in the 1950s and 60s. In bacteria, the smaller
subunit (or 30S subunit) (Figure 1-1B) is composed of a single ribosomal RNA (rRNA) strand
called the 16S rRNA and ~20 proteins of varying size (Figure 1-1C). This subunit is primarily
responsible for selecting the correct amino acids to add to the growing peptide chain. The large
subunit (or 50S subunit) is composed of two rRNA strands, the 23S and 5S rRNA, as well as ~30
proteins and is responsible for peptide bond formation. The 30S and 50S subunits come together
to form the 70S ribosome during active protein synthesis (Figure 1-1A). The rRNA/protein ratio
varies between different organisms, but is approximately two-thirds rRNA to one-third protein
by mass. The catalytic and functional core of the complex is composed of rRNA, making the
ribosome a ribozyme 1. The finding that RNA possesses catalytic activity lends support to the
RNA world hypothesis, which postulates that self-replicating, catalytic RNA were the precursors
to current living things based on DNA, RNA and proteins 2. The catalytic function of the
ribosomes is to facilitate peptide bond formation in a process called translation.

Translation
Translation is the intricate process of synthesizing proteins as encoded by the genetic
information; it occurs in four stages: initiation, elongation, termination and recycling, as outlined

1

in Figure 1-2 (for excellent
reviews, see 3–5). In its
simplest terms, initiation
involves the two subunits
of the ribosome assembling
on a messenger-RNA
(mRNA) encoding the
amino acid sequence that
makes up the protein. In
elongation, the ribosome
decodes the mRNA by
pairing the correct transferRNA (tRNA) with its
corresponding three
Figure 1-1. The Structure of the Ribosome. (A) ‘Top’ view of the 70S
ribosome with mRNA and A, P and E site tRNAs. B, C, Exploded view of
the 30S subunit (B) and 50S subunit (C). The structure of the L7/L12 arm10
was fit onto the 70S ribosome, with mRNA elongated by modeling. This and
all other figures were made with Pymol (Delano Scientific) and Photoshop
(Adobe). Reprinted by permission from Macmillan Publishers Ltd: (from
Ref. 3).

nucleotide codon in the
mRNA. Each tRNA has
already had its
corresponding amino acid

covalently attached to its 3’-end by enzymes called tRNA-synthetases, a process known as
aminoacylation. The amino acids are then linked together as new tRNAs enter the ribosome and
are moved through three ribosomal sites: the A site (aminoacyl-tRNA site), P site (peptidyltRNA site), and E site (exit site). Translation is completed at the termination step as the newly
synthesized protein and tRNAs are released from the ribosome. Recycling then occurs where the

2

Figure 1-2. Overview of bacterial translation. For simplicity, not all intermediate steps are shown. aa-tRNA,
aminoacyl-tRNA; EF elongation factor; IF, initiation factor; RF, release factor. Reprinted by permission
from Macmillan Publishers Ltd: (from ref. (3))

ribosomal subunits are separated and readied for the next round of translation. We will discuss
these steps in greater detail.

Initiation
Initiation starts on the 30S subunit with the co-operation of initiation factors 1, 2 and 3
(IF1, IF2 and IF3) (for reviews see 6,7). At the end of a translation cycle, IF3 binds to the 30S E
site and keeps the subunits separate after peptide release and subunit recycling (see Figure 1-3).
IF1 and IF2 associate with the 30S subunit and facilitate the binding of the specially modified
initiator methionine-tRNA (N-formyl-Met-tRNA) to the ribosome. IF1 binds at the A site and
also contributes to the binding and positioning of fMet-tRNA in the P site 8. IF2 recruits fMettRNA through recognition of the formylated α-amino group on the tRNA and subsequently
3

Figure 1-3. Schematic view of the initiation process. Formation of 30S (30SIC) and 70S (70SIC) translation
initiation complexes, containing ribosomes (30S subunit in orange, 50S in brown), initiator fMettRNAfMet,mRNA and initiation factors IF1 (in blue), IF2 (in green) and IF3 (in light blue). View of 30S
ribosomal subunit and ribosome from the top. The platform of the 30S is in red with the anti-Shine-Dalgarno
(aSD) sequence in cyan. Structured mRNA binds to 30S in two distinct steps: the docking of the mRNA on
the platform of the 30S subunit forms the pre-initiation complex that is followed by the accommodation of
the mRNA into the normal path to promote the codon anticodon interaction in the P site (9). The resulting
30SIC engages the 50S subunit to form the 70SIC from which the initiation factors are expelled and the
synthesis of the encoded protein can proceed through the elongation, termination and ribosome recycling
phases (adapted from ref. 9). Reprinted from ref. 7 with kind permission from Springer Science and
Business Media.

directs it to the P site 7. These interactions increase the on-rate of P site binding of fMet-tRNA
and decrease its dissociation rate. As the mRNA moves into its channel on the ribosome, the
fMet-tRNA is brought to pair with the start codon. If pairing is correct, IF3 stabilizes the 30S
initiation complex allowing the 50S subunit to associate (Figure 1-3). If the interaction is
incorrect, IF3 destabilizes the complex causing the 30S subunit and initiation factors to
dissociate before the 50S subunit can associate. In this way, IF3 acts as a kinetic fidelity control
4

mechanism 6. Association of the 50S subunit ejects IF1 and IF3 from the complex allowing 70S
formation. This triggers IF2 (a GTPase that binds the ribosome in its GTP bound form) to
hydrolyze GTP into GDP changing its conformation. IF2 is then released from the fMet-tRNA
and dissociates from the ribosome. The resulting complex (30S+50S+mRNA+tRNA) is termed
the 70S initiation complex.
As mentioned earlier, binding of the mRNA to the 30S subunit is critically important for
initiation and occurs in two stages. The first stage, binding of the mRNA, is a rapid step resulting
in inactive 30S initiation complexes where the mRNA and fMet-tRNA do not interact (see
Figure 1-3: 30S pre-Initiation Complex). A purine rich region in the 5’ untranslated region
(UTR) of the mRNA, termed the Shine-Dalgarno (SD) sequence, pairs with a complementary
pyrimidine rich region at the 3’-end of the 16S rRNA called the anti-Shine-Dalgarno region
(anti-SD) 9,10. If the SD-anti-SD interaction is weak, the complex lingers in the inactive form and
dissociates. A strong SD-anti-SD interaction prolongs the mRNA/ribosome association, allowing
the mRNA to proceed to the second stage: adaptation. In this step, the mRNA moves into its
proper channel on the 30S subunit (between the head and platform) to position the start codon
(typically AUG) in the P site (see Figure 1-3: 30S Initiation Complex). This step is slow and
requires the aid of IF1 and IF2 to align the start codon with the fMet-tRNA anti-codon. Correct
pairing leads to an active 30S initiation complex that is stabilized by IF3 and binds with the 50S
subunit as previously described. Once formed, the 70S initiation complex is ready for the second
stage of translation: elongation.
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Elongation
Elongation is the process by which the next codon on the mRNA is recognized by its
corresponding aminoacyl-tRNA and the encoded amino acid is added to the peptide chain
(Figure 1-2: Elongation) (for review see 4). This process begins when aminoacyl-tRNA is
brought from a pool of cellular tRNAs to the ribosome by the GTPase elongation factor Tu (EFTu). The tRNA-EF-Tu complex is directed to the A site of the ribosome through interactions
with multimeric ribosomal protein L7/L12 (Figure 1-4A) 11. The ribosome then determines if the
tRNA is the correct, or cognate, match for the mRNA codon in a process called decoding.
The ribosome is able to discriminate between cognate and non-cognate tRNAs with a
high degree of accuracy, making only one mistake per 1,000-10,000 amino acids incorporated.
To achieve this high level of fidelity, the ribosome uses more than just correct base pairing of the
mRNA codon/tRNA anticodon (Figure 1-4B,C). When the first two nucleotides of the
mRNA/tRNA duplex correctly pair, a conformational change in the 16S rRNA is induced 12.
Universally conserved nucleotides A1492, A1493 and G530 recognize correct base-pairing by
binding in the minor groove of the mRNA/tRNA helix, greatly stabilizing the mRNA/tRNA
interaction (Figure 1-4C) 12. The free energy generated from the combination of correct basepairing and minor groove interactions is more than adequate to explain the high fidelity of the
ribosome 13,14. Residual energy from this interaction is then used to facilitate conformational
changes in the ribosome including a large-scale domain closure of the 30S subunit (Figure 1-4CE) 14–16.
The tRNA body itself is also important for proper decoding. When the tRNA-EF-Tu
complex enters the ribosome, correct pairing causes a distortion in the tRNA body that allows the
tRNA-EF-Tu complex to interact with both the mRNA and the 50S-binding site. This position is

6

Figure 1-4. Schematic representation of the decoding pathway. (A) The L7/L12 stalk recruits the ternary
complex to the ribosome. Deacylated transfer RNA (tRNA) may be bound in the exit (E) site (yellow) and
peptidyl tRNA is in the peptidyl (P) site (green). The black rectangle represents the enlarged area in panels B-H.
(B) The tRNA (purple) samples codon:anticodon pairing until a match (C) is sensed, by decoding center
nucleotides G530 and A1492-A1493. Codon recognition triggers domain closure of the 30S subunit, bringing
the shoulder domain into contact with elongation factor Tu (EF-Tu) (red), and shifting regions in domain 2 of the
GTPase. (D) This results in a distortion of the acceptor arm of the aminoacyl tRNA. These conformational
changes are all critical for properly positioning EF-Tu on the ribosome to allow GTPase activation. (E) GTPase
activation does not require a large opening of the hydrophobic gate. Instead, residue A2662 of the sarcin-ricin
loop (SRL) of the 23S ribosomal RNA (rRNA) positions His84 into the GTPase center, resulting in rapid GTP
hydrolysis. (F) Release of Pi results in the disordering of the switch I loop and (G) a domain rearrangement of
EF-Tu. (H,I) This leads to dissociation of EF-Tu from the ribosome, accommodation of aminoacyl tRNA, and
peptidyl transfer. Abbreviations: A, aminoacyl; PTC, peptidyl transferase center. Republished with permission
of Annual Review, Inc, from ref. (4); permission conveyed through Copyright Clearance Center, Inc.
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known as the “A/T” state because the tRNA is bound in the 30S A site and to EF-Tu (Figure 14B) 17–19. EF-Tu also undergoes a conformational rearrangement as it contacts the ribosome,
reconfiguring its GTPase active site for hydrolysis (Figure 1-4C-D) 18. This distortion and
conformational change are energetically offset by the excess energy from decoding earlier
described 13,14. The ability the tRNA/EF-Tu to contact both the mRNA and 50S subunit is critical
for GTPase activation of EF-Tu.
Activation of the GTPase activity of EF-Tu, and subsequent GTP hydrolysis, results in a
large domain rearrangement in EF-Tu causing its release from tRNA and the ribosome. Prior to
activation, EF-Tu prevents hydrolysis by protecting GTP from catalytic residue His84 20 with a
hydrophobic gate composed of residues Val20 and Ile60 (Figures 1-4D and 1-5) 18,21. When
GTPase activation occurs, the previously mentioned conformational rearrangements draw the
GTPase center into contact A2662 of the sarcin-ricin Loop (SRL) of the 23S rRNA (Figure 14E-F) 21. This pushes His84 past the hydrophobic gate where it can coordinate with a water
molecule for an in-line attack on the γ-phosphate of GTP (Figure 1-5) 18,21. This results in a
massive 100° rotation of the nucleotide binding domain in EF-Tu (Figure 1-4G) 22 that causes its
release from the tRNA and the ribosome 18,23. While non-cognate tRNAs are able to illicit the
hydrolysis response, the reaction is much slower, more often resulting in tRNA-EF-Tu
dissociation from the ribosome than GTP hydrolysis 16. This induced-fit mechanism of A site
tRNA discrimination during initial selection acts as part of a kinetic control for translation,
favoring cognate tRNAs over non-cognate tRNAs 16. The other kinetic control of fidelity
involves the next step: accommodation.
When EF-Tu leaves, the tRNA is held to the ribosome primarily by interactions at the
decoding site, which are stronger for cognate vs. non-cognate tRNA. The structural stress from
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the distortions in the tRNA
body causes a rotation of the
tRNA-CCA end similar to the
unwinding of a coiled spring
(Figure 1-4H) 24. This places
the tRNA-CCA end and amino
acid in the peptidyl-transferase
center (PTC) of the 50S
subunit where it can be added
to the peptide chain 24.
Movement of the tRNA-CCA

Figure 1-5. EF-Tu Hydrophobic Gate. Prior to binding of the ternary
complex to the ribosome, the catalytic histidine is in an inactive
conformation, rotated away from GTP (23). Binding to the ribosome
and GTPase activation allows the phosphate of residue A2662 of the
sarcin-ricin loop (SRL) (cyan) to position His84 into the active site.
Finally, after GTP hydrolysis (18) and Pi release, the switch I loop is
disordered (dashed line) and His84 has returned to an inactive
conformation, contacting residue G2661 of the SRL. Republished with
permission of Annual Review, Inc, from ref. (4); permission conveyed
through Copyright Clearance Center, Inc.

end into the PTC is termed accommodation and, together with initial selection, are rate-limiting
steps in translation 16. This step is greatly accelerated with cognate tRNAs; non-cognate tRNAs
are much slower and fall off more often 14,25. Typically, non-cognate tRNAs will dissociate
during initial selection; however, they may also fall off after GTP hydrolysis in order to dissipate
torsional stress in the tRNA 25. In this manner, the ribosome is able to achieve proofreading up to
the point of peptide-bond formation.
After accommodation, the A and P site tRNA substrates are positioned at the PTC to
facilitate peptide-bond formation (Figure 1-4I). The CCA ends of the A site and P site tRNAs
pair with conserved nucleotides in the A-loop and P-loop of the ribosome, respectively 26. This
positions the carbonyl carbon of the P-site tRNA for nucleophilic attack by the α-amino group of
the A-site tRNA, forming the peptide bond 27. Peptide bond formation breaks the 3’ ester linkage

9

of the peptide to the P site tRNA, transferring the peptide to the A site tRNA (Figure 1-6). This
reaction occurs 107 times faster in the ribosome than in uncatalyzed reactions 3.
Structural studies show that the PTC is comprised entirely of RNA, suggesting that the
ribosome functions as a ribozyme (RNA enzyme) 1,28,29. The ribosome is thought to act primarily
as an entropy trap to facilitate peptide bond formation. This means that the ribosome positions
the substrates (CCA ends with A-loop and P-loop) and excludes water from the active site, rather
than participating in conventional catalytic strategies such as acid/base catalysis 30. Recent
studies suggest that it may also play a small role in transition state stabilization 31,32.
Many mechanisms for ribosome catalyzed peptide bond formation have been proposed.
Among these mechanisms,
the consensus is that the
peptide bond formation and
3’ ester break are step-wise
and not concerted 32,33, that

Figure 1-6. The peptidyl transferase reaction. In the tetrahedral intermediate
the α-amine is drawn in the deprotonated form based on resent biochemical
results (31). Reprinted with permission from ref. (31). Copyright 2011
American Chemical Society.

at least two protons are in
flight during catalysis 33, and that the 2’-OH of A76 of the A site tRNA acts in some capacity as
a proton shuttle 34,35. The basic mechanism is as follows: once in the PTC, the α-amine of the A
site amino acid is positioned as a nucleophile to attack the C-terminal carbonyl of the peptide
attached to the P site tRNA. This leads to the formation of a peptide bond and the addition of a
new amino acid to the nascent peptide. The 3’ ester linkage then breaks, transferring of the
growing peptide to the A site tRNA and leaving a deacylated P site tRNA (Figure 1-6).
After the peptide is transferred to the A site tRNA, both the A site tRNA and the mRNA
must move to P site to allow space for the next codon and cognate aminoacyl-tRNA to enter
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(Figure 1-7A). This process is termed translocation. Once the P site tRNA is deacylated, its CCA
end naturally moves into the E site on the 50S portion of the ribosome. This tRNA is now in a
“hybrid” state called “P/E” state, where its 3’ end now occupies the E site while the anticodon
portion still occupies the P site (Figure 1-7B) 17,36. The 3’ end of the peptidyl tRNA then moves
into the P site and occupies a hybrid position known as the “A/P” state because its anticodon
portion still occupies the A site (Figure 1-7B). These movements are facilitated by a factor
induced rotation of the 30S subunit relative to the 50S subunit 37.
The binding of GTPase elongation factor G (EF-G), in its GTP bound form, facilitates
rotation of the 30S and 50S subunits relative to each other 38–41 as well as internal “swiveling”
motions in the 30S subunit 42. Binding near the A site, EF-G hydrolyzes GTP to GDP in a
manner similar to EF-Tu 21 causing a structural rearrangement in EF-G (Figure 1-7C-D) 43. This
change in structure places a portion of EF-G directly into the A site, stabilizing the hybrid state,

Figure 1-7. Schematic of translocation. Translocation can be divided into two steps: the first in which the transfer
RNAs (tRNAs) move from their canonical conformations (panel a) relative to the 50S subunit (panel b), and the
second, catalyzed by the GTPase elongation factor G (EF-G) (brown), in which the messenger RNA (mRNA)
and tRNAs move relative to the 30S subunit (panels c and d). Although a high-resolution crystal structure of EFG bound to the ribosome in the post-GTP hydrolysis state (panel d) was recently determined (see ref (4)), the
detailed structures of A/P tRNA and EF-G bound in its GTP state to the ribosome are not known (panels b and
c). Abbreviations: A, aminoacyl; E, exit; P, peptidyl. Republished with permission of Annual Review, Inc, from
ref. (4); permission conveyed through Copyright Clearance Center, Inc.
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providing forward movement of the mobile
tRNA/mRNA duplex and also preventing back
translocation of the tRNA 44. Two nucleotides of the
16S rRNA are also used as “pawls” in a “ratchet” to
fix the position of the mRNA, preventing its
backward movement 44. The codon/anti-codon
interactions between the tRNAs and the mRNA cause
the mRNA to be pulled one codon into the ribosome
(Figure 1-7D). After GTP hydrolysis, the E site
tRNA leaves the ribosome and the small subunit
ratchets back into place (Figure 1-7E). EF-G-GDP
also leaves the A site and the ribosome is ready for
another round of elongation (Figure 1-7E) 45.
While elongation is occurring, the growing
peptide moves past the PTC and enters a tunnel in the
50S subunit known as the exit tunnel 28 (Figure 1-8).
This channel is approximately 100 Å long, 10-20 Å
wide and can hold approximately 40 amino acids of
the nascent peptide before the protein enters the
cytoplasm. It is comprised primarily of the 23S
rRNA, making it mostly hydrophilic 46. Though the
tunnel was originally believed to be non-interactive
28

, electron microscopy experiments have
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Figure 1-8. Sectional views of the bacterial
and eukaryotic ribosomes. Images from
Protein Data Bank (PDB) 2AW4/2AVY
(Escherichia coli ) were processed by the
MacPyMOL program to show surface
representations of ribosomal vertical sections,
with proteins contributing or close to the exit
tunnel represented as spheres. Nascent
polypeptide chains are shown schematically
by broken orange lines. Republished with
permission of Annual Review, Inc, from ref.
(50); permission conveyed through Copyright
Clearance Center, Inc.

demonstrated the nascent peptide chain can adopt both α-helical and extended chain
conformations in contact with the tunnel walls 47,48. While the tunnel allows for some secondary
structural formation, it is unlikely that the nascent peptide can adopt any higher order of folding
due to the limited space in the exit tunnel 49. One of the most notable features of the exit tunnel is
a kink in the tunnel approximately 30 Å from the PTC. Structures of the ribosome indicate that
this kink is formed by protrusions of ribosomal proteins L22 and L4 (Figure 1-8). This
constriction plays a key role in the methods many stalling peptides use to arrest translation 50.

Termination
Translation is terminated when a stop codon enters the A site of the ribosome and is
recognized by a class I release factor 51,52 (see reviews 53,54). Class I release factors include
release factor 1 (RF1), which recognizes stop codons UAG and UAA, and release factor 2 (RF2),
which recognizes UGA and UAA. These release factors are tRNA mimics 55) and enter the A site
of ribosome in a closed form (Figure 1-9A-B) 56. RF1 and RF2 are able to recognize stop codons
using a “tripeptide anticodon” that forms extensive interactions with the mRNA stop codons and
nearby rRNA bases 57. Once the stop codon is recognized, the RF moves into an open
conformation 56 moving its highly conserved GGQ motif into the peptidyl-transferase center
(Figures 1-9B and 9D) 58. This GGQ motif mimics the 3’-end of a tRNA and participates in the
activation of a water molecule for nucleophilic attack on the peptidyl carbonyl 59–61. Subsequent
cleavage of the 3’ ester releases the peptide from the tRNA (Figure 1-9E). The ribosome-RF1/2
complex then acts as a guanine exchange factor for the class II release factor RF3 62, catalyzing
the replacement of bound GDP with GTP. Binding of RF3-GTP to the ribosome accelerates the
release of RF1/2 by stabilizing the ratcheted state of the 30S subunit 63. Once RF1/2 leaves, RF3
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hydrolyzes GTP to GDP and dissociates from the ribosome. This leaves the 70S in complex with
mRNA and deacylated tRNA in P site.

Figure 1-9. Proposed mechanism for coordination of peptidyl-tRNA hydrolysis with stopcodon recognition via a
conformational switch in class I release factors. (A,B) Initially, the release factor binds to the ribosome in a
catalytically inactive conformation. (C) If a sense codon is located in the A site, the release factor quickly
dissociates (see ref. (53)). (D) If the release factor recognizes a stop codon in the A site, its switch loop along
with domain 3 and the decoding center rearrange. Interaction between the switch loop and the switch-loop
binding pocket in the decoding center results in tight binding of the release factor to the ribosome. (E) In this
catalytically competent conformation, the GGQ motif is inserted in the peptidyl-transferase center and is capable
of contributing to catalysis of peptidyl-tRNA ester bond hydrolysis. This figure is used with permission from ref.
(53).

Recycling
Ribosome recycling is the final step in translation, where the subunits are separated and
the translation cycle reset (for review see 64). To begin, ribosome-recycling factor (RRF) enters
the empty A site of the ribosome (Figure 1-2). This factor recruits EF-G bound with GTP (the
same factor from the elongation stage) which acts the same as it would if tRNA were bound in
the A site. EF-G hydrolyzes GTP, changes conformation and pushes RRF into the P site. This
facilitates the separation of the subunits. IF3 then binds to the 30S E site prompting the
dissociation of the tRNA and mRNA and remains bound to prevent re-association of the subunits
65,66

. In this manner, a peptide is made, released and the ribosome components made ready for

the next round of translation.
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Translational Arrest
Protein synthesis can pause or halt prematurely for several reasons. The ribosome can be
paused by starvation or stress, low concentrations of substrates such as charged tRNAs and GTP,
or the presence of antibiotics. In general, however, these pauses are reversible when the
metabolic state of the cell improves. A more serious threat to translation is when the ribosome
comes to the 3’-end of an mRNA without encountering a stop codon. Truncated mRNAs lacking
stop codons arise from incomplete transcription reactions or mRNA decay pathways. Non-stop
mRNAs are problematic because, in the absence of a stop codon, release factors are not recruited
and the stalled ribosome remains locked an inactive state at the 3’-end of the non-stop mRNA.
Cells have evolved rescue mechanisms to cope with non-stop mRNAs and other long-lived
stalling events.

Rescue Machinery: tmRNA, ArfA and ArfB
There are three mechanisms used by bacteria to recognize and recycle ribosomes stalled
on non-stop mRNAs 67. The best characterized of these is tmRNA which is encoded by the ssrA
gene (for reviews see 68,69). tmRNA is an RNA molecule that contains both a tRNA-like domain
(TLD) charged with alanine and an mRNA-like open reading frame. tmRNA enters the stalled
ribosome and replaces the problematic mRNA with its own ORF. This allows the ribosome to
resume translation and terminate normally using tmRNA as a template. The tmRNA ORF
encodes a short peptide tag that is recognized by proteases, leading to degradation of the
defective protein once translation is complete (Figure 1-10). Because it results in the synthesis of
a chimeric protein from two RNA templates, this process is called trans-translation.
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Figure 1-10. Diagram of tmRNA-mediated ribosome rescue. Acting as a tRNA, Alanyl-tmRNA (green)
recognizes ribosomes stalled on nonstop mRNAs and adds alanine to the nascent polypeptide. Following mRNA
swapping, tmRNA acts as a template (blue), encoding a 10 amino acid tag. RF1/RF2-mediated termination
releases the tagged protein for degradation by cellular proteases. This also liberates the 30S and 50S subunits for
new rounds of protein synthesis.

tmRNA identifies stalled ribosomes and performs trans-translation with the help of its
protein partner SmpB 70. SmpB is a small protein (160 residues) comprised of a core domain and
a C-terminal tail. The core of SmpB contains an oligonucleotide binding (OB) fold that creates
two RNA binding sites, one for binding tmRNA 71 and the other for binding ribosomal RNA in
the A and P sites. The 30 residue long C-terminal tail is unstructured in solution but adopts an αhelical structure upon ribosome binding 72,73.
To avoid prematurely aborting translation, the tmRNA/SmpB complex must discriminate
between stalled and actively translating ribosomes. Actively translating ribosomes have mRNA
in the A site and the downstream mRNA channel. When a ribosome stalls, cellular
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endonucleases cleave the mRNA, leaving the mRNA channel and A site empty 74. The empty A
site is recognized by SmpB, which binds in the decoding center in the A site and places its Cterminal tail into the empty mRNA channel 72. The tail follows the path of the mRNA, making
extensive contacts with the 16S rRNA and the S3, S4, and S5 proteins 72. These interactions with
the tail are essential for accommodation and peptidyl transfer to tmRNA/SmpB, as discussed
below. In this manner, the competition between tmRNA/SmpB and mRNA for the A site allows
discrimination between stalled and active ribosomes.
The tmRNA/SmpB complex is delivered to the A site by EF-Tu, as canonical tRNAs are,
and triggers GTP hydrolysis by EF-Tu through structural mimicry of a cognate tRNA 75. When
bound to tmRNA, the SmpB body mimics the anticodon stem of a tRNA 75 and facilitates
decoding through numerous contacts with the ribosomal decoding center. Conserved residue
His136 (E. coli numbering) of the SmpB tail makes one of the most critical interactions by base
stacking with G530 72, also a key nucleotide in canonical decoding. Loss or mutation of this
residue greatly diminishes activation of EF-Tu and GTP hydrolysis rates 76. Neighboring
conserved residues Lys138 and Arg139 also bind to the sugar phosphate of rRNA near G530,
stabilizing these stacking interactions 72. As with canonical decoding, recognition of the
tmRNA/SmpB complex causes domain closure in the 30S subunit head, leading to GTPase
activation and GTP hydrolysis. While the mechanism of EF-Tu activation resembles the
canonical mechanism in some aspects, it was also observed that conditions that block EF-Tu
activation may have little or no effect on the downstream peptidyl transfer step, suggesting that
tmRNA dissociates from EF-Tu rapidly, even without GTP hydrolysis 76.
After decoding and GTP hydrolysis, the aminoacylated tRNA-like domain of the tmRNA
moves into the PTC and facilitates peptidyl transfer. The peptide chain is transferred to tmRNA
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and canonical translation resumes. During translation, tmRNA and SmpB remain bound together
as they move through the ribosome, translocating from the A site to the P site and then out
through the E site 77. At the end of translation, the nascent peptide is released by binding of either
release factor to the UAA stop codon in tmRNA, after which tmRNA is presumably recycled
along with the ribosome subunits 69. Prior to translocation, tmRNA exchanges its ORF for the
non-stop mRNA 78. The tmRNA ORF encodes a 10 amino acid tag (ANDENYALAA) that is
added to the C-terminus of the peptide 79. This sequence is recognized by the adaptor protein
SspB, which enhances recruitment of cellular proteases like ClpXP that subsequently degrade the
tagged proteins 80,81. The sequence of the tmRNA ORF destines the protein for degradation but is
not essential for ribosome rescue and recycling and can be changed without impairing tmRNA
function.
Two other bacterial proteins, ArfA and ArfB, are engaged in translational rescue
mechanisms similar to that catalyzed by tmRNA/SmpB 82,83. All three systems recognize and
release ribosomes stalled on non-stop mRNAs 67. ArfA is a short peptide (72 residues in E. coli)
that recognizes stalled ribosomes by binding the large subunit and entering the A site through an
unknown mechanism 82–84. Once in the ribosome, ArfA recruits RF2 to hydrolyze the peptidyltRNA and resolve arrest 84. ArfB is a reduced paralog of translational RFs that has retained the
GGQ domain 83. It does not have an anticodon region, but it does have an unstructured tail that
may function in a similar manner as the SmpB C-terminal tail 83. Once in the A site, ArfB
hydrolyzes the peptidyl-tRNA using its GGQ domain 85,86. Together these three systems form a
highly redundant rescue network necessary for cell survival.
Ribosomes stalled on non-stop mRNAs necessitate rescue because translation is
irreversibly halted; however, not all stalling events are irreversible. In some instances the
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ribosome is only temporarily stalled and resumes translation before mRNA degradation occurs.
Known as ribosome pausing, this phenomenon often results from interference by nascent
peptides that are programmed to stall their own translation. This manner of stalling is transient,
reversible and serves a functional role within the cell.

The Scope and Significance of Ribosome Stalling
Certain proteins interfere with their own translation, arresting the ribosome due to a
specific combination of amino acids in the nascent chain. Why would a protein evolve to inhibit
its own synthesis? Many known biological examples demonstrate that ribosome stalling is
effective at rapidly altering expression of genes (for review see 87). For example, in Bacillus
subtilis, stalling of the protein MifM is used to up-regulate translation of YidC2, a functional
copy of the essential gene SpoIIIJ/YidC1, which is involved in membrane protein insertion 88,89.
yidC2 encodes a homolog of SpoIIIJ and is located downstream of small ORF named mifM.
When levels of SpoIIIJ are normal, translation of yidC2 is repressed through sequestration of its
SD region in mRNA secondary structure. When SpoIIIJ is defective or its cellular levels drop,
MifM stalls the ribosome using the consensus sequence R69IxxWIxxxxxMNxxxxDEED89 88.
Prolonged ribosome occupancy on mifM disrupts downstream mRNA secondary structure
unlocking the SD sequence of yidC2 88. This facilitates yidC2 translation, allowing the bacterial
cell to quickly up-regulate expression of this gene, restoring insertion of membrane proteins like
the c subunit of the F1F0 ATP synthetase 89,90.
A second example of gene regulation by ribosome stalling is in Neurospora crassa,
which uses arginine-induced ribosome stalling to down-regulate arginine biosynthesis 91,92. The
arg-2 mRNA encodes a subunit of an enzyme required for Arg biosynthesis in eukaryotes. This
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mRNA also contains an upstream ORF encoding short leader peptide called the arginine
attenuator peptide (AAP). AAP stalls the ribosome at termination in the presence of high levels
of Arg using the consensus sequence T9xxDYLxxxxWR20 93. This blocks other eukaryotic
ribosomes from pre-initiation scanning and thus effectively down-regulates arginine biosynthesis
92

.
Comparative analysis of stalling sequences reveals that stalling peptides have little

sequence similarity and rely on a few critical interactions with the ribosome to cause stalling (see
Table 1-1) 50. Despite the diversity of these motifs, many share the same three patterns of
interactions with the ribosome. First, conserved residues near the N-terminus of several stalling
motifs interact with the constriction site of the exit tunnel between proteins L4 and L22.
Consequently, mutations in L4, L22, or nearby rRNA nucleotides were shown in genetic screens
to reduce stalling 94,95. Second, conserved residues near the C-terminus of a motif are positioned
close to the PTC and may interact with nearby nucleotides 96. Third, some motifs encode a
specific aminoacyl-tRNA that binds in the A site but fails to undergo peptidyl transfer 97,98. A
variation of this rule involves stalling at termination where release factors are unable to facilitate
peptide release 99–101. All three of these interactions play a role in stalling in the SecM, ErmCL
and TnaC motifs and make them excellent candidates for in-depth investigation.

SecM Stalling
In E. coli, the Sec protein translocase is responsible for transporting proteins across the
inner plasma membrane and into the periplasm 102. In this system, nascent proteins are trapped in
their unfolded state and brought to the translocase machinery by the chaperone SecB 103. These
proteins are then transported across the membrane though the SecYEG protein channel, a process
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Table 1-1. Stalling Sequences. Stalling sequences that have been subjected to comprehensive mutational
analysis. Sequences that arrest translation elongation are aligned based on their likely positions in the stalled
ribosome, with numbering starting inversely from −1 for the position immediately preceding the P-site amino
acid. Approximate locations of amino acids in the ribosome are indicated at the top, on the basis of the structure
of the extended TnaC peptide–ribosome complex (118). Note that in the cases of SecM and others, the
intraribosomal peptide may be more compacted. Translation ends with the P-site amino acid as the last amino
acid of the nascent peptidyl-tRNA (note, however, that ribosomal occupancy has not been determined for
MifM). Residues essential for the elongation arrest are underlined. Residues denoted x are less important as they
can be changed to one or more different amino acid(s) without affecting the arrest. In all cases that have been
examined, the arrest-essential amino acids need to be separated with the exact spacings shown. The A-site amino
acids shown in lower case italics are not required for the arrest. The A-site prolines shown in reverse upper case
are essential for the arrest. In the case of E. coli TnaC, the A-site codon is a UGA stop (shown by asterisk). 1,
Leader peptide of the erythromycin resistance gene, ermC (96); 2, and 3, arrest sequence of the tryptophanase
operon of E. coli (135) and Proteus vulgaris (139), respectively; 4, arrest sequence of SecM from E. coli (95); 5,
a mutant form of the SecM arrest sequence having proline at −4 and −5 positions, of which the one at −4
(italicized) alleviates the specificity of the constriction-proximal residues (108); 6, arrest sequence of SecM from
Mannheimia succiniciproducens (108); 7, an experimentally evolved arrest sequence obtained by genetic
screening (98); 8, arrest sequence of MifM from B. subtilis (88). Used by permission from ref. (50).

driven by ATPase SecA 104. What little we know of the regulation of these genes suggests that
their expression is coordinated with housekeeping functions 105. However, the regulation of secA
by leader peptide SecM has been extensively characterized.
Expression of secA is regulated through a controlled feedback loop involving cellular
levels of SecA and translation of the 170 amino acid long leader peptide SecM 95,106. Both secM
and secA are transcribed on the same bicistronic mRNA, with secM located upstream of secA.
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Secondary structure in the mRNA sequesters the SD region of secA, effectively repressing its
translation unless disrupted (Figure 1-11A). This does not affect secM, however, which is
efficiently translated until the ribosome encounters an encoded peptide-stalling motif. When
cellular levels of SecA are low, the stalling event in SecM translation is prolonged, causing the
downstream mRNA secondary structure to dissolve. This frees the SD region of secA for
ribosome recognition, thus activating its translation (Figure 1-11A) 95,106. When SecA levels are
normal, the SecM peptide is quickly pulled from the stalled complex by SecA and translocated
across the membrane where it is degraded 106,107. In the absence of stalling, the mRNA structure
refolds and blocks initiation and translation of SecA.
SecM causes ribosome stalling using the consensus sequence
F150xxxxWIxxxxGIRAGP166 to interact with the exit tunnel and PTC of the ribosome 95,108
(Figures 1-11B and 11C). During translation, SecM residues Phe150, Trp155 and Ile156
compact at the constriction site in the exit tunnel, causing interactions with residue A751 of the
23S rRNA and residues Gly91 and Ala93 of the L22 beta-hairpin loop 109,110. These SecM
residues are important for stalling and require strategic placement to interact with exit tunnel
elements in order to facilitate translational arrest 95,111. Additional exit tunnel interactions have
also been observed between SecM, L22 (Gln72), L23 (Lys84), and 23S rRNA nucleotide
A1321109; however, these contacts are not essential for stalling, and can be compensated for by
the substitution of a Pro residue at position 161 95,108.
Compaction of SecM at the constriction site causes Arg163 to interact with the exit
tunnel and inactivate the PTC. Placement of Arg163 within the exit tunnel is critical and will not
tolerate even a +/− 1 residue shift 108. Once positioned, Arg163 presses against rRNA nucleotide
A2062, which otherwise is freely rotating 112, pushing it into A2503 (Figure 1-11C) 29,109,113.

22

Arg163, A2062 and A2503 are all highly conserved and are essential for SecM stalling 114,95,108.
Interactions between these elements initiate a relay mechanism through adjoining rRNA residues
resulting in the inactivation of the PTC (Figure 1-11D) 113–115 Part of this inactivation includes
movement of the P-site tRNA-peptide ester-linkage 2 Å away from the PTC 109. As previously
discussed, the P-site tRNA carbonyl carbon requires proper positioning in order to facilitate

Figure 1-11. Ribosome Stalling by SecM. (A) Nascent polypeptide-ribosome-mRNA complexes are
schematically depicted to show the effects of a ribosome stalled by an arrest sequence on the mRNA
secondary structure (B) Cross-section of the large ribosomal subunit of the SecM-stalled RNC revealing the
sites of interaction between the SecM nascent chain (green) and the ribosomal tunnel (gray). (C) Close-up of
the upper, middle, and lower regions of the ribosomal tunnel with density (gray mesh) and molecular models
for SecM nascent chain (green, with balls marking the Ca of the labeled residues; blue indicates the residue
is important for stalling), the 23S rRNA (gray, except for selected colored nucleotides), and ribosomal
proteins L4 (purple), L22 (orange), and L23 (cyan). (D) Positions of key relay residues after fitting
compared with canonical positions in 3WDK/3WDL. Residues are shown as colored sticks (fitted structure)
or in dark gray (2WDK/2WDL). (A) is used with permission from ref. (87)). (B) and (C) used with
permission from ref. (109). (D) is reprinted from ref. (113). Copyright 2012, with permission from Elsevier.
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nucleophilic attack by the A-site α-amino group. A 2 Å shift would dramatically reduce
translational efficiency 27,109.
Altered PTC geometry also depends on Pro166, which contributes to stalling from the A
site 95,116. Pro166 is highly conserved in bacterial SecM species and is essential for stalling 95,108.
Pro166 is not added to the growing peptide chain, indicating that its action is effected through
the A site as prolyl-tRNA 116. Its effect can be explained by the unique properties of proline that
make it both a poor peptidyl donor and acceptor 116–118. The presence of prolyl-tRNA in the A
site prevents both puromycin and cellular rescue-machinery from accessing the stalled ribosome
complex 117. Pro166 and Arg163 are considered the most important contributors to SecM
mediated stalling as is indicated by their high sensitivity to mutation 108.

ErmCL Stalling
Erythromycin (ERY) is a macrolide antibiotic that stops bacterial cell growth by
inhibiting translation and causing the accumulation of peptidyl-tRNAs 119–121. Bacteria have
evolved resistance to these drugs by using methyltransferases to dimethylate rRNA residue
A2058. This residue is located in the drug binding site in the peptide exit tunnel and prevents
antibiotic binding when methylated 122. However, methylation of this base also decreases overall
cell fitness by deregulating translation of certain proteins 123. Therefore, expression of the erm
genes that encode these methyltransferases is inducible and highly regulated 122,123.
Induction of the most extensively studied erm gene, ermC, occurs when ERY binds the
ribosome and induces translational arrest. The ermC mRNA contains an upstream ORF that
codes for a 19-amino acid long leader peptide known as ErmCL (Figure 1-12A) 124,125. Under
normal conditions, the SD site of ermC is sequestered by mRNA secondary structures
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prohibiting its translation. Its leader peptide, ermCL, is constitutively expressed. If, however,
ERY binds the ribosome during ErmCL synthesis, it results in translational arrest, dissolving the
downstream mRNA structure and activating ermC expression (Figure 1-11A) (for a review see
126

). In this manner, significant ERY concentrations within the cell induce the expression of the

resistance gene ermC.
The ErmCL leader peptide induces stalling by the strategic positioning of the conserved
stalling motif IVFI9 within the exit tunnel. Mutational studies have demonstrated that this
sequence is critical for stalling, with Ile9 stalling in the P site 96. The identity of A site
aminoacyl-tRNA is inconsequential, as studies demonstrate that peptidyl transfer from Ile9tRNA to any A site amino acid or even puromycin is inhibited 96.
The stalling event is initiated through the binding of ERY within the peptide exit tunnel,
near the PTC, partially blocking the exit tunnel entrance (Figure 1-12B and 12C) 127,128. The C3cladinose ring of ERY directly interacts with the I6VFI9 motif forcing the ErmCL peptide to
compact against the exit tunnel. This compaction pushes the peptide into contact with A2062 of
the 23S rRNA and Met82-Arg84 of L22. This causes A2602 to interact with A2503, a highly
conserved, modified rRNA nucleotide that resides in the exit tunnel near the PTC (Figure 1-12C
and 12D) 114. Interactions between A2602 and A2503 are believed to initiate a signal relay
ending with the inactivation of the PTC 96,114,115. ERY binding may also directly contribute to
PTC inactivation through contacts with rRNA residues like C2160 129.
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Figure 1-12. Ribsome Stalling by ErmCL.
(A) The structure of the inducible ermC
operon where the ermC gene is preceded by a
regulatory ORF ermCL. Drug- and nascentpeptide-dependent ribosome stalling at
ermCL ORF changes the conformation of the
mRNA intergenic region (schematically
shown as a two-hairpin structure), thereby
releasing translational attenuation of ermC.
(B, C) Erythromycin and the ErmCL nascent
peptide in the ribosome exit tunnel (viewed
from the PTC down the tunnel). In the vacant
tunnel (B), the nascent-peptide sensor,
A2062, is free to rotate into the tunnel lumen.
Binding of antibiotic (‘ERY') narrows the
tunnel (C). In the constricted tunnel, the
ErmCL nascent peptide drives A2062 toward
the tunnel wall, where it comes into close
proximity to A2503. (D) Conformational
flexibility of A2062. The orientations of the
A2062 base are shown for the apo structure
of the Haloarcula marismortui 50S
ribosomal subunit (blue) (PDB accession
number 3CC2) (see ref. (114)) and for the
50S subunit complexed with a transition state
analog (beige) (1VQ7) (27). The A2503 base
is colored red. A possible hydrogen bond
between A2062 and A2503 is indicated by a
dashed line. Used by permission from ref.
(114).

TnaC Stalling
The final case study of gene regulation through ribosome stalling involves genes that
degrade tryptophan in E. coli and P. vulgaris. The tnaCAB operon includes a tryptophanase
(tnaA) that degrades Trp to indole, pyruvate and ammonia, effectively making Trp a source of
carbon and nitrogen 130 as well as the tryptophan transporter tnaB 131. Upstream of tnaA is a
separate ORF encoding a 24 (E. coli) or 36 (P. vulgaris) amino acid long leader peptide called
tnaC 131.
Bacteria are able to modulate Trp levels through a combination of transcriptional and
translational controls. After transcribing tnaC, RNA polymerase pauses at the intergenic spacer
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region between tnaC and tnaA (Figure 1-13A) 132. Co-transcriptional translation is also occurring
during this time period. When cellular levels of Trp are low, translating ribosomes reach the end
of tnaC, terminate translation normally, and dissociate from the mRNA. This allows the Rho
termination factor to bind to the mRNA and catch up to the transcriptional machinery and induce
Rho-dependent termination before tnaA or tnaB can be transcribed 133. When cellular levels of
Trp are high, Trp binding to the ribosome during TnaC translation stalls the termination reaction
99

. The stalled ribosome blocks the Rho termination factor from binding the mRNA, allowing

transcription of tnaA and tnaB to proceed (Figure 1-13A) 133,134. In this way, bacteria are able to
rapidly modulate levels of tryptophan within the cell.
Successful arrest of translation is dependent on free L-Trp binding and TnaC interactions
with the exit tunnel. The binding site of L-Trp is proposed to overlap with the sparsomycin
binding site and aminoacyl portion of the A-site tRNA 99,135–137. Despite recent studies that
implicated Ile19 of the TnaC peptide and A2058 (a PTC residue that sits at the entrance of the
exit tunnel) in the creation of the binding pocket 138, the exact location of L-Trp could not be
visualized in the cryo-EM structures, making the exact binding site still unknown 115.
Binding of free L-Trp causes the TnaC leader peptide to arrest translation. In E. coli,
studies have determined that three conserved residues (Trp12, Asp16 and Pro24) are responsible
for TnaC mediated arrest 135. Another semi-conserved residue Ile19 also contributes to stalling
making the consensus sequence in E. coli W12xxxD16xxI19xxxxP24stop 135. With P24 in the P site,
stalling occurs at termination. A similar conserved sequence, W20xxxD24xxI27xxxxP32, is found
in P. vulgaris where two additional lysine residues after P32 indicate that stalling occurs during
elongation 139. It is interesting to note that despite having different peptide lengths, the spacing
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Figure 1-13. Ribosome Stalling by TnaC. (A) Nascent polypeptide-ribosome-mRNA complexes are
schematically depicted to show access of a bacterial transcription termination factor. (B) Ribosomal components
potentially involved in a relay mechanism to inactivate the PTC, with those implicated in stalling in bold. The
TnaC nascent chain is in green, with residues essential for stalling colored yellow. The isolated TnaC-tRNA
density is shown as a transparent gray surface. (C) Schematic indicating potential relay pathways from Trp12
(W12) of TnaC to the PTC, either through the nascent chain itself (R1) or through networks of interconnected
23S rRNA nucleotides (R2 and R3). (D) Conformation of 23S rRNA nucleotides at the PTC when tRNA CCAend mimics are bound to A (cyan) and P sites (green) (PDB1VQN). (E) View into the PTC of 70S-RNC
complex, with fitted models as in (D). Note the lack of density (gray) for nucleotide A2602. (F) View into the
PTC of the TnaC-70S complex, with the MDFF model of the TnaC-tRNA (green) and nucleotides of the 23S
rRNA (blue). The cryo-EM density is shown as a transparent gray surface, with an asterisk indicating the
connection between P-tRNA and nascent chain. (G) As in (D), but with the antibiotic sparsomycin (SPAR, red;
PDB1VQ9) and the terminal A76 and aminoacyl moiety of an A-tRNA (cyan, PDB1VQN) included. (A) Used
with permission from ref. (87)). (B)-(G) From ref. (115). Reprinted with permission from AAAS.
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between the stalling elements in E. coli and P. vulgaris is conserved. This spacing is essential for
stalling in both organisms 139.
In E. coli, biochemical, structural and molecular modeling evidence suggests that
consensus sequence residues form extensive contacts with amino acids and rRNA residues
within the exit tunnel and near the PTC (Figure 1-13B) 94,115,135,140,141. These include Trp12
interactions with R92 of L22, Asp16 interactions with K90 of L22, Ile19 interactions with
A2058, A2059 and U2609 and Pro24 interactions with U2585 141. Interestingly, exit tunnel
interactions by Trp12 prevent puromycin release of Pro24, suggesting a relay mechanism exists
that transmits signals from the exit tunnel to inactivate the PTC (Figure 1-13C) 115,136. This
theory is supported by mutational studies showing that substitution of exit tunnel relay elements
A748-A752 and U2609 of the 23S rRNA greatly diminish stalling capability 140.
Cryo-EM structures of the stalled TnaC-ribosome complex offer some insight as to how
the PTC is inactivated in E. coli. Residues A2602 and U2585 of the PTC adopt altered
conformations in the TnaC-ribosome complex (Figure 1-13E) 115 when compared to other
ribosome structures (Figure 1-13F) 27. During stalling with TnaC, A2602 adopts a rigid
conformation as apposed its typical flaccid state 27,115. This rigid conformation is reminiscent of
the structures showing the ribosome bound with sparsomycin, a translational inhibitor (Figure 113G) 142. U2585 is also seen to shift position to directly interact with Pro24, presumably an effect
of L-Trp binding (compare Figures 13E and 13F). These conformational changes are
incompatible with proper positioning of the GGQ motif of RF2, potentially explaining why
stalling occurs at termination 115,143. These changes must also prevent proper aminoacyl-tRNA
positioning, since stalling also occurs during elongation in P. vulgaris 139 and substitution of a
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Trp codon UGG for the UGA stop codon after Pro24 inhibits elongation and puromycin release
in E. coli 99.
Overall, the stalling mechanisms used by SecM, ErmCL and TnaC have many
similarities. First, both SecM and ErmCL regulate gene expression by sequestering downstream
SD elements and use stalling as a means of dissolving those elements. All three facilitate stalling
through strategic positioning of their residues to induce peptide compaction in the exit tunnel.
Both TnaC and SecM target the constriction site in the exit tunnel using aromatic residues. TnaC
and ErmCL both rely on small molecule binding near the PTC to initiate stalling. Finally, all
three facilitate PTC inactivation via signal relay through peptide constriction near A2062.
Despite these similarities, however, SecM, ErmCL and TnaC require different elements in the
exit tunnel for stalling, specifically in portions of the proposed relay mechanisms, suggesting that
multiple relay mechanisms likely exist 108,113–115.
Even though SecM, ErmCL and TnaC and the other known stalling peptide sequences
have been studied thoroughly, much remains to be explored. What is the scope of gene
regulation by peptide stalling? What are the combinations or patterns of amino acids that cause
stalling? Are there universally conserved motifs? How do programmed stalling events evade
tmRNA and other rescue machinery? Our efforts to answer these questions and to better
understand peptide mediated stalling have led to the identification of novel stalling motifs and
their characterization in both bacteria and yeast. The following chapters detail some of these
results and highlight some of the new techniques that have been developed to identify novel
stalling motifs.
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Chapter 2. Genetic Identification of Nascent Peptides that Induce Ribosome Stalling

Author’s Note: This chapter details the discovery and characterization of novel stalling peptides,
for which I performed the toeprinting and peptidyl-tRNA release assays. The results of this study
were published in the Journal of Biological Chemisty in 2009 98.

Abstract
Several nascent peptides stall ribosomes during their own translation in both prokaryotes
and eukaryotes. Leader peptides that induce stalling can regulate downstream gene expression.
Interestingly, stalling peptides show little sequence similarity and interact with the ribosome
through distinct mechanisms. To explore the scope of regulation by stalling peptides and to
better understand the mechanism of stalling, we identified and characterized new examples from
random libraries. We created a genetic selection that ties the life of E. coli cells to stalling at a
specific site. This selection relies on the natural bacterial system that rescues arrested ribosomes.
We altered tmRNA, a key component of this rescue system, to direct the completion of a
necessary protein if and only if stalling occurs. We identified three classes of stalling peptides:
C-terminal Pro residues, SecM-like peptides, and the novel stalling sequence FxxYxIWPP. Like
the leader peptides SecM and TnaC, the FxxYxIWPP peptide induces stalling efficiently by
inhibiting peptidyl transfer. The nascent peptide exit tunnel and peptidyl-transferase center are
implicated in this stalling event, although mutations in the ribosome affect stalling on SecM and
FxxYxIWPP differently. We conclude that ribosome stalling can be caused by numerous
sequences and is more common than previously believed.
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Introduction
The ribosome efficiently synthesizes an enormous diversity of peptide sequences without
regard to their chemical properties. This generality is not universal, however. Several
polypeptides interact with the ribosome to stall their own translation, either in the elongation or
termination steps 144,145. Programmed stalling events regulate gene expression in both
prokaryotes and eukaryotes 144–146, and may affect the folding of nascent polypeptides 147–149.
In two well-characterized examples from E. coli, ribosome stalling on a leader peptide
increases the expression of a gene further downstream on the same mRNA. The secretion
monitor peptide SecM, for example, regulates secA in response to changes in protein
translocation activity 102. If translocation activity is low, ribosome stalling on the SecM peptide
alters the secondary structure of the mRNA and upregulates the translation of secA, a key
component of the secretory machinery 106. When activity is high, the SRP-Sec system binds the
signal peptide sequence in SecM and pulls it from the stalled ribosome 106,107. A second example
is the regulation of tnaA, a gene required to break down tryptophan, by the leader peptide TnaC
in response to Trp levels. When Trp concentrations are high, ribosome stalling on TnaC blocks a
transcriptional terminator upstream of tnaA, increasing its expression 99,150. Low tryptophan
levels do not support ribosome stalling and lead to attenuation of the transcript.
Stalling on the SecM and TnaC peptides is the result of three interactions: the binding of
the nascent peptide to the exit tunnel and the peptidyl-transferase center, and the binding of an
effector in the ribosomal A site. The peptide exit tunnel in the large ribosomal subunit is 100 Å
long and 15 Å wide on average 28. Mostly made of RNA, it provides very few hydrophobic
surfaces for elongating proteins to bind, accounting for their ability to pass through unhindered.
A significantly constricted portion of the tunnel is formed by loops in proteins L4 and L22 151,152.
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SecM and TnaC interact with the tunnel near this constriction, using critical Trp residues 10-12
amino acids upstream of the stalling site. Ribosomal mutations that reduce stalling map to the
exit tunnel, implicating A751, A2058, and U2609 in the 23S rRNA and specific residues in the
L22 protein in the stalling mechanism 94,95. A cryo-electron microscopy study of the SecMstalled ribosome revealed a network of conformational changes in 23S rRNA emanating from the
exit tunnel 153.
Nascent peptides also interact directly with the peptidyl-transferase center (PTC) to
induce stalling. In the case of SecM, the identity of the final six residues is critical for stalling on
the FxxxxWIxxxxGIRAGP166 sequence 95. Likewise, the C-terminal Pro residue in TnaC is
essential for stalling on the sequence WxxxDxxxxxxxP* 99. These amino acids must be acting
within the PTC to inhibit its catalytic activity, either peptidyl transfer for SecM or peptidyl
hydrolysis for TnaC. In some cases, the peptide sequence in the PTC is sufficient to induce
stalling without exit-tunnel interactions. A C-terminal Pro residue in the YbeL protein inhibits
termination. Peptide release is especially inefficient when Pro-stop is preceded an Asp, Glu, or
Pro residue 100.
In addition to nascent-peptide interactions with the exit tunnel and the PTC, stalling on
SecM and TnaC requires a specific effector molecule to bind in the A site. This binding event is
thought to create a PTC conformation that is inactive. For example, SecM stalls during
elongation with unreacted Pro-tRNA bound in the A site 116,154. Mutation of this Pro codon to
Ala alleviates stalling. Likewise, TnaC stalling requires the binding of free tryptophan at an
unknown site near the PTC 136,137. The action of free tryptophan can be mimicked by Trp-tRNA
if the tnaC stop codon is mutated to a Trp codon. Other aminoacyl-tRNAs (Phe, Met, Pro) do not
induce stalling on TnaC 99.
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Although stalling peptides interact with the exit tunnel and PTC, they do so differently
and share little sequence similarity. This led us to hypothesize that there are additional, unknown
peptide sequences that might inhibit peptidyl transfer or hydrolysis. Here, we report the genetic
identification and characterization of peptides that stall at high efficiency during elongation.

Results
A genetic selection for novel stalling sequences.
We set out to systematically identify peptide sequences like SecM and TnaC that
interfere with peptidyl transfer or hydrolysis and induce ribosome stalling. To identify stalling
peptides from random libraries, we modified a genetic selection that we previously developed to
link ribosome stalling and rescue to the life of the cell 155. In this selection, stalled ribosomes are
recognized by transfer-messenger RNA (tmRNA), a small, stable RNA found in eubacteria and a
key component of a quality control system for protein synthesis; for a review, see 69. tmRNA’s
natural function is to release stalled ribosomes and tag the aborted nascent peptide for
destruction. Acting as a transfer RNA, tmRNA enters the empty A site of the ribosome and adds
Ala to the nascent polypeptide chain. tmRNA then serves as a template, encoding a short peptide
tag that is recognized by cellular proteases. After this tag is translated, the ribosome is released at
a stop codon within tmRNA and the aborted protein product is degraded. For the purposes of our
selection, it is important to note that although tmRNA was first characterized as rescuing
ribosomes stalled on mRNAs lacking stop codons 81, it can also act on ribosomes stalled by
nascent peptides 100,156.
To create a genetic selection for ribosome stalling based on this ribosome rescue
machinery, we altered tmRNA so that instead of tagging proteins for proteolysis, it completes the
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synthesis of an essential protein, linking stalling to the life of the cell (Figure 2-1). The
kanamycin resistance protein (KanR) from Tn10 has a C-terminal helix of 15 amino acids that is
structurally critical 157; truncation of this helix leads to loss of activity. To complement the
truncated KanR protein, we changed the tmRNA template to encode the last 14 residues of KanR
(ANKLQFHMLDEFF), referred to hereafter as tmRNA-K1. Together with the Ala from
aminoacylated-tmRNA, these residues complete the KanR protein and restore KanR activity—
but only if the ribosome stalls at exactly the right site. This serves as the basis for our selection:
peptide sequences that stall the ribosome at the end of a truncated KanR protein can be easily
identified in random libraries because they recruit tmRNA, complete KanR, and confer
resistance to kanamycin.
How can stalling be induced at the end of the KanR protein without interfering with the
final structure and activity of KanR? Two mutations, Asn255Glu and Asp257Opal, create a GluPro-(Stop) sequence that induces stalling during translational termination in a kanR gene lacking
the C-terminal helix. We previously showed that expression of this truncated kanR-EP construct
and the altered tmRNA, tmRNA-K1, allows cells to survive equally well on selective (15 µg/mL
kanamycin) or non-selective plates at 37 °C 155. Under the same conditions, bacteria lacking the
modified tmRNA-K1 gene survive at the rate of 5 cfu in 107 plated. These results demonstrate
that the introduction of the Glu-Pro-Ala “scar” from the stalling and tagging process does not
destroy KanR activity. Analysis of the crystal structure of the homologous Aph(3’)-IIa protein 157
suggests that the C-terminal helix in KanR is preceded by a surface-exposed loop of poorly
conserved residues (Ile253 through Pro256). We anticipated that this loop region might tolerate a
variety of sequences that induce stalling while maintaining robust KanR function.
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Nucleotide sequences that induce stalling and tagging were isolated from a randomized
library fused to a truncated kanR gene. 18 amino acids were deleted from KanR, including the Cterminal helix and three residues in the preceding loop. 18 random nucleotides (six codons) were
cloned downstream of this truncated kanR gene, beginning with residue 254. No stop codon was
specified. We generated a library of 5
x 106 mutants and introduced it,
together with tmRNA-K1, into an E.
coli strain lacking wild-type tmRNA.
We selected for survival on plates
containing 15 µg/mL kanamycin at 37
°C. Roughly 1 in 104 colonies
survived, suggesting that a substantial
fraction of the sequences induce
ribosome stalling.

Three classes of stalling peptides.
Although we were interested
primarily in peptides that induce
Figure 2-1. Genetic selection for sequences that induce
ribosome stalling. (A) Structure of the Aph(3’)-IIa protein,
homologous to KanR (see ref. 98). Kanamycin in shown in
black. The C-terminal helix (14 residues), shown in red, is
essential for KanR activity. A four-residue surface-exposed
loop prior to this helix is highlighted in blue. (B) 18 random
nucleotides (six codons) were introduced at the C-terminus of a
KanR protein lacking its last 18 amino acids (yellow). If the
random sequence induces stalling, tmRNA-K1 rescues the
stalled ribosome and directs the synthesis of the remaining
KanR residues (red). Cellular survival on kanamycin plates is
therefore tied to stalling on the C-terminus of KanR.

36

stalling, our selection identifies any
nucleic acid sequences that elicit
tagging by tmRNA. In principle,
nucleotide sequences containing rare
codon clusters 158,159, secondary

structures, transcriptional terminators 81, or other novel mechanisms might also survive the KanR
selection. Analysis of the surviving clones, however, revealed sequences that share common
features at the amino acid level. These were grouped into three classes (Table 2-1).
The most common cause of stalling, found in over 90% of the clones, is inefficient
termination at the sequence Pro-Stop. The Pro residue is found almost exclusively at position
three of the six random codons, corresponding to native KanR residue Pro256. While there is no
significant codon bias for any particular Pro codon, the opal stop codon (UGA) is highly
overrepresented (23/29 clones). There is also selection for the residue just upstream of Pro-Stop:
Glu is overrepresented (16/29) and Asp, Pro, and Gly are each seen several times in the –2
position.
A second class of peptides must induce stalling during elongation, not termination. These
clones contain two consecutive Pro codons, most commonly at codons three and four in the
random sequence with no nearby stop codon. The majority of these clones were found by
performing the selection at lower stringency, lowering the temperature to 25 °C. When tested
individually, they showed poor survival at 37 °C, roughly 1-10%, much weaker than the 100%
survival seen with the Pro-Stop sequences above.

Table 2-1. Stalling peptides isolated from the KanR selection. The variable region (6 codons) is shown in bold.
Class I contains Pro-Stop residues at the third and fourth variable position. Class II contains a Pro-Pro sequence
at positions three and four with no nearby stop codon. Class III contains Trp-Pro-Pro at the first three positions
without an adjacent stop codon.
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A third class of clones contain the sequence Trp-Pro-Pro without a nearby stop codon
(Table 2-1). Like the other Pro-Pro sequences, these peptides also stall during elongation rather
than termination. Unlike the second class of clones, however, where the two consecutive Pro
codons appear at positions three and four, here they occur at positions two and three (e.g.
WPPWYR). Another difference is that WPP-containing clones survive robustly (100%) in the
KanR selection at 37 °C when characterized individually. Further experiments on these
sequences are described below.
The sequence Pro-Stop occurs commonly and elicits tagging at high levels; to prevent
such clones from overwhelming other novel sequences, we created a second library of 18 nt (six
codons) in which codons four through six could not be stop codons. This was done by allowing
only C, G, and A at the first nucleotide of these codons; this eliminates Phe, Tyr, Cys and Trp as
well. We screened an 8 x 106-member library at high stringency, obtaining colonies at rates of
0.01% survival. 21/23 sequenced clones contained the sequence WPPP at the first four positions
(data not shown). This result confirms that WPP-containing sequences are robust inducers of
stalling, particularly when coupled with a third Pro codon.
Selection of this second library at low stringency yielded higher levels of survival
(0.25%). Nearly all of surviving clones fall into the second class of stalling peptides, with two
consecutive Pro codons at codons three and four of the random sequence. An alignment of 46 of
these sequences reveals that Arg or His are strongly preferred at the first position, with Ala, Asp,
Ser, and Pro at the second position (Figure 2-2). Including the constant Gly-Ile upstream, the
consensus sequence becomes GI(R/H)xPPxx. These appear to be weaker versions of the SecM
C-terminal sequence GIRAGP. A clone closely resembling this sequence (GIRAPP) is more

38

Figure 2-2. Alignment of the variable region of clones surviving the KanR selection at low stringency.
Created by Weblogo. Position 1: R > H > n. Position 2: A > D > S > P. Positions 3 and 4 were Pro only.
Positions 5 and 6 showed little conservation

active than the other members of this class and survives the KanR assay 100% at high
stringency.

Stalling and tagging occur following WPP.
The peptide sequences in class three (containing WPP) show high levels of activity in the
KanR assay and stall translation during the elongation step. We chose to further characterize
three sequences: WPPPSI, WPPDV*, and WPPWYR. Where does stalling occur in these
sequences? Where is the tag added by tmRNA? To analyze the tagged proteins by mass
spectrometry, we first transferred the stalling sequence to the C-terminus of the GST protein.
This full-length, stable protein served as a scaffold enabling overexpression of the stalling
peptide. Some of the KanR protein context was fused to GST as well, from 12 amino acids
upstream of the random hexamer through the stop codon 27 codons downstream. To isolate
proteins tagged by tmRNA, we used a modified tmRNA encoding six His residues in its template
sequence (tmRNA-H). GST-fusions tagged by tmRNA-H were purified by affinity
chromatography using Ni-NTA resin and digested with trypsin. From this tryptic digest, the Cterminal tagged peptide was purified again with Ni-NTA resin.
The C-terminal peptide contains both the stall sequence from KanR and the tmRNA tag;
determining its mass by MALDI-MS revealed the site of stalling and tagging by tmRNA. A
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Figure 2-3. Identification of the site of stalling by MS. WPPWYR, WPPPSI, and WPPDV* were cloned with 12
upstream residues onto the C-terminus of GST. Stalled peptides were tagged by tmRNA-H encoding a His6-tag.
Following Ni-NTA resin purification, the tagged proteins were digested with trypsin and the C-terminal tagged
peptide was repurified on Ni-NTA resin. These peptides were ionized by MALDI and analyzed by MS. All three
stalling sequences produce a peak at m/z 2041, corresponding to YGIWPPAANDH6D. The WPPDV* sequence
also contains a strong peak at m/z 2255 corresponding to YGIWPPDVAANDH6D.
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single large peak in the mass spectra for the WPPPSI and WPPWYR C-terminal tagged peptides
corresponded to a m/z of 2041 (Figure 2-3). This is the predicted result if the tmRNA tag is
added after the second Pro (YGIWPPAANDH6D). The mass spectrum of the WPPDV* peptide
fragment contained the same peak at 2041 together with a more abundant peak at 2255,
corresponding to the peptide YGIWPPDVAANDH6D. In the WPPDV* clone, stalling occurs
both after WPP and during termination at the stop codon. Peptide fingerprinting by tandem
MS/MS was performed on all four of these peptides to confirm the amino acid sequence directly.

Determination of residues necessary and sufficient for stalling and tagging.
The MS data indicate that tagging occurs immediately after WPP in these three clones.
What amino acids cause this stalling event? In the case of SecM and TnaC, residues essential for
the highest levels of stalling are found upstream and interact with the exit tunnel. For this reason
we included 12 upstream amino acids (SLQKRLFQKYGI) from KanR along with the hexamers
in making the GST-fusions. To assay for stalling and tagging in the GST-fusions, we detected
the tag added by tmRNA-H with anti-His6 antibodies (Figure 2-4). High levels of tagging were
detected for the full-length GST-WPPPSI fusion, referred to hereafter as 1-18 (i.e. 12 residues
from KanR followed by the hexamer, Figure 2-4A). Deletion of the first four amino acids had
little or no effect (5-18), but removal of the first eight nearly eliminated tagging (9-18, Figure 24B). We conclude that residues upstream of the WPPPSI sequence play a critical role in highefficiency tagging. Interestingly, some minimal activity resides in the hexamer sequence alone
(13-18) with no KanR upstream sequence.
To identify how each residue contributes individually to stalling, we performed alanine
scanning on the full-length stalling peptide, 1-18. Residues 1 to 16 were individually mutated to
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Figure 2-4. Essential elements of a stalling peptide. (A) WPPPSI and 12 upstream residues were divided into
four groups for analysis. (B) N-terminal deletions of the 18-mer stalling peptide were fused to the C-terminus of
GST. The fusions were analyzed by immunoblot for tagging by a modified tmRNA (tmRNA-H) that encodes a
His6-epitope. The +1FS vector contains the same 18-mer sequence shifted into the +1 frame to test if translation
of WPPPSI is necessary for stalling. (C) Each residue of the 18-mer was mutated individually to Ala and
assayed as above. A GST-Stop construct served as a negative control and the intact full-length WPPPSI 18-mer
as a positive control.

alanine and assayed by immunoblot (Figure 2-4C). Consistent with the truncation results,
mutating residues 1-4 has little or no effect on tagging. Alanine substitutions for Arg5, Leu6,
Gln8 and Lys9 likewise make little difference in the level of tagging. In contrast, mutation of
Phe7, Tyr10, Ile12, or the WPP sequence dramatically decreases tagging levels. Notably, tagging
is also strongly reduced by the Pro16Ala mutation. This is surprising because the MS data shows
that the third Pro in WPPPSI is not incorporated into the stalled peptide. In summary, residues in
the consensus sequence FxxYxIWPPP are required for tagging.
tmRNA rescues ribosomes stalled on broken mRNA templates; perhaps these tagging
events arise from RNA synthesis defects in the kanR mRNA or from nucleolytic cleavage. To
prove that tagging requires translation of the peptide sequence, we created a mutant of the GSTWPPPSI fusion in which a single nucleotide is added upstream of the full-length stall peptide.
The resulting +1 frameshift changes the identity of every amino acid in the stalling sequence
except for Phe7 and Lys9 while retaining the same nucleotide sequence. Immunoblot analysis of
this mutant revealed that tagging was completely abolished, demonstrating that tagging of the
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GST-WPPPSI fusion is due to the amino acid sequence and not the nucleotide sequence (Figure
2-4B).

Tagging at termination in WPPDV*.
The MS data show that tagging occurs in the WPPDV* sequence both immediately after
WPP and during termination. To further understand the effect on termination, we measured
tagging levels for a series of GST-WPPDV* variants in the immunoblot assay (Figure 2-5).
Mutation of the opal stop codon (UGA) to the more efficient ochre codon (UAA) reduced
tagging slightly; replacing the stop codon altogether with an Ala codon reduced it even further.
We propose that the substantial tagging that remains in the WPPDVA variant represents stalling
directly after the WPP as seen in the MS data.
If the WPPDV sequence is interfering with termination, how far downstream does this
effect carry? An opal stop codon immediately following WPPD tagged at the same level as the
original WPPDV* sequence (Figure 2-5). Moving the stop codon one or two codons downstream
by inserting Ala residues, however, reduces the tagging levels to those lacking a stop codon
altogether (WPPDVA). These
results show that the stop
codon must be only one or two
codons downstream of WPPD
for stalling to occur during
termination.
Figure 2-5. Stalling during termination at WPPDV*. Tagging of the
GST-WPPDV* fusion by tmRNA-H was monitored by anti-His6
antibodies. Mutations in bold were introduced to determine the role of
spacing, stop codons, and the DV residues in this stalling event.
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We next examined the
role of the Asp and Val

residues. Val is not known to inhibit termination when found at the C-terminus of proteins;
indeed, the Val17Ala mutant showed no loss of tagging. The Asp16Ala mutation, however,
completely alleviated tagging (WPPAV*). The Asp residue must therefore be critical for tagging
after WPP as well as after WPPDV during termination. This role is consistent with the critical
nature of the third Pro residue in the WPPPSI clone.

The residue after WPP is critical for tagging by tmRNA.
Alanine-scanning mutagenesis of the WPPDV* and WPPPSI clones demonstrates that
the residue after FxxYxIWPP plays a key role in stalling ribosomes. What amino acids besides
Asp and Pro can fulfill this role? We created a library of peptide trimers following WPP in the
KanR selection (WPPXXX), constrained as above to exclude stop codons. Of the clones
surviving at high stringency, ~80% contain the sequence WPPPxx and another ~20% the
sequence WPPDxx (data not shown). No selection was apparent for the final two amino acids.
To perform a more quantitative analysis, we created mutants of the GST-WPPPSI fusion
expressing all 20 amino acids in the position immediately following WPP. These were subjected
to immunoblot analysis with tmRNA-H. Confirming the genetic data, the Pro, Asp, and Trp
mutants showed high levels of tagging. The Asn mutant tagged moderately, while the other 16
amino acids showed much lower levels of tagging (Figure 2-6).
How does the residue after FxxYxIWPP contribute to stalling and tagging? The incoming
aminoacyl-tRNA does not react, yet its identity is critical. It must therefore contribute to stalling
by interacting with the ribosome in the A site. During ribosome stalling on SecM, Pro-tRNA
performs exactly this function 154.
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But if Pro-tRNA is
bound in the A site, how is
the GST-WPPPSI fusion
tagged by tmRNA? It
should block tmRNA from
entering the ribosome at
all. One possibility is that
ribosomes stalled on
FxxYxIWPPP deplete ProtRNA from the available

Figure 2-6. Identification of the site of stalling by MS. WPPWYR, WPPPSI,
and WPPDV* were cloned with 12 upstream residues onto the C-terminus of
GST. Stalled peptides were tagged by tmRNA-H encoding a His6-tag.
Following Ni-NTA resin purification, the tagged proteins were digested with
trypsin and the C-terminal tagged peptide was repurified on Ni-NTA resin.
These peptides were ionized by MALDI and analyzed by MS. All three
stalling sequences produce a peak at m/z 2041, corresponding to
YGIWPPAANDH6D. The WPPDV* sequence also contains a strong peak at
m/z 2255 corresponding to YGIWPPDVAANDH6D.

cellular pool, leading to
some stalling events with empty A sites. Depletion of Pro-tRNA leads to tagging of the SecM
peptide by tmRNA 154. If this is also the case with FxxYxIWPPP, then overexpression of
tRNAPro should alleviate tagging. To test this hypothesis, we altered the GST-WPPPSI fusion to
include one or more CCC codons. CCC is decoded by only one tRNA, Pro2, which also
recognizes CCU. The original WPPPSI sequence contains neither CCC nor CCU; we altered it to
include CCC at the first two Pro codons (WppPSI) or the third (WPPpSI).
The immunoblot assay was used to visualize the tagging levels of these GST-fusions with
or without overexpression of Pro2 tRNA from the pRARE plasmid (Figure 2-7A). Tagging of
the GST-WPPPSI fusion lacking CCC codons was unaffected by overexpression of Pro2.
Likewise, little or no change in tagging occurred when the first two Pro residues were encoded
by CCC (WppPSI). In contrast, when the third Pro codon was CCC, tagging was sharply reduced
by Pro2 tRNA overexpression. In addition to the loss of tagging, the overall expression of the
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GST-WPPpSI fusion was dramatically
reduced. Pro2 overexpression had no
effect on GST levels in WPPPSI or
WppPSI fusions. These results show
that depletion of the tRNA decoding
the third Pro codon is necessary for
tagging.

Figure 2-7. The effect of tRNA levels on stalling and tagging.
(A) One or more Pro codons in the WPPPSI sequence was
switched to CCC (lower case p) so that it would only be
recognized by Pro2 tRNA. An upper case P represents a Pro
codon not recognized by Pro2 tRNA. Tagging of the GSTWPPPSI fusion was monitored in the presence or absence of a
plasmid (pRARE) overexpressing the Pro2 tRNA. pRARE
also expresses several other rare tRNAs.
(B) Stalling
sequences containing one or three rare Arg codons (AGG) were
fused to the C-terminus of GST. Tagging by tmRNA-H was
monitored with anti-His6 antibodies in the presence or absence
of a plasmid (pRARE) overexpressing the cognate tRNA,
Arg5.

The role of codon usage.
We anticipated at the outset of
our KanR selection experiments that
we might isolate stalling sequences
with rare codons. Overexpression of
proteins containing consecutive rare
codons induces high levels of stalling

and tagging by tmRNA 158,159. The three tRNAArg isoacceptors decoding the CGG, AGA, and
AGG codons are present at low levels in E. coli 160. Why do such sequences not survive the
KanR selection? To address this question, we measured tmRNA tagging levels for a GST-fusion
construct containing SEPR* and SEPRRR encoded by the rare Arg codon AGG. SEPR* tagging
was barely detectable, much lower than SEP*, while SEPRRR tagged at very high levels in the
immunoblot assay (Figure 2-7B). Tagging at both sequences was completely alleviated by
overexpression of the cognate tRNA (Arg5) from the pRARE plasmid. The same SEPR* and
SEPRRR sequences were then cloned in place of the randomized cassette of the KanR selection
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plasmid. The sequence SEP in the first three positions is known to be compatible with KanR
activity; in the SEP* context it conveys 100% survival. Cells expressing SEPR* or SEPRRR
sequences survived no better than an empty vector control under low stringency conditions (data
not shown). These results show that tagging activity at rare codons is either insufficient or
incompatible with restoring KanR function.

Direct detection of stalled ribosome complexes.
Both the KanR and the tmRNA-H immunoblot assays rely on tmRNA tagging to measure
levels of ribosome stalling. To analyze stalling directly, we performed in vitro translation
reactions and detected stalled ribosome complexes with toeprinting assays. Peptides
corresponding to the C-terminal 64 residues of the GST fusions described above were expressed
in a cell free transcription and translation system. The protein sequence includes the full 18-mer
stalling peptide, 22 residues of upstream GST sequence, and 24 residues downstream of the
predicted stalling site. A radiolabeled primer was annealed to the 3’-end of the transcript and
extended by reverse transcriptase. Analysis of the FxxYxIWPPP peptide translation reaction
revealed that reverse transcriptase is blocked 15-16 nt downstream of the first nucleotide in the
second Pro codon (Figure 2-8). In contrast, no toeprint was seen in the translation of the
FxxYxIWPAP peptide, consistent with the finding that mutation of the second Pro codon
dramatically reduces tagging (Figure 2-4C). As a control, the antibiotic thiostrepton was added to
trap ribosomes in the initiation stage. The disappearance of the toeprint in the FxxYxIWPPP
peptide reaction when thiostrepton is added demonstrates that the block in reverse transcription
is due to stalled ribosomes and not an artifact of mRNA sequence or structure. Together with the
mass spectrometry and immunoblot analyses of tmRNA tagging above, the toeprinting data
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demonstrate that ribosomes stall at the
FxxYxIWPPP sequence with the second
Pro codon in the ribosomal P site and the
third Pro codon in the A site.
Ribosome stalling leads to the
accumulation of peptidyl-tRNA within the
ribosome. We detected this trapped
peptidyl-tRNA by including [35S]methionine in the translation reaction. To
prevent hydrolysis of the peptidyl-tRNA,
we analyzed the products by gel
electrophoresis in an acidic buffer system.
Three lines of evidence support the
identification of stalled peptidyl-tRNA in
the FxxYxIWPPP peptide translation
reaction. First, the high molecular weight
band disappears upon treatment with
RNase and a far smaller band appears
(lanes 1 and 3). Secondly, the peptidyltRNA band remains in the aqueous layer
following phenol extraction, while the
other peptide bands disappear (lane 5).
Finally, the stalled peptidyl-tRNA is less

Figure 2-8. Direct detection of stalled ribosome
complexes. (A) Stalled ribosome complexes were formed
by cell-free translation of a template encoding the
FxxYxIWPPP sequence in a larger (64-mer) peptide. The
non-stalling Ala mutant FxxYxIWPAP served as a
negative control. The position of the ribosome was
determined by reverse transcription of the mRNA template
and C and G sequencing lanes were run alongside.
Thiostrepton was added in lanes four and six to trap the
ribosome in the initiation stage, demonstrating the
observed toe-print signal in lane three (marked by arrows)
requires translation of the stalling site. The nucleotide and
peptide sequence of the stalling site is shown at left. (B)
The [35S]-Met labeled products of the cell-free translation
of the FxxYxIWPPP peptide or the non-stalling
FxxYxIWPAP control were analyzed by Tricine-SDS
PAGE. Under these conditions, the peptidyl-tRNA linkage
is not hydrolyzed during electrophoresis. The stalled
peptidyl-tRNA disappears when treated with RNase (lane
3) but remains in the aqueous layer upon extraction with
phenol (lane 5).
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abundant in the FxxYxIWPAP peptide reaction (lane 2), where it is not expected to accumulate
as stalling is dramatically reduced.

Ribosomal interactions necessary for stalling.
To better understand the interactions between the nascent peptide and the ribosome that
lead to stalling, we quantified stalling levels with a series of ribosome mutants. This was done by
inserting the WPPPSI 18-mer after residue nine of lacZ and assaying for the activity of βgalactosidase. Our stalling peptides were compared to SecM and a non-stalling SecM control that
has an Ala substitution of
Stalling Peptide

LacZ activity

FSTPVWISQAQGIRAGP

8.2 +/– 2.0

FSTPVWISQAQGIRAGA

10812 +/– 1288

SLQKRLFQKYGIWPPPSI

117 +/– 14

SLQKRLFQKYGIWPAPSI

11172 +/– 3580

Table 2-2. Efficiency of stalling of the SecM and FxxYxIWPPP peptides.
The peptide sequences shown were inserted into the full-length lacZ gene
following the ninth codon. β-galactosidase activity is shown in Miller Units
along with the standard deviation. The Ala substitutions in bold are known
to prevent stalling in SecM (top) and FxxYxIWPPP (bottom).

the C-terminal Pro. As
shown by Nakatogawa and
Ito 95, the SecM peptide
dramatically inhibits lacZ
expression; β-galactosidase
activity is 1300-fold higher
in the non-stalling

Pro166Ala mutant (Table 2-2). The FxxYxIWPPP peptide also reduced lacZ expression, though
not as well as SecM (116 versus 8 Miller Units, respectively). Mutation of the second Pro residue
in FxxYxIWPPP results in 96-fold higher LacZ activity (Table 2-2), as expected by the reduction
in tagging observed above. These results show that this selected peptide sequence induces
stalling with high efficiency in a tmRNA-independent assay.
Ribosomal RNA mutations that map to the exit tunnel have been shown to affect stalling
on SecM and TnaC. Does the FxxYxIWPPP peptide interact with the same ribosomal RNA
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nucleotides? Using β-galactosidase
assays, we measured the effect of
several 23S rRNA mutations on
stalling on this peptide. 23S rRNA
mutants were overexpressed in the
presence of wild-type ribosomes.
Stalling was reduced seven-fold by
both the U2609A and U2609C
mutations (Figure 2-9), first studied in
connection with TnaC. The U754A
and A751 insertion mutations, in
contrast, showed no significant effect.
Surprisingly, the A2058G mutation
actually increases stalling eight-fold.

Figure 2-9. Effects of ribosome mutations on stalling on SecM
and FxxYxIWPPP. The SecM stalling sequence or the
WPPPSI 18-mer (see Table 2-2) were inserted after residue
nine of the full-length lacZ gene. β-galactosidase activity was
measured for the resulting SecM (white) and FxxYxIWPPP
(grey) lacZ fusions in a strain overexpressing mutant 23S
ribosomal RNA. The activity is reported in Miller Units. The
data represent at least three independent experiments. Error
bars represent the standard deviation.

Analysis of SecM-mediated
stalling with the same set of rRNA mutants yielded quite a different picture. Although the
U2609A mutation reduced stalling moderately (eight-fold), as it did with FxxYxIWPPP, the
U2609C mutation had little or no effect. Although the A751 insertion had no effect on
FxxYxIWPPP, this mutation decreased stalling on SecM six-fold. The most striking difference,
however, is that the A2058 mutation increases stalling on FxxYxIWPPP but is the most effective
at reducing stalling on SecM (78-fold), consistent with the findings of Nakatogawa and Ito 95.
These results show that while stalling on FxxYxIWPPP involves some of the same rRNA
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nucleotides as SecM or TnaC, a unique pattern of exit tunnel interactions is required for each
peptide.

Discussion
We performed a genetic selection to identify novel peptides that inhibit their own
synthesis. The selection is based on the ability of tmRNA to recognize and rescue stalled
ribosomes. When stalling occurs at the C-terminus of a truncated KanR protein, tmRNA encodes
the missing amino acids to complete the protein and restore KanR activity.
Our library covered roughly 10% of the theoretical diversity of a library of random
peptide hexamers. We recognize that some peptides that induce stalling were missed in our
selection because they were either too long or incompatible with the structure and activity of
KanR. We were surprised that consecutive rare codons, known to induce tagging 158,159, were not
isolated in the selection. We demonstrated that tagging does occur at SEPR* and SEPRRR by
immunoblot (Figure 2-7), but these sequences do not support KanR rescue by tmRNA. In the
case of SEPR*, tagging is probably at too low a level to support robust KanR activity. While
SEPRRR induces higher levels of tagging, the tag is probably not added at precisely the
necessary site to restore the KanR protein sequence properly. Alternatively, depletion of low
abundance tRNAs may be too taxing for cells. Immunoblot analysis of tagging is performed after
a brief period of strong overexpression. In contrast, our genetic selection requires overexpression
and tagging of KanR over long periods of cell growth and division.
The simplest and most common cause of stalling that we identified is inefficient
termination at Pro-Stop sequences. Several components need to be present to cause highefficiency stalling during termination. First, the opal stop codon (UGA) was strongly preferred
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over the other two stop codons in the selection. UGA is the least efficient stop codon, leading to
recoding events such as the programmed frameshift in the prfB gene encoding RF2 161,162. Proopal sequences cause strong +1 frameshifting at CCC_UGA 163 and significant levels of stalling
and tagging by tmRNA 100. As seen in previous studies, the residue upstream of Pro also affects
the efficiency of termination 100,164. In particular, Glu, Asp, and Pro were overrepresented in the
–2 position (e.g. Glu-Pro-opal) in our selectants. These results validate our selection and
demonstrate that survival in the KanR assay requires high levels of ribosome stalling.
A second set of sequences with the consensus GI(R/H)xPP show weaker activity
(surviving only at low stringency). It is interesting to note that the GI residues were not part of
the random hexamer library; by chance, these were the two amino acids immediately upstream.
These peptides appear to be subtle variants of the SecM sequence GIRAGP166. The GIRAPP
clone that matches SecM the most closely survives even at high stringency. This suggests that
some alterations in this critical SecM sequence are tolerated. Mutation of Arg163 to His or
replacing Ala164 with Asp, Ser, or Pro yields substantial though weaker stalling activity. These
results agree with the recent findings of Yap and Bernstein, who showed that the GIRAGP
sequence in SecM exhibits significant plasticity, with only Arg and Pro residues playing key
roles 108.
Our third class of selectants (containing FxxYxIWPP) stall with peptidyl-tRNA in the P
site. In the case of the WPPPSI clone, for example, the mass spectrometry data show that the
tmRNA tag is added after WPP. Yet the Ala scanning data show that the next residue (the third
Pro) is required for tagging, even though it does not react with the nascent peptide. We propose
that the aminoacyl-tRNA binds and remains unreacted in the A site, and that peptidyl-transferase
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activity is inhibited by FxxYxIWPP-containing peptides. This implicates changes in the
conformation of the PTC in the stalling mechanism.
The amino acid Pro plays two different roles in FxxYxIWPPP stalling. First, Pro-tRNA
acts as a poor peptidyl acceptor in the A site. It fails to react with the nascent peptide. Nalkylamino acids such as Pro have been shown to act as slow nucleophiles in the peptidyltransferase reaction 165. Using full-length tRNAs, Pavlov et al. demonstrated that the unnatural
Pro-tRNAPhe reacts 23-fold slower than Phe-tRNAPhe with initiation complexes containing fMettRNA. They speculate that this is due to steric constraints and lower nucleophilicity.
Interestingly, the rate of Pro reactivity is accelerated by the natural tRNAPro isoacceptor; ProtRNAPro only has a three to six-fold defect. A-site bound Pro-tRNA plays a role in stalling on
SecM and the 2A peptides found in viral genomes that stall at the Gly residue in the sequence
D(V/I)ExNPGP 166. One possible explanation for the necessity of Pro-tRNA is that the reduced
rate of peptidyl transfer to Pro gives the nascent peptide time to interact with the exit tunnel and
PTC, shifting the 23S rRNA to an inactive conformation 167.
Our results suggest that aminoacyl-tRNAs other than Pro-tRNA can induce stalling by
binding in the A site. WPPD and WPPW sequences were isolated from our selections, and
immunoblot analysis revealed that efficient tagging only occurs if the residue following WPP is
Pro, Asp, or Trp. While we cannot say for certain, it is probably binding of the amino acid that is
critical, not the codon or tRNA. The amino acid is the key component of Pro-tRNA in SecM; the
Pro analog azetidine dramatically reduces stalling 106. Likewise, the binding of free tryptophan
causes stalling on TnaC 99. A second explanation for the role of the A site aminoacyl-tRNA in
stalling is that amino acid-binding near the PTC changes the ribosome or peptide conformation.
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This possibility is supported by the finding that the SecM peptide undergoes a conformational
change in the tunnel upon Pro-tRNA binding in the A site 110.
If aminoacyl-tRNA is bound in the A site, how can tmRNA enter the stalled ribosomes to
release them and tag the nascent peptide? SecM, TnaC, and ErmCL (another stalling leader
peptide) are not tagged by tmRNA because the A site of the ribosome is occupied 94,96,116,154.
Stalling on these peptides must be determined by cellular conditions to regulate gene expression;
tmRNA would interfere with their biological function. But our selection and immunoblot assays
rely on tagging by tmRNA to detect stalling events. We propose that overexpression of
FxxYxIWPPP leads to depletion of Pro-tRNA by stalled ribosomes, creating a subset of
ribosomes stalled with empty A sites that are acted on by tmRNA. Overexpression of SecM
results in high levels of tagging 156,168 for exactly this reason 154. For both SecM and
FxxYxIWPPP, increasing tRNAPro levels abolishes tagging (Figure 2-7). At the same time, we
see that tRNA overexpression actually lowers GST levels, perhaps because stalling is more
robust with the tRNA in the A site and no GST-stalled ribosomes are released by tmRNA.
The second role of Pro in FxxYxIWPPP stalling is that of a poor peptidyl donor. Peptides
ending in Pro react with puromycin far slower than peptides ending in other amino acids 117,118. It
is the amino acid that inhibits peptidyl transfer, not the codon or tRNA—incorporation of Pro
analogs azetidine or thiaproline restore rapid reactivity 117. In uncatalyzed reactions, however,
Pro-tRNA is as reactive as other aminoacyl-tRNAs 169, suggesting that the reduced rate is not
purely due to the chemistry of prolyl-esters but the interaction of the Pro residue with the
ribosome. These findings suggest that the conformationally strained Pro side chain inhibits
ribosome activity 118. In nature, C-terminal Pro residues inhibit termination in proteins in TnaC
and in the UL4 gene of the mammalian virus CMV 170. It appears that the cyclic Pro residue
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interferes with conformational changes in the PTC that are required for both elongation and
termination.
The WPP-containing peptides stall ribosomes robustly: in the lacZ assay, the WPPPSI
18-mer sequence reduced activity nearly 100-fold over the WPAPSI mutant. The sequence
context has a great effect—upstream peptide sequences are required for high-efficiency tagging.
Tagging in the WPPPSI clone requires the consensus peptide sequence FxxYxIWPP. Phe7 and
Tyr10 are aromatic residues that may bind rRNA in the exit tunnel. At nine residues, the
FxxYxIWPP is the same length as the ErmCL peptide (MGIFSIFVI) when it stalls upon binding
of erythromycin in the nascent peptide exit tunnel 96. Shortening the ErmCL peptide by deleting
N-terminal residues reduces stalling significantly; this length may allow interaction with
elements farther into the tunnel, such as the L22 loop 96. The sequences of these four stalling
peptides are different, the only commonality being an Ile four residues from the P site in
FxxYxIWPP, ErmCL, and SecM.
Analysis of stalling levels with mutant ribosomes reveals nucleotides that are required for
efficient stalling on FxxYxIWPP peptides. A2058 is near the L4 / L22 constriction; the A2058G
mutation reduces stalling on SecM by nearly 80-fold, but it actually increases stalling on the
WPPPSI clone by eight-fold. Likewise, mutation of U2609 has different effects on these three
peptides. In TnaC, the U2609C mutant completely abolished stalling while U2609A only
affected it partially 94. SecM stalling is more reduced by the A mutant, while stalling on
FxxYxIWPPP is reduced by either the C or A mutant equally. These data show that stalling on
FxxYxIWPPP involves the same players as these other peptides, though the specifics of each
interaction vary, suggesting that the peptides bind differently in the tunnel.
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The plasticity of nascent peptide interactions with the PTC and exit tunnel is further
highlighted by our finding that stalling on the WPPDV* clone occurs both after WPP and during
termination. Presumably stalling requires upstream amino acids so the active sequence is
FxxYxIWPPDx*. If specific interactions with the tunnel and PTC are lined up properly with the
second Pro codon in the P site, it is difficult to imagine how they are aligned again to inhibit
termination after the peptide has moved two amino acids farther into the tunnel. We believe that
the simplest explanation for this is that the FxxYxIWPP sequence engenders a constrained
peptide conformation that promotes interaction with the tunnel at several possible sites. This
speculation is supported by the finding of Yap and Bernstein that SecM mutants containing ProPro dipeptides (e.g. PPIRAGP) induce stalling even in the absence of the upstream arrest motif
elements 108.
Like SecM and TnaC, FxxYxIWPP-containing sequences stall due to nascent peptide
interactions in the PTC and exit tunnel, with an effector bound in the A site. In spite of this
common mechanism, these peptides rely on different ligands in the A site and different
interactions with the exit tunnel to inhibit peptidyl transfer or hydrolysis. The lack of sequence
similarity in these peptides argues that many solutions exist and that regulation of gene
expression by nascent peptides may be more common than the few examples characterized so
far. Further characterization of the mechanism of stalling on WPP-containing sequences and its
biological significance is ongoing.
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Experimental Procedures
Library creation
The initial 18 nt library was created by amplifying the truncated kanR gene by PCR with
the forward primer CATATGGCTAGCATGAGCCATATTCAACGGGAAAC and the
degenerate reverse primer
CGAAAGGGTACCN18ATTACCATATTTTTGAAAAAGCCGTTTCTG. 18 random nt (six
codons) were added to the 3’-end of kanR following residue 253. To create a second library
lacking stop codons in codons four through six, the random region (N18) in the degenerate primer
was replaced by (NNB)3N9 where B is a mix of C, G, and T phosphoramidites. The PCR
products were cloned into pBAD-KT2 155 with NheI and BamHI and the resulting plasmids were
amplified in DH10B. The libraries were then selected in X90 ssrA::cat as described 155 in media
containing 15 μg/mL kanamycin at either 25 or 37 °C. The KanR fusion sequences from
surviving colonies were amplified, sequenced, and recloned to verify their activities.

Mass spectrometry
The pGEX-3X vector was amplified with inverse PCR to create new restriction sites
using the primers AGAGTAGCTAGCACGACCTTCGATCAGATCCG and
AGAGTAGCATGCTTGACTGACGATCTGCCTCG. The library cassette was amplified by
PCR from 12 residues upstream of the six random codons to the stop codon downstream,
including the nucleotide sequence encoding
SLQKRLFQKYGIxxxxxxGYRGSRVDRQAWLFWRMREDFQPDTD*, using the primers
AGAGTAGCTAGCTCATTACAGAAACGGCTTTTTC and
AGAGTAGCATGCTTTAATCTGTATCAGGCTGAAAATC. The resulting PCR products were
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digested with NheI and SphI and ligated to create the pGEX-WPPPSI, WPPDV*, and WPPWYR
vectors.
These plasmids and pCH201 (expressing tmRNA-H encoding a His6 tag 101) were
introduced into X-90 ssrA::cat. Cultures were grown to mid-log phase and induced with 1 mM
IPTG for 2.5 h. The cells were then harvested and lysed in B-PER reagent (Thermo-scientific)
and the cell lysate was cleared in an SS-34 rotor at 15,000 RPM for 20 minutes. His-tagged GST
was purified on a Ni-NTA agarose resin from the supernatant. 50 µg of protein was acetone
precipitated and digested with trypsin for 14 h at 37 °C. Tryptic fragments were purified again in
a Ni-NTA slurry and the peptides were loaded on a reverse-phase ZipTip column, spotted on a
MALDI-plate and overlayed with an alpha-CHC matrix (Agilent Technology). Samples were
analyzed with a QSTAR Pulsar QqTOF mass spectrometer.

Immunoblot assays
Ala mutations were introduced by PCR into the pGEX-WPPPSI vector described above.
X-90 ssrA::cat cells were transformed with a GST vector together with pCH201 (expressing
tmRNA-H). Overnight cultures were diluted to OD600 of 0.1, grown to OD600 = 0.5, induced for 2
h with 1 mM IPTG, and pelleted. The pellets were resuspended, lysed in SDS-lysis buffer, and
quantitated. Equal amounts of protein were separated by 12% SDS-PAGE, transferred to a
PVDF membrane, and analyzed with mouse anti-His6 and rabbit anti-GST antibodies (Cell
Signaling Technology) as detected by fluorescently labeled anti-mouse and goat anti-rabbit
secondary antibodies (LICOR biosciences). Images were taken on a Licor Odyssey IR scanner.
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Cell-free translation
Templates were prepared by PCR with the following primers:
CTGTACATTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATATGCA
GGGCTGGCAAGCCAC and
GGTTATAATGAATTTTGCTTATTAACCAGCCAAGCTTGCCGGTC, adding the T7
promoter and a binding site for the NV1 primer. The PURExpress cell-free transcriptiontranslation system (New England Biolabs) was used for in vitro protein synthesis. Briefly, 0.2
pmol template was combined on ice with 2.5 µl Solution A and 1 µl Solution B along with either
0.5 µl DMSO (5%) or thiostrepton (0.5 mM in 5% DMSO) and then incubated at 37 ºC for 30
min. 1 pmol of [32P]-ATP labeled NV1 primer (GGTTATAATGAATTTTGCTTATTAAC) was
added and reverse transcription performed as described 96. Samples were then extracted with
phenol and chloroform, precipitated with ethanol, separated by 6% denaturing PAGE with C and
G sequencing lanes, and visualized with a phosphoimager. To detect peptidyl-tRNA in stalled
complexes, [35S]-Met was added to the translation reactions. Samples were analyzed by TricineSDS PAGE and visualized with a phosphorimager.

Miller Assays
The reporter plasmid was created by inserting the WPPPSI stalling sequence plus 12
upstream residues after the ninth codon of full-length lacZ (derived from pNH122 95). The SecM
sequence FSTPVWISQAQGIRAGP was used as a control. Cells bearing a lacZ plasmid and a
ribosomal mutant plasmid were induced with 1 mM IPTG at mid-log phase and analyzed for βgalactosidase activity using ONPG as described 171.
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Chapter 3. Nascent peptides that block protein synthesis in bacteria.
Author’s Note: This chapter details a study in the discovery and characterization of novel
stalling peptides and was published in the Proceedings of the National Academy of Sciences in
2013 172.

Abstract
Although the ribosome is a very general catalyst, it cannot synthesize all protein
sequences equally well. Ribosomes stall on the SecM leader peptide, for example, in order to
regulate expression of a downstream gene. Using a genetic selection in E. coli, we identified
novel nascent peptide motifs that stall ribosomes. Kinetic studies show that some nascent
peptides dramatically inhibit rates of peptide release by release factors. We find that residues
upstream of the minimal stalling motif can either enhance or suppress this effect. In other stalling
motifs, peptidyl transfer to certain aminoacyl-tRNAs is inhibited. In particular, three consecutive
Pro codons pose a challenge for elongating ribosomes. Translation factor EF-P, which alleviates
pausing at polyproline sequences, has little or no effect on other stalling peptides. The motifs that
we identified are underrepresented in bacterial proteomes and show evidence of stalling on
endogenous E. coli proteins.

Introduction
We commonly think of the ribosome as capable of synthesizing any protein, regardless of
its sequence. But it turns out that some nascent peptides contain stalling motifs that inhibit core
functions of the ribosome 50,126. Why would a protein evolve to arrest its own synthesis? In one
of the best characterized examples, stalling in the SecM leader peptide up-regulates translation of
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SecA, a protein encoded downstream on the same mRNA 95. Known stalling motifs have
typically been identified based on their function as genetic switches, regulating gene expression
in response to levels of protein translocation factors 88,95 or changes in the concentration of small
molecule metabolites 99,126. Further understanding of the scope and mechanism of ribosome
stalling may yield additional insight into programmed ribosome stalling events that regulate gene
expression in organisms from bacteria to humans 144,173. In addition, by fine-tuning the rate of
protein synthesis, stalling peptides may affect protein folding and function, as reported
previously with rare codons 174,175.
Analyses of natural motifs have identified three sites of interaction within the ribosome
that lead to stalling. First, conserved residues at a motif’s N-terminus often interact with the
ribosome near a constriction in the exit tunnel between proteins L4 and L22. Ribosomal
mutations near this site were isolated in genetic screens for reduced levels of stalling 94,95.
Second, conserved residues near a motif’s C-terminus interact with nucleotides surrounding the
ribosomal active site, the peptidyl-transferase center or PTC 96. Third, some motifs encode a
specific aminoacyl-tRNA that acts as a poor peptidyl acceptor when bound in the A site 97,98. The
SecM consensus motif (FxxxxWIxxxxGIRAGP) showcases all three of these interactions, each
of which contributes to stalling. A Trp side chain eleven residues upstream of the stall site binds
near the constriction in the tunnel, the Arg residue three residues upstream is positioned close to
the PTC 95, and Pro-tRNA binds in the A site, but does not react 116. A recent cryo-EM structure
of the stalled SecM complex directly visualized these interactions and begins to provide some
molecular rationale for how stalling is induced 109.
A full understanding of the molecular mechanism underlying ribosome stalling has not
been forthcoming because of the complexity of natural stalling motifs. In each case, stalling is
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reversible and is controlled by changes in the cellular environment. Stalling in TnaC, for
example, is induced by high tryptophan concentrations through the binding of free tryptophan at
an unknown site within the ribosome 99. Given that a single stalling motif interacts with the
ribosome at multiple sites, deconvoluting the role of the conserved residues in the peptide is
difficult enough without the added complexity of small molecule binding. Moreover, even at
well-validated sites of interaction, such as the L4/L22 constriction, different stalling motifs
appear to work via different mechanisms. Ribosomal mutations that reduce stalling by one motif
may have no effect or even increase stalling by another 98,114. These complexities make it
challenging to obtain general conclusions about the mechanism of ribosome stalling by natural
stalling peptides.
To better characterize the scope and mechanism of ribosome stalling, we set out to find a
series of artificial motifs that inhibit translation during their own synthesis. We reasoned that by
selecting directly for stalling peptides, we might find new motifs that are simpler than natural
ones because they are not required to stall reversibly or to regulate downstream genes. The fact
that only a few residues are essential for stalling by SecM, TnaC, and ErmCL 50, and the fact that
these motifs share little or no sequence similarity, led us to believe that more stalling motifs exist
but have not yet been identified. To this end, we developed a powerful genetic selection in E.
coli that ties stalling on a reporter protein to cellular survival.
Here we report several new stalling motifs, some that block peptide release during
translational termination and others that block peptidyl transfer. Because these motifs are short,
we are able for the first time to recapitulate the stalling phenomenon using pre-steady state
kinetic assays, an important step towards achieving mechanistic insights. Of particular interest,
we show that polyproline sequences induce ribosome stalling. The translation factor EF-P, which
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alleviates stalling at polyproline stretches, does not affect the other short motifs we identified,
further defining its scope of action. Finally, our analysis of bacterial proteomes reveals that
stalling motifs are underrepresented, implying that they have been selected against. Where they
do occur in endogenous E. coli proteins, pausing is detectable by ribosome profiling. These
findings argue that these short motifs have an impact on protein synthesis in bacteria.

Results
A genetic selection for stalling motifs
We previously reported the first systematic search for nascent polypeptide motifs that
induce ribosome stalling 98. In that study, we identified stalling motifs from random libraries
using a genetic selection based on tmRNA, part of the machinery that rescues stalled ribosomes
in bacteria 68,69. tmRNA recognizes stalled ribosomes and directs the addition of a short peptide
tag to the nascent polypeptide; this allowed us to detect stalling events in living cells. We linked
tmRNA tagging of the KanR protein to cellular survival and identified a novel stalling motif,
FxxYxIWPPP 98. Because the selection depended on functional KanR, we suspect that many
motifs were missed. To survive the selection, a motif within the KanR sequence had to induce
ribosome stalling but not interfere with the enzyme’s folding and activity.
To overcome these limitations, we developed a new selection that allows more variability
in the motif length and sequence than was possible in our earlier study. We established a variant
of the bacterial two-hybrid system 176,177 that links stalling with cellular survival (Figure 3-1A).
In this system, cells cannot synthesize histidine unless transcription of a HIS3 reporter gene is
activated. Driven from a weak promoter, HIS3 expression is insufficient for cellular survival
unless RNA polymerase is recruited to the transcriptional start site by a DNA-binding protein, in
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this case a modified form of lambda
cI. We encoded stalling motifs at the
C-terminus of the full-length cI
protein, where they have little or no
effect on protein structure or function.
When ribosomes stall during cI
synthesis, the protein is tagged by
tmRNA and can therefore recruit RNA
polymerase fused to SspB. The SspB
protein binds specifically to the
peptide tag encoded by tmRNA 178;
the resulting interaction between
tagged cI and RpoA-SspB leads to
Figure 3-1. Two-hybrid selection for nascent peptides that stall
ribosomes. A) The lambda cI protein binds to DNA upstream
of the HIS3 gene. When ribosomes stall during cI synthesis, a
short tag is added to the protein by tmRNA, recruiting an SspBRNA polymerase fusion protein. In this way, ribosome stalling
in cI activates transcription of HIS3, restoring the cell’s ability
to synthesize histidine and survive on minimal media. B) Four
cI constructs were tested for their ability to recruit SspB-RpoA,
activate HIS3, and grow on media lacking histidine: cI
translationally fused to the tmRNA tag; cI fused to two known
inducers of stalling, Glu-Pro-stop and an mRNA lacking a stop
codon; and cI with no stalling motif.

recruitment of RNA polymerase to the
HIS3 gene, transcriptional activation,
and survival of cells on selective
media lacking histidine. Note that the
natural function of SspB is to deliver
tagged proteins to the ClpXP protease

for destruction 178. By including only the tag-binding domain of SspB (residues 1-117), not the
ClpXP binding domain 179, and by changing the last two residues of the tmRNA tag to DD 159,
we prevent degradation of tagged cI.
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We validated the selection with four control cI constructs. First, expression of cI alone,
with no stalling motif, does not support growth on minimal media lacking histidine, because cI is
not tagged by tmRNA and thus does not bind RpoA-SspB. When the modified tmRNA tag is
translationally fused to the C-terminus of cI in a second construct, the resulting protein recruits
RpoA-SspB and activates HIS3 transcription, leading to robust survival on selective media (cItag, Figure 3-1B). Furthermore, we showed that known stalling motifs survive the selection by
generating sufficient levels of tmRNA-tagged cI. We added Glu-Pro-stop to the C-terminus of cI;
this short sequence was previously shown to induce high levels of stalling and tagging in vivo 100.
In another construct, we expressed cI on a non-stop mRNA, where ribosomes translate to the 3’end of the message because there is no stop codon. These ribosomes are effectively stalled and
are known to be rescued by tmRNA 81. Both of these constructs support cellular survival on
selective media that is as robust as the cI-tag translational fusion (Figure 3-1B). These data
demonstrate that the selection successfully ties ribosome stalling during cI synthesis with cellular
survival on selective media.
To identify novel stalling motifs, we fused twenty random codons onto the C-terminus of
cI and subjected the resulting library to the two-hybrid selection. Although we could only sample
a tiny sliver of sequence space (~108 clones out of ~1026 possibilities), we found that a
significant fraction of the library survived the selection, roughly 1 in 104 colonies plated. This
high rate of survival suggests that it is remarkably easy to find sequences that induce stalling and
tagging by tmRNA. Because two-hybrid systems are notoriously rich in false positives, we
performed a secondary screen in which lysates from 150 colonies were immunoblotted with
antibodies against the tmRNA-DD tag 180. Over a quarter (41/150) showed significant levels of
tmRNA-tagged cI protein, suggesting that they survived the selection because ribosome stalling
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occurred during cI synthesis. Known causes of stalling could be attributed to 21 of these 41
clones. The most common motif was Pro-stop at the C-terminus of the cI protein (18 clones). Pro
is known to induce stalling during termination 100. In contrast, clusters of rare codons, another
known cause of stalling, were found in only three clones. For the remaining 20, no known cause
of stalling was apparent, though tagged cI was clearly being produced. Presumably something in
the variable region led to tagging, but the site of stalling and the residues responsible for stalling
had to be identified for each clone by additional experiments.

Determination of the site of stalling and the consensus stalling motifs
We used two different approaches to determine the site of stalling in clones that survived
the two-hybrid selection. First, we selected ten clones that showed the highest levels of tagging
in the immunoblot assay above and performed toeprinting assays to directly detect stalling in
these clones during in vitro translation. A radiolabeled primer was annealed to the 3’-end of the
cI transcript and extended by reverse transcriptase. When it encounters a stalled ribosome,
reverse transcriptase stops 15–16 nt downstream of the first nucleotide in the P site codon. This
reveals which codon is in the P site when stalling occurs. As a control, the antibiotic thiostrepton
was added to trap ribosomes in the initiation stage. The disappearance of the toeprint band when
thiostrepton is added demonstrates that the block in reverse transcription is due to stalled
ribosomes and not an artifact of mRNA sequence or structure.
The toeprinting results show that the ten clones fall into two classes. Some stall with a
stop codon in the A site, indicating that termination is inhibited; toeprinting data for three
examples of this class, T1-T3, are shown in Figure 3-2A. Others stall with a sense codon in the A
site, indicating that elongation is inhibited; toeprinting data are also shown for two such motifs,
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Figure 3-2. Stalling motifs that block termination (T1-T3) or elongation (E1, E2). A) Stalling sites for
five motifs were determined by toeprinting assays. Blocks in cDNA synthesis are marked with arrows.
The antibiotic thiostrepton traps ribosomes in initiation complexes; bands seen in both treated and
untreated lanes are reverse transcriptase artifacts. B) Key amino acids in each motif are highlighted in
bold. The codon labeled in yellow is positioned in the P site of the stalled ribosome. The site of stalling
in vivo was confirmed by purifying tagged cI, digesting the protein with trypsin, and determining the
mass of the C-terminal peptide (highlighted in blue) by MALDI-MS.

E1 and E2. All ten sequences and their stalling sites are given in Table 3-1. The fact that stalling
was recapitulated in a reconstituted translation system (the PURE system) rules out alternate
explanations such as mRNA cleavage or degradation that might have led to tagging by tmRNA
and survival in the two-hybrid selection.
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Motif

Elongation

E1

S L K V V R Q T Y Y P P R L S R S P P M *

E2

S V E T G R V R F L L E H G P P I A C I *

E3

E Q V I N L G P D E E W G A T R K C V H *

E4

C E I K G Y L L P L K I A P Y S S L A K *

E5

K F G G T I S C M Q S L R D I L E L A A *

E6

F Y G L L S D G G G K K R V N I P W S L *
Termination

T1

L T K K G W E K R E E L L W I L F H G T *

T2

G G I R G S Y V L R T P N G G F W N S G *

T3

R V I I Q T E E V W I K K Q A K H D T S *

T4

R P H Q R F V I P H V G F D *

Table 3-1. Sequence of ten stalling motifs. The underlined codon (red) is found in the P site in toeprinting
analyses. The full sequence is shown but it is likely that not all of these residues are essential for stalling.

We performed a second series of experiments to detect where stalling and tmRNA
tagging occurred in vivo. This was done by analyzing tagged cI protein by mass spectrometry;
the residue upstream of the tag corresponds to the codon positioned in the P site in the stalling
event. We analyzed the five clones depicted in Figure 3-2A because they gave strong toeprints.
We expressed each cI clone with a modified tmRNA that encodes six His residues in its tag
sequence 181. Tagged cI was purified over Ni-NTA resin and digested with trypsin. The peptide
fragment corresponding to the C-terminus of the tagged cI protein contains the altered tmRNA
tag and a few upstream residues, depending on where trypsin cleavage occurs. This peptide was
enriched on an Ni-NTA resin and its mass was determined by MALDI-MS. The amino acid
sequence of the peptide was also confirmed by tandem MS/MS. The five peptides and their
masses are shown in Figure 3-2B. In each case, the residue immediately before the tag
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corresponds to the codon in the P site in the stalled complex in the toeprinting assays, confirming
that stalling occurs at the same site in vitro and in vivo.
We determined which residues in these five stalling motifs are required for stalling
through a process of mutagenesis and reselection. We introduced mutations into the 20 codons of
a given motif at a frequency of 30% per nucleotide. The resulting library was subjected to the
two-hybrid selection and a consensus sequence of surviving clones was determined. Taken
together, the toeprinting, mass spectrometry, and reselection experiments define five new stalling
motifs, their stalling sites, and consensus sequences. Data from the motifs that inhibit termination
(T1-T3) will be discussed first, followed by the data for the elongation motifs (E1 and E2).

Stalling motifs that inhibit termination
The T1 motif contains the consensus residues WILFxxT-stop, where x is any amino acid.
When the T1 sequence was subjected to mutagenesis and reselection, the highest enrichment was
seen at the C-terminal residue, Thr, with P < 10-5 (Figure 3-3A). We found that mutation of this
Thr to Ala abolishes stalling in the toeprinting assay (Figure 3-3B). The Trp residue seven
codons back from the stop codon is also selected for (P < 10-4); it lies in a stretch of hydrophobic
residues. Ala substitutions have little or no effect on stalling by this motif, with the exception of
the Phe residue at the –4 position. In contrast, Glu substitutions often reduce stalling efficiency,
presumably by blocking hydrophobic interactions between these residues and the ribosomal exit
tunnel. It appears that stalling in the T1 motif is induced by the C-terminal Thr residue and this
stretch of upstream hydrophobic and aromatic residues.
The T2 motif is FWNSG-stop. Although two additional sites of stalling are detectable in
the toeprinting assay (Figure 3-2A), only trace amounts of the corresponding peptides were
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detected in the MS analysis. This
suggests that stalling during
termination was the predominant
cause of tmRNA tagging in vivo.
The mutagenesis and reselection
experiments show conservation of
the final four codons WNSG (each
with P < 0.01), though some
flexibility is evident. Asn and Asp
occur at the –3 position and Ser
and Thr occur at the –2 position
(Figure 3-3A). We found that the
Asn to Asp mutation and the Ser to
Thr mutation both retain
significant stalling activity,
whereas replacing any residue in
the FWNSG motif with Ala
abolishes stalling in the toeprinting
assay (Figure 3-3B). These

Figure 3-3. Key residues in motifs that block termination. A) The
consensus sequence of each motif was determined by randomizing
all twenty codons at 30% per nucleotide and subjecting the resulting
library to the two-hybrid selection. B) Toeprinting analyses of a
series of mutants for each motif. The original residues are shown
above the line and the substitutions are given below. A thiostreptontreated control reaction (TS) is shown in the left lane.

mutations can also occur in
combination: changing the final three amino acids from NSG to DTG had little or no effect on
stalling efficiency.
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The T3 motif, DTS-stop, is sharply defined by the consensus sequence from the
mutagenesis and reselection data. Each codon is conserved with a P value < 0.001 (Figure 3-3A).
While the Asp and Thr codons are invariant, in a few surviving clones the final Ser codon is
replaced with Gly. Toeprinting analyses confirm that the Ser to Gly mutation has little or no
effect, whereas mutating any residue in the DTS sequence to Ala abolishes stalling (Figure 33B). As the T2 motif was able to accommodate either Asp or Asn at the first codon and Thr or
Ser at the second, we reasoned that T3 might also exhibit some sequence plasticity. We found,
however, that both the Asp to Asn and the Thr to Ser mutations strongly inhibit stalling. We
conclude that DTS-stop or DTG-stop is sufficient for stalling ribosomes but that NSG-stop stalls
poorly without the upstream FW residues found in T2. In support of this conclusion, we found
that replacing the last three residues of T1 with DTS yields robust stalling, whereas replacing
them with NSG does not (Figure 3-3B). Finally, we note that DTS only stalls during the
termination step, not during elongation. Although stalling occurs at both UAG (recognized by
RF1) and UGA (recognized by RF2) stop codons, mutating the stop codon to an Ala sense codon
abolishes stalling (Figure 3-3B). Taken together, our analysis of the T1-T3 motifs show that
short, polar peptides can induce ribosome stalling at stop codons.

Stalling motifs that inhibit elongation
Characterization of the two elongation motifs with the strongest toeprints, E1 and E2,
revealed that the amino acid Pro plays a dual role in both motifs. The toeprinting data indicate
that stalling occurs with the first Pro codon in the P site and the second Pro codon in the A site
(Figure 3-2A). Analysis of tmRNA-tagged cI protein by mass spectrometry confirmed that
ribosomes stall in this same position in vivo (Figure 3-2B). Randomization of the E1 motif and
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reselection define the key residues
as RxPP, where x can be Ser, Ala,
Gly, and Pro (Figure 3-4A).
Similarly, the consensus E2 motif
is HGPP. In both cases, the two
Pro codons are invariant, and
mutation of either to Ala
completely abolishes stalling in
toeprinting assays (Figure 3-4B).
An analysis of the nucleotide
sequence of surviving clones in the
E2 library shows that there is
strong selection for the first two
nucleotides of each Pro codon, but
not for the third (Figure 3-4A).
This observation suggests that the
amino acid is critical, not the
nucleotide sequence, or even a
particular tRNA.
While these two motifs
have clear similarities, a subtle

Figure 3-4. Key residues in motifs that block elongation. A) The
consensus sequence of the E1 and E2 motifs was determined
through random mutagenesis and reselection. In addition, the
nucleotide consensus for the HGPP codons is shown below E2. B)
Toeprinting assays reveal the effects of substitutions in the E1 motif
(RxPP), left, and the E2 motif (HGPP), right. C) Toeprinting assays
of E1 and E2, including the minimal motif alone (4), the minimal
motif plus seven additional upstream codons (11), and the fulllength construct (FL). Ch1 is a chimera containing the minimal
motif of E1 (RSPP) with seven upstream codons taken from E2.
Ch2 corresponds to the minimal motif of E2 (HGPP) with seven
upstream codons from E1.

context dependence arises from residues upstream of the consensus motif. At first glance, it
seems that E1 and E2 are both examples of the same family, R/HxPP, where x is a small amino
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acid. The first residue (R or H) is critical for both motifs: stalling is lost when it is mutated to
Ala. However, replacing the Arg residue in E1 with His significantly reduced stalling levels, as
did replacing the His residue of E2 with Arg (Figure 3-4B). We thought that the requirement for
a particular residue (Arg or His) might arise from the peptide context; perhaps R/HxPP is
sufficient for stalling, but the upstream sequence imposes a specific requirement for either Arg or
His. In support of this idea, we found that the minimal motifs of E1 (RSPP) and E2 (HGPP)
induce robust stalling, as strong as the original 20-codon sequence (compare the lanes labeled 4
and FL in Figure 3-4C). This demonstrates that no upstream residues are necessary. We then
created chimeras containing elements of both motifs. In Ch1, the seven residues upstream of the
E2 motif were put upstream of the minimal E1 motif, RxPP. As shown in Figure 3-4C, the
toeprint was dramatically reduced, indicating that these additional seven residues block stalling
at the minimal E1 motif. Likewise, stalling was inhibited in the Ch2 chimera, where the seven
residues upstream of the E1 motif were added to the N-terminus of the minimal E2 motif, HGPP.
These findings show that secondary elements in the extra seven residues somehow restrict which
residues work in the minimal motif, making the sequence specific for either Arg or His.
Not only is stalling by the E1 motif sensitive to the upstream peptide sequence, it is also
sensitive to the length of the nascent polypeptide. Although ribosomes stall robustly on the
minimal E1 sequence RSPP, stalling is dramatically reduced when a longer truncated form of the
E1 motif is translated, YYPPRLSRSPP (compare lanes labeled 4 and 11, Figure 3-4C). Note that
we have not altered the motif sequence; this truncated form is part of the full motif. The
explanation for this paradox may be that the RSPP residues cannot achieve the right
conformation in the context of the longer YYPPRLSRSPP sequence. In the context of the full
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motif, however, the peptide conformation permits productive stalling; in effect, the stalling
suppressor is suppressed.

The nascent peptide dramatically influences rates of peptide release and peptidyl transfer
One limitation in the study of ribosome stalling has been the lack of biochemical tools to
probe the mechanism. Because they are short, simple, and robust, the motifs defined above
enabled us to recapitulate stalling in pre-steady state kinetic assays 60,182,183. For example, we
observed inhibition of peptide release on the T3 motif, DTS-stop. From purified components, we
assembled ribosome complexes with MDTS peptidyl-tRNA bound in the P site and the UAA
stop codon poised in the A site. We reacted this complex with saturating concentrations of RF1
and measured the rate of release of the peptide from its tRNA. We found that this rate was quite
slow, 0.006 s–1.
Peptides containing single Ala substitutions (MATS, MDAS, MDTA) were released
about 10-fold faster than the original MDTS peptide (Figure 3-5A). This corroborates the
consensus sequence and toeprinting data, indicating that each of these three residues is important
for stalling by the T3 motif. In addition, we found that although Phe substitutions at the first two
positions yielded a similar 10-fold decrease in stalling, changing the final residue to Phe
decreased stalling by 70-fold. We speculate that the larger Phe side chain prevents Asp and Thr
from making necessary contacts due to steric effects or conformational changes in the peptide.
In considering the importance of the size and geometry of the final residue, we wondered
about the effect of Pro on termination rates. In this selection and in previous studies 98,100,
proteins ending in Glu-Pro, Asp-Pro, and Pro-Pro were found to induce high levels of stalling
and tagging by tmRNA in vivo. We measured the rate of release of the MEP peptide by RF1 and

74

found it to be 0.006 s–1, about the
same as MDTS. Changing the last
residue from Pro to Phe increased
the rate of release 275-fold (MEF,
Figure 3-5B), highlighting the
importance of Pro at the final
position. The –2 position is also
critical: replacing Glu with Arg led
to a 190-fold rate increase (MRP,
Figure 3-5B). These data are
consistent with earlier findings
that when a protein ends in Pro,
tagging by tmRNA is lowest when
Figure 3-5. Pre-steady state kinetic analysis of ribosome stalling. A)
A ribosome complex containing MDTS-peptidyl-tRNA in the P site
and the UAA stop codon in the A site was reacted with RF1 to
determine the rate of peptidyl-tRNA hydrolysis. Ala (grey) and Phe
(black) mutants were characterized to test the contribution of each
residue in the DTS motif. B) A ribosome complex containing MEPpeptidyl-tRNA or derivatives was reacted with RF1. C) Peptidyltransfer rates for the E1 motif were obtained by reacting ribosome
nascent chain complexes with excess ternary complex composed of
Pro- or Phe-tRNA, EF-Tu, and GTP.

Arg is found in the –2 position 100.
Taken together, these data show
that the peptide sequence, and in
particular the final three amino
acids of the protein, can have a

profound effect on the rate of release by RF1. The effect is primarily on catalysis, not binding, as
saturating concentrations of RF1 were used (representative rate data are shown in Figure 3-6).
In addition to these studies on peptide release, we also recapitulated stalling during
peptidyl transfer in a pre-steady state kinetic assay 183. To further characterize the E1 motif,
RxPP, we assembled ribosome complexes on an mRNA encoding MRAPP. A ribosome complex
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containing MRA peptidyl-tRNA was
formed, purified, and reacted with a
ternary complex of Pro-tRNA, EF-Tu,
and GTP. Products were resolved by
electrophoretic TLC, and, importantly,
the appearance of MRAP and MRAPP
could be distinguished. The rate of
peptidyl transfer of MRAP to ProtRNA was determined to be 0.003 s–1.
In contrast, we found that the rate of
peptidyl transfer of MRAP to PhetRNA was 5.5 s-1, nearly 2,000-fold
faster (Figure 3-5C). These data show
that the incoming aminoacyl-tRNA in
the A site can have dramatic effects on
peptidyl-transfer rates. Taken together,

Figure 3-6. Representative rate profiles from peptide release
(top) and peptidyl transfer reactions (bottom). A) Ribosome
complexes containing a tripeptidyl-tRNA in the P site and a
UAA stop codon in the A site were reacted with release factor
1. The fraction of the peptidyl-tRNA that is hydrolyzed is
plotted against time. Curves for MEP (red), MEF (blue), and
MRP (black) are shown. B) Ribosome complexes containing a
peptidyl-tRNA in the P site were reacted with a ternary
complex of EF-Tu, GTP, and aminoacyl-tRNA. The fraction of
tetrapeptide converted to pentapeptide is plotted against time.
The reaction with Phe-tRNA is shown in blue and Pro-tRNA is
shown in red.

these studies of the kinetics of peptide
release and peptidyl transfer demonstrate the value of these motifs in providing tools for future
mechanistic studies.

Stalling occurs at various PPX motifs in vitro
It is striking that peptidyl transfer is blocked in the E1 and E2 motifs by such short
peptide sequences. This led us to ask if a motif we had identified previously, FxxYxIWPPP,
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might also contain a shorter minimal motif capable of inducing stalling 98. To test this, we
monitored stalling using toeprinting assays with various derivatives of the original FxxYxIWPPP
motif. As reported previously, stalling in the full-length sequence occurs with the second Pro
codon in the P site and the third Pro codon in the A site. Mutation of the second Pro to Ala
abolishes stalling (Figure 3-7A).
Additional analysis of the FxxYxIWPPP motif established that three Pro codons are
sufficient to induce a high level of stalling in toeprinting assays. Two strong pauses are detected
during translation of WPPP and APPP; these correspond to either the first or second Pro codon
positioned in the P site (Figure 3-7A). Pausing at these two sites is interdependent: mutation of
any of the three Pro codons to Ala reduces stalling at both sites dramatically. Although a low
level of stalling is detectable with two consecutive Pro codons in the WAPP and WPPA mutants,
these data argue that three Pro codons are necessary and sufficient for robust stalling.
Our previous in vivo studies on the FxxYxIWPPP motif indicated that, in addition to ProtRNA, other aminoacyl-tRNAs can also act as poor peptidyl acceptors when bound in the A site,
prohibiting peptidyl transfer 98. When the third Pro codon is mutated to Trp or Asp (e.g.
FxxYxIWPPW), robust ribosome stalling and tmRNA tagging occur in vivo. We revisited this
phenomenon in the context of the shorter, core PPP motif, testing all twenty amino acids as
peptidyl acceptors in toeprinting assays. We found that robust stalling by PP(X) occurs when X
is an Asn, Asp, Glu, Gly, Pro, or Trp codon (Figure 3-7B). These aminoacyl-tRNAs act as poor
peptidyl acceptors for peptides ending in Pro-Pro, further defining the scope of this phenomenon.
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Figure 3-7. EF-P alleviates stalling at polyproline stretches but not other stalling motifs. A) Toeprinting analyses
of Ala substitutions in the FxxYxIWPPP motif and a truncated derivative, WPPP. B) Analysis of pausing in the
20 PPX motifs. The arrow points to the toeprint with the second Pro codon in the P site and the X codon in the A
site. C) Toeprinting analyses of three endogenous E. coli genes with polyproline stretches: lepA, ligT, and amiB.
D) Various motifs were translated in the presence or absence of purified EF-P; the relevant toeprint is labeled
with an arrow. E) MWPPP and MFQKYGIWPPP were translated in vitro with [35S]-methionine in the presence
or absence of EF-P. Peptidyl-tRNA accumulates in stalled ribosomes; it was visualized by SDS-PAGE and
autoradiography after 3 or 7 minute reactions.
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Stalling at polyproline stretches in endogenous E. coli proteins
Due to the simple nature of these motifs, they occur often in endogenous proteins; we
next asked how these proteins can be translated in vivo given the strong pauses that occur in
vitro. The E. coli MG1655 genome encodes ~100 proteins containing three or more consecutive
Pro codons, and even more if Asn, Asp, Glu, Gly, or Trp are allowed at the third position.
Perhaps the context of the motif within the proteins prohibits stalling, as we have seen with the
E1 and E2 when upstream sequences are swapped. To address this question, we performed in
vitro translation of LepA and LigT, both of which contain PPP motifs, and AmiB, a protein with
eight consecutive Pro codons. As shown in Figure 3-7C, toeprinting analyses reveal that protein
synthesis of LepA and LigT does stall dramatically at the PPP motif, with the second Pro codon
in the P site. These are the clear pause sites in these genes. In AmiB, where there are eight Pro
codons in a row, the stalling occurs primarily with the second Pro codon in the P site, but also to
a lesser extent at downstream Pro codons. These data show that endogenous E. coli proteins stall
at PPP motifs in vitro; their sequence context does not effectively suppress stalling.

EF-P alleviates stalling at polyproline stretches but not other stalling motifs
During the course of these studies, it was discovered that the translation factor EF-P
relieves translational stalling at polyproline stretches, thus explaining how proteins with
polyproline sequences are translated efficiently in living cells 184,185. Elongation factor P (EF-P)
was initially characterized 40 years ago as a ribosome bound translation factor that facilitated the
first peptide bond 186,187. Structural studies show that EF-P is comprised of three domains that
mimic the structure of tRNA 188. This allows EF-P to bind the ribosome between the E and P
sites, contacting both the mRNA and PTC 189 (Figure 3-8A). Once bound, EF-P inserts domain I
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(mimic of 3’ end of tRNA)
into the ribosome’s active
site, placing conserved
lysine residue, Lys34, near
the peptidyl-tRNA (Figure
Figure 3-8. EF-P binds the ribosome near the PTC. A) Representation of EFP bound between the E and P sites of the 70S ribosome in T. thermophilus.
B) Conserved residue Arg32 (Lys34 in E.coli) is positioned in the PTC near
the peptidyl-tRNA. Both A) and B) were prepared using MacPyMOL and
structure coordinates from ref. (189) (PDB codes 3HUW & 3HUX).

3-8B). Lys34 is modified
with β-lysine by the
enzymes YjeK and YjeA

190,191

. This creates a long, flexible cofactor that can reach into the ribosome’s active site and

alter the PTC geometry or the chemistry of peptide bond formation. Studies have shown that this
modification is essential for EF-P activity 190.
As expected, addition of EF-P to the translation reactions abolishes stalling at the
polyproline stretches present in LepA, LigT, and AmiB as seen in the toeprinting assays (Figure
3-7D). Furthermore, although a peptidyl-tRNA intermediate is the primary product in the
absence of EF-P, synthesis of the full-length protein is strongly enhanced by addition of EF-P
(Figure 3-9).
We next asked whether EF-P functions universally to alleviate stalling. Toeprinting
assays revealed that EF-P has little or no effect on stalling by the E1 (RxPP), T3 (DTS-stop), and
Glu-Pro-stop motifs (Figure 3-7D). Likewise, EF-P had no effect on stalling by the full-length
FxxYxIWPPP motif, though it abolished stalling by the minimal WPPP motif (Figure 3-7D).
Analysis of the products of in vitro translation further confirmed the ability of EF-P to prevent
stalling at WPPP but not at the full-length FxxYxIWPPP motif (Figure 3-7E). Translation of the
MWPPP peptide led to the synthesis of a ~20 kD intermediate, consistent with the size of the
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tRNA with a
tetrapeptide attached.
This intermediate does
not accumulate,
however, when EF-P is
added to the translation
reaction (Figure 3-7E).
Figure 3-9. Endogenous genes prevent peptide release. Three endogenous E. coli
genes, amiB, lepA, and ligT, were translated in vitro with [35S]-methionine in the
presence or absence or presence of EF-P. The reactions were stopped after 3 or 7
minutes. Peptidyl-tRNAs are labeled with a cartoon and the full-length, released
protein is labeled ‘FL’.

In contrast, during
MFQKYGIWPPP
synthesis, peptidyl-

tRNA accumulates regardless of whether EF-P is added or not. Taken together, these data show
that our motifs identified by genetic selection are resistant to EF-P, further defining its scope of
action.

Stalling motifs have been selected against
The motifs we identified from random libraries induce ribosome stalling both in vivo and
in vitro.What effect would these motifs have on the synthesis of endogenous proteins in vivo?
Are they found in endogenous bacterial proteomes? Or have they been selected against?
Analysis of bacterial proteomes supports the idea that some of these motifs have in fact
been selected against. We searched for stalling motifs in ~13.7 million bacterial proteins in the
RefSeq database from 4,277 organisms in the bacterial kingdom. We found that the DTS motif
occurred sixfold less at the C-terminus of proteins than one would expect based on amino acid
frequencies in this dataset. Glu-Pro-stop and Pro-Pro stop were underrepresented by 1.7- and 1.8-
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fold, respectively, and Asp-Pro-stop was underrepresented by 3.6-fold. Elongation motifs RSPP
and HGPP were also underrepresented, by 3.3- and 2.8-fold, respectively. All of these changes
were significant with P < 10–6. These findings suggest that stalling motifs may have been broadly
selected against during the course of evolution. In contrast, the six PP(X) motifs that stall in
vitro occur at expected levels in bacterial proteomes; when analyzed together, they were slightly
enriched at < 0.1% above the expected frequency (P > 0.35). We conclude that there is no
evidence of selection against the six stalling PP(X) motifs.

Stalling occurs at several motifs in endogenous E. coli proteins
Ribosome-profiling data published by Weissman and co-workers allow us to quantify
ribosome occupancy at potential stalling sites in endogenous E. coli proteins 192. We define a
pause score as the number of reads at the pause site divided by the median number of reads for
the entire open reading frame. Sites where ribosomes are enriched have higher pause scores than
sites of low ribosome occupancy. We calculated pause scores for all 8,000 tripeptide
combinations. The highest reliable pause score was 5.9 +/– 0.3 for the tripeptide GGT. Indeed,
many of the top 100 tripeptide motifs are rich in Gly residues (Table 3-2). In contrast, PPP has a
pause score of 4.4 +/– 0.4 and other PPX stalling motifs have lower scores (PPD = 4.3 +/– 0.5;
PPG = 3.9 +/– 0.4; PPE = 3.1 +/– 0.3).
Stalling motifs identified in our genetic selection have higher pause scores in the
ribosome profiling data. We first looked at motifs that block termination. No proteins in the E.
coli MG1655 genome end in Pro-Pro-stop. At the Asp-Pro-stop sequence in the SgrR gene, the
ribosome pauses robustly with a score of 84, meaning that a ribosome is 84 times more likely to
be found at this site than a typical position in the SgrR open reading frame. The Glu-Pro-stop
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Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

motif
GGT
GGS
GAG
WGP
GTC
MGT
GGA
GGG
GTI
GSD
GTT
GCG
GDG
GGV
GPN
GGF
GDC
GAT
GGD
GGI
CTF
GTG
GVT
GWT
GST
GPG
GGM
GCI
VA*
GSG
GGY
AGP
GAK
GTS
GSY
LS*
GTH
GDT
GGK
WGI
GIT
GIF
PPP
GVY
GGC
GTF
GPQ
PPD
WGT
EPP

pause
score
5.88
5.68
5.44
5.38
5.31
5.30
5.28
5.28
5.21
5.13
5.09
5.05
5.05
4.96
4.94
4.93
4.91
4.87
4.85
4.78
4.73
4.71
4.70
4.70
4.68
4.68
4.64
4.64
4.55
4.54
4.53
4.53
4.52
4.52
4.51
4.50
4.49
4.46
4.45
4.44
4.44
4.43
4.39
4.38
4.37
4.36
4.35
4.33
4.32
4.32

error
0.33
0.24
0.26
1.09
0.81
0.78
0.30
0.24
0.47
0.57
0.66
0.42
0.46
0.24
0.59
0.35
0.65
0.27
0.31
0.20
1.12
0.24
0.24
0.69
0.35
0.30
0.41
0.86
0.93
0.20
0.34
0.94
0.53
0.29
0.41
0.95
0.65
0.48
0.25
0.72
0.26
0.73
0.42
0.57
0.40
0.40
1.05
0.49
0.67
0.77

%
error
5.7
4.2
4.7
20.2
15.2
14.7
5.6
4.6
8.9
11.1
13.0
8.3
9.1
4.8
12.1
7.1
13.2
5.6
6.3
4.3
23.6
5.1
5.2
14.7
7.5
6.3
8.9
18.5
20.5
4.3
7.6
20.8
11.8
6.4
9.0
21.2
14.5
10.8
5.7
16.1
5.8
16.5
9.6
13.0
9.2
9.1
24.1
11.3
15.5
17.8

# of
hits
302
311
521
25
25
85
436
444
221
186
225
128
233
429
79
221
33
370
244
357
22
362
338
57
222
167
182
71
26
352
172
158
270
200
112
21
76
234
266
46
314
151
81
154
74
138
90
67
39
56

Rank
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

motif
GTD
GGQ
GGH
CGY
GTN
MGI
GPT
GTY
GAI
TGT
GAS
DGP
GYG
EGY
GTV
GSS
GVG
GTA
WGA
VYG
GKS
APP
GTW
GSV
GAW
GPI
GAD
RR*
GTR
GAA
GCT
GWG
GFG
AGT
GIC
GSI
GVM
GWA
GSP
GIV
GSA
GTL
GIQ
DGS
GGN
KGT
DGA
GEG
GCE
GKT

pause
score
4.30
4.27
4.25
4.24
4.23
4.23
4.21
4.21
4.20
4.19
4.19
4.19
4.16
4.16
4.16
4.16
4.16
4.15
4.15
4.13
4.13
4.12
4.11
4.10
4.09
4.08
4.08
4.08
4.07
4.07
4.07
4.07
4.06
4.06
4.05
4.04
4.03
4.02
4.02
4.02
4.02
4.01
4.01
4.00
4.00
3.99
3.99
3.99
3.99
3.97

error
0.30
0.31
0.38
0.91
0.56
0.40
0.41
0.36
0.21
0.33
0.17
0.38
0.31
0.59
0.25
0.29
0.19
0.42
0.49
0.86
0.21
0.41
0.44
0.35
0.67
0.34
0.23
0.83
0.33
0.19
0.45
0.52
0.32
0.47
0.41
0.26
0.70
0.68
0.41
0.21
0.28
0.16
0.30
0.29
0.44
0.36
0.62
0.25
0.43
0.18

%
error
6.9
7.4
9.0
21.5
13.2
9.5
9.7
8.6
5.1
7.8
4.1
9.1
7.4
14.3
6.1
7.0
4.6
10.1
11.9
20.8
5.2
10.0
10.7
8.5
16.4
8.4
5.7
20.3
8.2
4.6
11.1
12.8
7.9
11.5
10.1
6.4
17.4
17.0
10.3
5.3
6.9
4.0
7.5
7.4
11.0
9.1
15.5
6.3
10.8
4.4

# of
hits
166
194
103
34
94
126
118
79
402
235
375
111
193
151
299
230
418
328
78
158
299
107
46
325
95
101
356
33
174
570
56
64
289
321
53
224
167
79
138
397
303
477
138
257
207
132
250
270
69
386

Table 3-2. Pause scores of stalling peptides. Pause scores were calculated for all 8,000 tripeptides using
published ribosome profiling data from E. coli MG1655 (see ref. (193)). The pause score is the ribosome
density at the three codons of the tripeptide motif divided by the median density for the opening reading
frame. Tripeptides were excluded if they had fewer than 20 occurrences (hits) or pause scores with higher than
25% error.
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motif in TreF has a pause score of 28. None of our termination motifs (T1-T3) are found in this
strain, but the RxPP elongation motif in the RecG protein has a pause score of 14, and the HGPP
motif in the YaaX protein has a pause score of 10. Ribosome profiles for these four genes are
shown in Figure 3-10. These data argue that these motifs indeed delay ribosomes in vivo, even in
endogenous proteins.

Figure 3-10. Ribosome profiling data highlight pauses at stalling motifs in vivo.
Ribosome density is shown across four genes that contain stalling motifs
highlighted in red. Read densities are reported in units of reads per million
mapped reads (rpM). These analyses are of published datasets of E. coli MG1655
ribosome profiling experiments (193).
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Discussion
Our selection yielded novel nascent peptide motifs that induce ribosome stalling and
tmRNA tagging. Several lines of evidence support the claim that the peptide is the primary cause
of stalling. First, stalling occurs in a reconstituted in vitro translation system, where cleavage or
degradation of the mRNA is ruled out. Second, the consensus sequences show a high degree of
conservation of the first two nucleotides in a codon but considerable variation at the wobble
position. Third, the nascent peptide and incoming amino acid seem to play a key role in slowing
reaction rates in kinetic assays. We cannot rule out a role for associated tRNAs, however, since
many aspects of tRNA structure and function are common between the isoacceptors for a given
amino acid.
Several of the peptides we identified inhibit translational termination with small, polar
residues at the C-terminus. For example, the sequence DTS-stop is sufficient for stalling. This
motif expands to D/N, T/S, and S/G if additional aromatic residues are present upstream. With an
even longer stretch of hydrophobic residues, termination is slowed by a single Thr residue at the
C-terminus of the WILFxxT-stop motif. Perhaps the potential of Thr to block peptide release
explains why Thr is the most underrepresented residue at the C-terminus of bacterial proteins
(2.1-fold). These findings define a new class of stalling peptides and argue that release factors
are sensitive to the sequence of the polypeptide being released.
In these examples, upstream aromatic or hydrophobic residues probably enhance stalling
through increasing the binding of the peptide to the ribosomal exit tunnel. Conserved upstream
residues in natural stalling motifs such as SecM and TnaC work in the same way 109,115. But in
some motifs we identified, the upstream sequence has the opposite effect, suppressing stalling by
a motif that otherwise stalls effectively. In the R/HxPP motif, for example, upstream residues
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impose sequence specificity for either Arg or His. In addition, although the minimal motif
R/HxPP is sufficient to block peptidyl transfer, stalling is suppressed if the peptide is of
intermediate length (~11 amino acids), perhaps because specific upstream residues induce a
peptide conformation that disrupts interactions between the ribosome and the minimal motif. We
speculate that longer versions of this motif (~20 amino acids) stall efficiently because the Nterminus of the peptide moves past the L4/L22 constriction, restricting which conformations are
available to the nascent peptide.
Proline poses a particular challenge for the ribosome, serving as both a poor peptidyl
donor and a poor peptidyl acceptor 117,118. These roles are combined in the PPP motif, where the
ribosome stalls with the second Pro codon in the P site and the third in the A site, such that
transfer of peptidyl-tRNA to Pro-tRNA is blocked. We found that peptidyl transfer to Asn-, Asp, Glu-, Gly-, and Trp-tRNA is also inhibited after two Pro residues. Two of these tripeptide
motifs, PPD and PPE, were recently shown to pause ribosomes in mammalian cells 193,
suggesting that stalling at Pro-rich motifs may be a general phenomenon, not limited to bacteria.
Stalling by the PPP motif is abolished by EF-P, explaining how ~100 E. coli proteins
containing this motif are translated in vivo 184,185. Proteins with PPD, PPE, PPG, PPN, or PPW
probably also require EF-P for their synthesis. The fact that the PP(X) motifs are not
underrepresented in bacterial proteomes suggests that EF-P alleviates stalling by these motifs
efficiently. In contrast, EF-P has no effect on our newly identified motifs, even those including
proline residues, such as FxxYxIWPPP and RxPP. This makes sense as these were selected for
their ability to induce tmRNA tagging in vivo, where EF-P is present. We speculate that the
aromatic residues in FxxYxIWPPP interact with the ribosomal exit tunnel to stabilize the stalled
conformation, blocking the activity of EF-P, which could otherwise resolve stalling by the PPP
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motif. In addition, it seems that EF-P primarily affects peptidyl transfer and not peptide release,
given that it does not alleviate stalling at Glu-Pro-stop, even though stalling occurs with a Pro
codon in the P site. These findings begin to define the scope of EF-P’s ability to relieve
translational pauses.
The requirement in the PP(X) motifs for specific aminoacyl-tRNAs bound in the A site is
intriguing. In a similar manner, peptidyl transfer to Asp-, Glu-, Gly-, and Trp-tRNA were also
found to act as poor peptidyl acceptors in the analysis of the ErmAL1 stalling peptide by Mankin
and co-workers 97. In contrast, the strongest stalling in the ErmAL1 study was with Lys-, Arg-,
and His-tRNA, but these did not stall robustly after two Pro codons. It appears that different
nascent peptides modulate the reactivity of different subsets of aminoacyl-tRNAs.
Insight into the mechanism of ribosome stalling has been limited by the lack of
biochemical assays to directly measure individual steps in the synthesis of stalling peptides. In
many studies, stalling is inferred from changes in gene expression or tagging of the protein by
tmRNA. Although stalling can be detected directly in toeprinting assays, this method cannot
always pinpoint the precise step that is blocked nor determine reaction rates. In theory, many
steps in the translational cycle could be inhibited during ribosome stalling, including tRNA or
factor binding, translocation, peptide-bond formation, and peptide release. We were able to
recapitulate stalling in pre-steady state kinetic assays using our new motifs, showing that peptide
release and peptidyl transfer are inhibited by roughly 100- and 1000-fold, respectively. The fact
that our motifs are short makes interpretation of their interactions with the ribosome far simpler
than interpreting the function of natural motifs like SecM. These new stalling peptides cannot
contact the L4/L22 constriction; we speculate that they interact directly with rRNA nucleotides
near the peptidyl-transferase center to induce conformational changes that inhibit chemistry at
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the active site. Going forward, these assays will allow us to determine the role of the peptide,
tRNA, and rRNA sequence in the stalling mechanism.
What do our data tell us about the likelihood of finding more stalling motifs in the
future? On one hand, well-characterized motifs containing Pro residues appeared often in the
two-hybrid selection. The Pro-stop motif, for example, was found in half of the clones that
induce tmRNA tagging. On the other hand, several new motifs were discovered that block
termination with polar residues, and the cause of stalling remains unknown for several new
elongation motifs. Given the tiny fraction of sequence space we accessed in our library, and the
high rate of survival in the selection, it seems likely that more motifs remain undiscovered.
Ribosome profiling has potential for shedding light on variation in translational rates and
for identifying new stalling motifs. A recent ribosome profiling study showed that most strong
pauses could be explained by Shine-Dalgarno-like sequences 6 to 12 nt upstream of the pause
site 192. In the E5 motif (Table 3-1), stalling occurs with the nucleotides GGAGGA within 6 to
12 nucleotides of the A site codon, consistent with this report. Our analysis of the same profiling
dataset revealed that Gly-rich tripeptide motifs have the highest pause scores in E. coli. Since
Gly is encoded by GGN, it may be tempting to attribute this result to SD-like sequences.
However, the middle codon of the tripeptide is positioned in the P site in our analysis, making it
unlikely that these codons bind strongly to the anti-SD sequence in 16S rRNA during pausing.
Consistent with the high pause score for the GGG tripeptide (Table 3-2), we note that the E6
motif stalls on three Gly codons with the second Gly in the P site (Table 3-1).
Our data argue that bacterial proteomes have been shaped by the demand for translational
efficiency. The motifs that we identified were 3- to 6-fold underrepresented in a dataset
including ~13.7 million bacterial proteins. For those stalling motifs that are retained in the E. coli
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genome, we find substantial accumulation of ribosome density at the motif in ribosome profiling
data sets. This shows that short motifs stall on endogenous proteins in vivo and have the potential
to modulate protein synthesis rates in a biologically relevant way.

Experimental Procedures
Two-Hybrid Selection
The selection for stalling motifs is based on Bacteriomatch II (Agilent). Residues 1-117
of SspB were fused to the C-terminus of RNA polymerase alpha. To generate the library, 20
random codons were added to the 3’-end of the cI coding sequence. A modified tmRNA
encoding the ANDENYALDD tag was expressed in the reporter strain, which lacks hisB and
expresses HIS3 from a weak promoter downstream of cI binding sites. A library of 3 x 108 cI
mutants was introduced into the reporter strain and transformants were plated at 30 °C on M9
minimal media with His dropout supplement, 10 µM IPTG, and 5 mM 3-aminotriazole. The cI
gene was PCR amplified from the pool of surviving clones, inserted into fresh expression vector,
and passaged through the selection again. About 10% of clones survived in this second round;
150 were sequenced from this enriched pool. Additional details on plasmid construction and the
cI controls are given in the Experimental Procedures.

In Vitro Translation Assays
In vitro translation and toeprinting assays were performed in the PURExpress translation
system (New England Biolabs) as described previously 98. Each set of experiments was repeated
at least twice. The DNA constructs are described in the Experimental Procedures. Where
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indicated, 1 µM EF-P was added to the translation reaction. Modified EF-P was purified as
described previously 194.

Mass Spectrometry
cI clones were expressed in pET-15b in BL21 (DE3) cells together with a modified
tmRNA encoding the ANDHHHHHHD tag. Tagged cI was purified over Ni-NTA resin, digested
with trypsin, and the C-terminal tagged peptide purified and analyzed as previously described 98.

Kinetics
Ribosome nascent chain complexes were assembled and reacted with excess release
factor 1 or excess ternary complex containing EF-Tu, GTP, and aminoacyl-tRNA at 23 °C in
polymix buffer. Reported rates are the average of three independent experiments and standard
error is given. Details of the reaction conditions and materials are discussed in the Experimental
Procedures.

Statistical Analysis
We developed a likelihood ratio test to detect conserved motifs in sequences of surviving
clones from the two-hybrid selection. Under the null hypothesis, we assume that the mutation
rate is uniform across all the bases in the sequence. Enriched motifs are therefore the locations
that deviate from the overall frequencies across the entire 20-codon sequence. Details are
provided in the Experimental Procedures.
Pause scores for specific stalling motifs were obtained from E. coli MG1655 ribosome
profiling data from the Weissman lab 192. The pause score for known motifs was computed by
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averaging the number of reads per base over the P-site codon and two codons downstream,
normalized to the median number of reads per base for the given open reading frame. This
approach was used because it effectively captured the increased read density in the SecM motif.
Pause scores for tripeptides (Table 3-2) were computed with the average of density at all three
codons and were calculated using only well-translated genes (> 10 rpkm). Motifs with fewer than
20 occurrences in the genome were discarded, as were motifs with higher than 25% error in the
pause score. The error in the distribution in the pause scores was computed by bootstrapping.

Plasmid Construction
The two-hybrid selection uses three plasmids. The first, pSP100, has a pCDF origin and
expresses tmRNA-DD and β-lactamase. The second, pTRG, contains the ColE1 origin and
encodes the alpha subunit of RNA polymerase (RpoA) and TetR (Agilent Technologies). We
amplified the first 117 codons of the sspB gene using the primers CCGCAAGAATTCAGATGGATTTGTCACAGCTAACACCACGTCG and GATCTCACTAGTTTACATGATGCTGGTATCTTCATCGTAGGCAGC. This PCR product was subsequently cloned at the
3’-end of the rpoA gene in pTRG with EcoRI and SpeI.
The cI control constructs used in Figure 3-1B (cI-tag, cI-Glu-Pro-stop, and cI-nonstop)
were expressed from the pBT vector (CamR and p15A origin, Agilent Technologies). The cIalone construct is simply the original pBT plasmid. The primers TTGGCGCGGCCGCAGGGGAGCCAGCCGCAAACGACGAAAACTACGCTTTAGACGACTAAGATCTTAGGCG and
CGCCTAAGATCTTAGTCGTCTAAAGCGTAGTTTTCGTCGTTTGCGGCTGGCTCCCCTG
-CGGCCGCGCCAA were used to amplify the cI gene and add the tmRNA tag
(AANDENYALDD) to the C-terminus of cI. The primers TTGGCGCGGCCGCATCTG-

91

AACCGTGACTAAGATCTTAGGCG and
CGCCTAAGATCTTAGTCACGGTTCAGATGCG-GCCGCGCCAA were used to add the GluPro-Stop sequence. The primers
GATGATCGGCCGGCAGCCCGCCTAATGAGCGGGCTTTTTTTAGATCTGATGAT and
ATCATCAGATCTAAAAAAAGCCCGCTCATTAGGCGGGCTGCCGGCCGATCATC were
used to add the trpA terminator after the cI gene, in order to create an mRNA transcript of
defined length without a stop codon (cI-nonstop). These three PCR products were ligated into the
pBT plasmid following digestion with EagI and BglII.
cI clones were overexpressed for purification for MS analysis. The gene encoding the cIstalling motif fusion was PCR amplified from the pBT plasmid using the following primers:
GATATACCATGGGCAGCACAAAAAAGAAACCATTAACACAAG and
GCAGCCGGATCCCCGGCGCGCCTAAGATCT. These PCR products were digested with
NcoI and BamHI and cloned into the pET15b vector. The resulting plasmids and tmRNA-His6
plasmid pCH201 101 were used to transform BL21 (DE3) E. coli cells. The cI protein was
expressed, purified, and analyzed as described previously 98.

Library Construction
20 random codons were added to the 3’-end of the lambda cI protein by PCR with the
primers GATAAAATATTTCTAGATTTCAGTGCAATTTATCTCT and the reverse primer
TTATGCAGATCTTTACTTACTTAN60TGCGGCCGCGCCAAACGTCTC where N is an
equal mixture of all four bases. The PCR product was cloned into pBT using XbaI and BglII, and
the resulting plasmids were amplified in XL1-Blue. 30% mutagenesis libraries of individual
clones were created with the same scheme, except that the reverse primer contained the motif
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sequence, not N60. The motif sequence was synthesized with phosphoramidite mixtures
containing 70% original nucleotide and 10% each of the other three nucleotides.

In Vitro Translation Constructs
All toeprinting DNA templates start with the following 5’-sequence, including a T7
promoter, ribosome binding site, and start codon which is underlined: CTGTACATTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATATG. The 3’-end of all
templates includes the following primer-binding site; the DNA primer in all the experiments was
NV1, GTTAATAAGCAAAATTCATTATAACC. To PCR amplify the cI clones for toeprinting,
including 18 amino acids of cI and the 20-codon variable region, we used the 3’-primer
GGTTATAATGAATTTTGCTTATTAACGGTAGCCAGCAGCATCCT. This places the end of
the random sequence 40 nt from the NV1 primer-binding site. For the toeprints shown in Figures
3-2 and 3-4, the 5’-primer was CTGTACATTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATATGTGTTCCGTTGTGGGGAAAGTTAT.
For toeprinting analysis of PPP stalling, three endogenous genes were PCR amplified
from genomic DNA. The constructs were synthesized with the upstream sequence shown above,
such that translation starts with the natural ATG codon. The NV1 primer-binding site was added
51 nt downstream of the second Pro codon in the PPP motif in the gene. The primers used were:
lepA,
AGCTACCGGCCGTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATA
TGAAGAATATACGTAACTTTTCGATCATAGCTCAC and
AGCTACCTCGAGGGTTATAATGAATTTTGCTTATTAACCCATGAGTCGATAATTAGT
GCCTGCAACGG;
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ligT,
AGCTACCGGCCGTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATA
TGTCTGAACCGCAACGTCTGTTCTTTGCT and
AGCTACCTCGAGGGTTATAATGAATTTTGCTTATTAACGGAGGCGTAAAGGGTGAAC
TCCGTCACCGC;
amiB,
AGCTACCGGCCGTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATA
TGATGTATCGCATCAGAAATTGGTTGGTAGC and
AGCTACCTCGAGGGTTATAATGAATTTTGCTTATTAACAACCGCAGGCGTTTCAACG
CGTTTCGCAAC.
Analysis of WPPP and FxxYxIWPPP was performed with the following dsDNA
constructs: for WPPP,
CTGTACATTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATATGAC
CATGATTACGAATTCGAGCTCATGGCCACCGCCATCGATTCGGCATGCAAGCTTGGC
ACTGGCCGTCGTTTTACAACGTCGTGTTAATAAGCAAAATTCATTATAACC encodes
MTMITNSSSWPPPSIRHASLALAVVLQRRVNKQNSL*. For the whole motif, the construct
CTGTACATTAATACGACTCACTATAGGGAGATTTTATAAGGAGGAAAAAATATGAC
CATGATTACGAATTCGAGCTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTTG
GCCACCGCCATCGATTCGGCATGCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCG
TGTTAATAAGCAAAATTCATTATAACC encodes
MTMITNSSSLQKRLFQKYGIWPPPSIRHASLALAVVLQRRVNKQNSL*.
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Kinetics
Materials: E. coli MRE600 tightly coupled 70S ribosomes were prepared as described
previously 60. Overexpressed native IF1 and IF3 and His-tagged IF2 were purified as described
195

. Amino-terminally His-tagged RF1 and aminoacyl-tRNA synthetases were expressed and

purified as previously described 196. His-tagged EF-Tu and EF-G were purified over Ni-NTA
resin and the His-tag was removed by tobacco etch virus protease, followed by a second passage
over a Ni-NTA column 197. tRNAfMet, tRNAPhe, tRNAArg, tRNAGlu were purchased from
Chemical Block (Russia). tRNAPro and tRNAAla were purified from bulk E. coli tRNA (Roche)
with biotinylated oligos Pro1 CCGAACGAAGTGCGCTACCAGGCTG3BioTEG, Pro2
CCCATGACGGTGCGCTACCAGGCTG3BioTEG, and Ala1
GCAAAGCAGGCGCTCTCCCAGCTGA3BioTEG as described 198. mRNA templates were
synthesized by T7 RNA polymerase using DNA templates annealed to a short primer
corresponding to the minimal promoter sequence. The mRNA transcripts have the following
sequence: GGGUGUCUUGCGAGGAUAAGUGCAUUAUG(X)UUUGCCCUUCUGUAGCCA where the start codon is underlined and additional
codons are inserted at the X site. UAA stop codons are used in termination motifs.
tRNA aminoacylation: Initiator tRNAfMet was aminoacylated with formylated
radiolabelled [35S]-methionine using MetRS and methionyl-tRNA formyltransferase as described
199

. Pure tRNAs were charged by incubating the tRNA at 5 µM with the corresponding

synthetase (~ 1 µM) in the presence of 2 mM ATP and 50 µM amino acid for 30 min at 37 °C in
the following buffer: 100 mM HEPES-KOH pH 7.6, 1 mM DTT, 10 mM KCl, 20 mM MgCl2.
The aminoacyl-tRNA was purified by extraction by phenol and CHCl3, precipitated with ethanol,
and resuspended in 2 mM NaOAc pH 5.0. The following tRNAs were aminoacylated as purified
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tRNAs: Pro-tRNA, Ala-tRNA, Arg-tRNA, Glu-tRNA, and Phe-tRNA. Bulk E. coli tRNA
(Roche) was charged with a similar procedure in making the DTSA and DTSF aminoacyl-tRNA
mixes for the DTS complex and related mutants, except the tRNA concentration was 100 µM
and the corresponding aminoacyl-tRNA synthetases and amino acids were added.
Ribosome complex formation: Initiation complexes were prepared by incubating 70S
ribosomes (2 µM) with IF1, IF2, IF3, fMet-tRNA (3 µM each), and mRNA (6 µM) in polymix
buffer with 2 mM GTP at 37 °C for 45 min. 100 µL of the resulting complex was reacted with
200 µL of pre-incubated mixture containing EF-Tu (15 µM), charged tRNA (2 µM), EF-G (2
µM), and GTP (2 mM) in polymix buffer for 37 °C for 5 min. The complexes were then purified
over a 1 mL sucrose cushion (1.1 M sucrose, 20 mM Tris-HCl, pH 7.5, 500 mM NH4Cl, 10 mM
MgCl2, 0.5 mM EDTA) and spun at 260,000 g in a TLA100.3 rotor for 2 h. The pellet was
resuspended in polymix buffer (95 mM KCl, 5 mM NH4Cl, 5 mM magnesium acetate, 0.5 mM
CaCl2, 8 mM putrescine, 1 mM spermidine, 5 mM potassium phosphate pH 7.5, 1 mM DTT),
aliquoted, and stored at –80 °C.
Release assays: ~25 nM RNCs were incubated with 5 µM RF1 in polymix buffer at 23
°C. The reaction was stopped at various time points by addition of formic acid to a final
concentration of 1%. Reactions with fast rate constants (> 0.1 s–1) were performed an RQF-3
quench-flow instrument (KinTek). Released peptides were separated from unreacted peptidyltRNA on cellulose TLC plates using electrophoretic TLC in pyridine-acetate buffer pH 2.8 183.
The fraction of released peptide at each time point was quantified and plotted against time and
the data fit with a single exponential equation. The reported rates are the averages of three
separate experiments, with the standard error given.
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Peptidyl transfer assays: 40 µM EF-Tu was incubated with 2 mM GTP in polymix buffer
for 15 min at 37 °C to exchange GDP for GTP. This reaction was then combined with
aminoacyl-tRNA to form a ternary complex, with final concentrations of 20 µM EF-Tu, 2 µM
charged tRNA, and 2 mM GTP in polymix buffer. The complex was incubated for 10 min on ice,
then reacted at 23 °C in polymix buffer with an equal volume of ~50 nM RNC. The reaction was
stopped by addition of KOH to a final concentration of 100 mM. Peptides were resolved on
electrophoretic TLC and analyzed as above. The reported rates are the averages of three separate
experiments, with the standard error given.

Statistical Analysis of Peptide Libraries
We developed a likelihood ratio test to detect conserved motifs in sequences of surviving
clones from the two-hybrid selection. Under the null hypothesis, we assume that the mutation
rate is uniform across all the bases in the sequence. Enriched motifs are therefore the locations
that deviate from the overall frequencies across the entire 20-codon sequence. Specifically, we
let Xi(k) be the kth ordered base count at the ith position. We then define:

where p(k) represents the estimate of the base frequency of the kth ordered base across all
positions under the null hypothesis, and ri(k) estimates the kth ordered frequency at the ith at
position. Assuming that the base positions are independent of each other and that the base
occurrences across the sequences follow a multinomial distribution, we define our likelihood
ratio test statistic for position i as:
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We note that –2log(Λi) approximately follows a chi-squared distribution with three degrees of
freedom. We evaluated the significance of each codon, by summing the logged ratio statistics for
all three positions in the codon, and then appropriately comparing the codon level statistic to a
chi-squared distribution with nine degrees of freedom to obtain a p-value.
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Chapter 4. eIF5A Promotes Translation of Polyproline Motifs
Author’s Note: This chapter details the characterization of translation factor eIF5a and its
ability to relieve ribosome stalling, for which I performed the toeprinting assays and aided with
the kinetic assays. The results of this study were published in Molecular Cell in 2013 200.

Abstract
Translation factor eIF5A, containing the unique amino acid hypusine, was originally
shown to stimulate Met-puromycin synthesis, a model assay for peptide bond formation. More
recently, eIF5A was shown to promote translation elongation; however, its precise requirement
in protein synthesis remains elusive. We use in vivo assays in yeast and in vitro reconstituted
translation assays to reveal a specific requirement for eIF5A to promote peptide bond formation
between consecutive Pro residues. Addition of eIF5A relieves ribosomal stalling during
translation of three consecutive Pro residues in vitro, and loss of eIF5A function impairs
translation of polyproline-containing proteins in vivo. Hydroxyl radical probing experiments
localized eIF5A near the E site of the ribosome with its hypusine residue adjacent to the acceptor
stem of the P site tRNA. Thus, eIF5A, like its bacterial ortholog EFP, is proposed to stimulate
the peptidyl transferase activity of the ribosome and facilitate the reactivity of poor substrates
like Pro.

Introduction
Ribosomes catalyze protein synthesis with the assistance of transfer RNAs (tRNAs) and
translation factors. There are three tRNA binding sites on the ribosome: a centrally located
peptidyl-tRNA (P) binding site, an aminoacyl-tRNA (A) binding site, and an exit (E) site that
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binds deacylated tRNA following its transfer from the P site. Translation initiation factors aid in
the assembly of an 80S ribosome in eukaryotes in which the initiator methionyl-tRNA (MettRNAiMet) is bound in the P site with its anticodon base-paired to the start codon on the
messenger RNA (mRNA). To extend the polypeptide, the eukaryotic elongation factor eEF1A
(EFTu in bacteria) delivers aminoacyl-tRNA to the A site in a codon-dependent manner.
Following accommodation of the tRNA, the amino acid attached to the A site tRNA is
juxtaposed to the peptidyl portion of the P site tRNA in the active site (peptidyl transferase
center [PTC]) of the large (60S) ribosomal subunit. Peptide bond formation links the extended
polypeptide to the A site tRNA, leaving a deacylated tRNA in the P site. Next, elongation factor
eEF2 (EFG in bacteria) promotes translocation of the tRNAs and mRNA such that the A site is
vacant and ready to accept the next aminoacyl-tRNA (reviewed in 18). A common misconception
is that the ribosome is a monolithic machine that catalyzes all peptide bonds at equivalent rates
regardless of the amino acid. In fact, certain residues, including the imino acid Pro, are poor
substrates for peptide bond formation 118,165 Recently, it was shown that the translation
elongation factor EFP is essential for translation of polyproline (polyPro) sequences by bacterial
ribosomes 184,185; however, it is currently unclear how eukaryotic ribosomes manage to
synthesize peptide bonds with poor substrates.
In addition to the canonical elongation factors eEF1A and eEF2, eIF5A has also been
linked to translation elongation. eIF5A was initially discovered and characterized based on its
ability to stimulate Met-puromycin synthesis 201–203 a reaction analogous to the synthesis of the
first peptide bond. The aminoacyl analog puromycin reacts with Met-tRNAiMet bound in the P
site of 80S initiation complexes. Based on its ability to stimulate Met-puromycin synthesis,
eIF5A was initially thought to function as a translation initiation factor, stimulating formation or
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reactivity of 80S initiation complexes. However, since the assay involves formation of a peptide
bond between puromycin and methionyl-tRNA, puromycin reactivity also reports on the peptidyl
transferase activity of the ribosome, a key component of translation elongation. Depletion of
eIF5A in vivo or inactivation of a temperature-sensitive mutant of yeast eIF5A impaired
translation elongation and stabilized polysomes in the absence of cycloheximide 204 and
increased the average ribosomal transit time in vivo 204,205. Moreover, addition of eIF5A resulted
in a 2-fold stimulation in the rate of tripeptide synthesis using a reconstituted yeast in vitro
translation system. Taken together, these data revealed a role for eIF5A in translation elongation.
However, it is difficult to rationalize the essential requirement for eIF5A in yeast with the
modest 2-fold stimulation of tripeptide synthesis, suggesting that eIF5A may have a more
specialized and critical requirement in translation elongation.
eIF5A is of particular interest because it is the only protein that contains the modified
amino acid hypusine and because eIF5A and hypusine have been linked to tumorigenesis and
cancer 206,207. The hypsuine modification is present in all archaea and eukaryotes that have been
examined, and it is formed by the transfer of an n-butylamine moiety from spermidine to the εamino group of a specific lysine side chain (K51 in yeast eIF5A), followed by addition of a
hydroxyl group. The hypusine modification is essential for eIF5A function: deoxyhypusine
synthase, which catalyzes the first step in hypusine formation, is essential for yeast viability, and
derivatives of eIF5A lacking hypusine fail to stimulate in vitro Met-puromycin 208,209 and
tripeptide synthesis 204. Interestingly, bacterial EFP and eIF5A are orthologs; in some bacteria, a
lysine side chain in EFP corresponding to the site of hypusine modification in eIF5A is
posttranslationally modified by the addition of a β-lysine residue 190,191,194,210. Like eIF5A, EFP
was found to stimulate Met-puromycin synthesis, and this activity was dependent on the β-lysine
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modification 211. Earlier studies revealed that the impact of EFP on dipeptide synthesis varied for
different aminoacyl analogs 187,212, suggesting that EFP, and eIF5A by extension, may facilitate
the reactivity of certain amino acids in peptide bond synthesis. Consistent with these findings,
recent reports showed that EFP enhances the synthesis of proteins containing stretches of
consecutive Pro residues 184,185.

Results
eIF5A Stimulates Translation through PolyPro Sequences In Vivo
To further define the role of eIF5A in translation elongation and to determine whether
eIF5A, like EFP, stimulates translation of specific amino acid motifs, we monitored the
expression of a set of dual-luciferase reporters in isogenic yeast strains expressing wild-type
eIF5A or the temperature-sensitive eIF5A-S149P mutant 204,213. The dual-luciferase reporters,
developed by Beth Grayhack and colleagues to examine codon bias in translation 214, express a
single mRNA in which the 5′ Renilla luciferase and 3′ firefly luciferase open reading frames
(ORFs) are joined in frame by sequences encoding repeats of 10 identical codons for each of the
20 amino acids (Figure 4-1A). For the initial analysis, the inserted sequences repeated the
optimal codon for each amino acid 214. As shown in Figure 4-1B (upper panel) and as previously
observed 214, the ratio of firefly to Renilla luciferase activity varied depending on the repeated
codon. Whereas the ratios for most constructs were similar to the no-insert control, low ratios
were observed for the ArgAGA and CysUGU reporters (Figure 4-1B, upper panel) and high
ratios were observed with GluGAA and PheUUC codon insertions (see Figure 4-2D). These
eIF5A-independent effects might reflect codon or aminoacyl-tRNA abundance or the impact of
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Figure 4-1. eIF5A Stimulates Translation of Polyproline Motifs in vivo. (A) Schematic of Renilla-firefly
luciferase reporter construct. Codon repeats were inserted in-frame between the Renilla and firefly luciferase
ORFs (214). (B) Dual luciferase reporter constructs containing ten repeats of the indicated codon were
introduced into isogenic yeast strains expressing wild type eIF5A or temperature-sensitive eIF5A-S149P. (Top
panel) Following growth at semi-permissive 33°C, luciferase activities were determined, and the firefly-toRenilla luciferase ratio for each construct was normalized to the ratio obtained from controls in which the
reporter contained no insert between the ORFs. (Bottom panel) The fold difference in luciferase ratios between
cells expressing wild-type eIF5A and eIF5A-S149P was quantitated and then normalized to the values obtained
from the no insert control. *Statistical significance for ProCCA(10) was measured by student’s t-test with a pvalue <0.05. Error bars were calculated as propagated standard errors of the mean for three independent
transformants.
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Figure 4-2. The Temperature-sensitive eIF5A-S149P Mutant Impairs Yeast Cell Growth, Translation Elongation,
and Synthesis of Polyproline Sequences, Related to Figure 4-1. (A) Isogenic wild-type and eIF5A-S149P
mutants strains were grown to saturation, and 4-µl volumes of serial dilutions (OD600 = 1.0, 0.1, 0.01, 0.001, and
0.0001) were spotted on YPD medium and incubated for 2 days at 30°C, 33°C, and 37°C. (B) Whole cell
extracts (WCEs) from yeasts strains expressing wild-type eIF5A or eIF5A-S149P and grown at permissive
(30°C) and semi-permissive (33°C) temperatures were subject to immunoblot analysis using antisera specific for
eIF5A or eIF2Bε (GCD6). (C) Polysome profiles were analyzed from wild type and eIF5A-S149P mutant strains
grown under permissive (25°C) or semi-permissive (33°C) conditions, or following a temperature-shift from
25°C to 37°C for 2 h, were treated with 50 µg/ml cycloheximide (+CHX) or left untreated (-CHX), and WCEs
were separated on sucrose gradients and fractionated to visualize polysomes and the indicated ribosomal species.
Polysome/monosome (P/M) ratios were calculated by comparing the areas under the polysome and 80S peaks.
(D) Summary of the firefly:Renilla luminescence ratios obtained following introduction of dual luciferase
reporters containing 10 repeats of the indicated codon (see Fig. 4-1) into wild-type eIF5A and eIF5A-S149P
mutant yeast strains and growth at 33°C. Ratios of firefly-to-Renilla luciferase activity were determined for three
independent transformants of each construct, and the average ratio (x 103) and standard deviation (SD) are
presented. The values in Figure 4-1 were obtained by normalizing the ratios to the respective no insert control for
each of the three sets of constructs.
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the inserted amino acids on luciferase activity in the bifunctional Renilla-firefly luciferase fusion
protein.
If eIF5A stimulates the translation of specific amino acids, then the ratio of firefly to
Renilla luciferase activity is expected to decrease when these reporters are analyzed in the strain
containing eIF5A-S149P when grown at the semipermissive temperature (33°C). As shown in
Figure 4-2A, the slow-growth phenotype of the eIF5A-S149P mutant at 30°C is exacerbated at
33°C, and the mutant strain fails to grow at 37°C. The impaired growth at 33°C is marked by
reduced levels of eIF5A (Figure 4-2B) and by retention of polysomes in the absence of
cycloheximide (Figure 4-2C), indicative of a general translation elongation defect in the strain.
Analysis of all 20 luciferase reporter constructs revealed that only the Pro codon insertions
revealed a strong dependence on eIF5A (Figure 4-1B, upper panel). For the ProCCA reporter,
the ratio of firefly to Renilla luciferase in the strain expressing wild-type eIF5A was ∼
3.7-fold
greater than the ratio observed in the strain expressing eIF5A-S149P (Figure 4-1B, lower panel),
whereas this normalized ratio ranged from 0.75 (ArgAGA) to 1.35 (GlyGGU) for reporters
containing any of the other 19 codon insertions.
To test whether the impaired expression of firefly luciferase from the construct
containing the ProCCA codon repeats was specific to the mutation of eIF5A, two other
translation elongation factors were evaluated. No significant differences in firefly:Renilla
luciferase ratios were observed when constructs containing Pro or Ala codon insertions were
examined in strains expressing temperature-sensitive mutants of translation elongation factors
eEF2 or eEF3 (Figures 4-3A and 3B). Thus, polyPro peptide bond formation shows a unique
dependence on eIF5A. Alternatively, this result could reflect a specific requirement for eIF5A to
promote peptide bond formation by Pro-tRNA. Consistent with this hypothesis, reporters
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containing 10 repeats of the Pro codons CCA, CCG, or CCU displayed a strong requirement for
eIF5A, whereas no Ala codon insertions conferred a dependence on eIF5A (Figure 4-3C). While
these data are not definitive, they suggest that the imino acid Pro, rather than the tRNA, likely
determines the requirement for eIF5A.
To define the number of consecutive Pro residues needed to impose a requirement for
eIF5A, the dual-luciferase reporters were modified to contain one, two, three, four, six, eight, or
ten consecutive ProCCA or PheUUC codons. As shown in Figure 4-4, luciferase ratios for the
Phe codon insertion constructs were the same in the wild-type and eIF5A-S149P mutant strains
(wild-type/mutant ≈ 1.0). Likewise, insertion of one or two Pro codons did not significantly
impact luciferase ratios in the eIF5A mutant strain compared to the wild-type control. In contrast,
insertion of four Pro codons resulted in reduction of the luciferase ratio in the eIF5A-S149P
mutant strain; some reduction may be evident with insertion of three Pro codons as well.
Insertion of six, eight, or ten Pro codons further exacerbated the defect, and the normalized ratio
of firefly to Renilla luciferase in the strain expressing wild-type eIF5A was ∼
3- to 4.5-fold greater
than the ratio observed in cells expressing eIF5A-S149P. These results indicate that at least four
(or perhaps three) consecutive Pro codons are needed to impose an eIF5A dependency on protein
synthesis.

Expression of Yeast PolyPro-Containing Proteins Requires eIF5A In Vivo
Analysis of the Saccharomyces cerevisiae genome identified 549 proteins (out of 5,886
ORFs) that contain polyPro motifs with at least three consecutive Pro residues. To test whether
expression of yeast proteins containing polyPro motifs is dependent on eIF5A, selected plasmids
from the Yeast ORF Collection (Open Biosystems) were introduced into isogenic strains
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Figure 4-3. eEF2 and eEF3 Mutants do not Specifically Impair Polyproline Synthesis, Related to Figure 4-4. (A)
Yeast strains expressing the indicated temperature-sensitive mutant of eEF2 or eEF3, or their respective isogenic
strain expressing the wild type factor, were grown to saturation, and 4-µl volumes of serial dilutions (OD600 =
1.0, 0.1, 0.01, 0.001, and 0.0001) were spotted on YPD medium and incubated for 2 days at 30°C, 33°C, and
37°C. (B) Dual luciferase reporter constructs containing 10 repeats of AlaGCU or ProCCA codons were
introduced into the respective wild type and eEF2 (left panel) or eEF3 (right panel) mutant strains, and luciferase
activities were determined following growth at semi-permissive 33°C. Results were quantitated as described for
Figure 4-1B, and error bars were calculated as propagated standard deviations (SD) for three independent
transformants. (C) Dual luciferase reporters containing ten consecutive repeats of the indicated Ala or Pro
codons were assayed in wild type or eIF5A-S149P mutant strains and the data was normalized to the no insert
control as described in Fig. 4-1. Error bars were calculated as propagated standard deviations (SD) for three
independent transformants. While these data are not definitive, as the yeast tRNAPro UGG has been reported to
decode all four proline codons (see ref. (200)), they suggest that the amino acid proline rather than the tRNA
likely determines the requirement for eIF5A.

expressing wild-type eIF5A or the temperature-sensitive mutant eIF5A-S149P. Transformants
were grown at the semipermissive temperature of 33°C to partially inactivate eIF5A-S149P and
in galactose medium to induce the GAL1 promoter used to drive ORF expression. Protein
expression was monitored by western analysis using antibodies to detect the hemagglutinin
(HA)-tag incorporated at the C terminus of each ORF 215. As shown in Figure 4-5A, expression
of Ldb17 (one motif of nine consecutive Pro residues), Eap1 (two motifs of six Pro residues; one
motif of three Pro residues), and Vrp1 (multiple polyPro sequences, including one motif of nine
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Pro residues, one motif of eight Pro
residues, one motif of six Pro residues,
four motifs of five Pro residues, three
motifs of four Pro residues, and two
motifs of three Pro residues) was
dramatically reduced in the eIF5A
mutant strain relative to the wild-type
Figure 4-4. Translation of Three or More Consecutive Proline
Codons Reveals eIF5A Dependency. Dual luciferase reporters
containing 1, 2, 3, 4, 6, 8, or 10 consecutive PheUUC (F) or
ProCCA (P) codons were assayed in wild type or eIF5A-S149P
mutant strains and the fold difference in luciferase ratios were
quantitated and normalized to the no insert control as described
in Figure 4-1.

eIF5A strain and the loading control
eIF2α (no polyPro motifs). Stable
expression of Tif11 (eIF1A, no
polyPro motifs) from a Yeast ORF

Collection plasmid in the wild-type and mutant eIF5A strains indicates that the eIF5A-sensitive
expression of the polyPro proteins is not due to impacts on the expression system (e.g., the GAL1
promoter, growth at 33°C) (Figure 4-5A). In addition, substituting Ala in place of the nine Pro
residues in the C-terminal Pro motif restored Ldb17 expression in the eIF5A-S149P mutant
(Figure 4-5B), directly linking eIF5A function to the synthesis of polyPro motifs.

eIF5A Plays an Essential Role in PolyPro Peptide Synthesis
An in vitro reconstituted yeast translation assay was used to directly examine the eIF5A
requirement for polyPro synthesis. As shown in Figure 4-6A, minimal translation initiation (48S)
complexes encoding polyPro or polyPhe were assembled using unstructured model mRNAs to
avoid the requirement for initiation factors that function in mRNA recruitment. Following
ribosomal subunit joining and assembly of an 80S initiation complex with [35S]Met-tRNAiMet in
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Figure 4-5. Expression of Polyproline-containing Proteins Requires eIF5A in vivo. (A) Plasmids expressing HAtagged forms of the yeast proteins Ldb17, Eap1, Vrp1 or eIF1A under the control of the yeast GAL1 promoter
were introduced into isogenic strains expressing wild-type eIF5A or eIF5A-S149P. Cells were grown at semipermissive 33°C in galactose medium, broken with glass beads in the presence of 10% trichloroacetic acid
(TCA), and two different amounts of each extract differing by a factor of two were loaded in successive lanes
and subject to immunoblot analysis using monoclonal anti-HA or polyclonal anti-yeast eIF2α antiserum. (B) The
experiment in (A) was repeated using an Ldb17 construct in which Ala codons were substituted for the nine Pro
codons in the polyproline motif.

the P site of the ribosome, the complex was pelleted through a sucrose cushion to remove
initiation factors and unbound Met-tRNAiMet. Next, elongation factors and the necessary
aminoacyl-tRNAs were added to the purified 80S complexes in the absence or presence of
excess recombinant eIF5A. The recombinant eIF5A was prepared from E. coli that coexpresses
the hypusine formation enzymes (Figure 4-7A), and the presence of hypusine in the recombinant
eIF5A was confirmed by electrospray ionization quadrupole time-of-flight mass spectrometry
(ESI-QTOF-MS) analysis (Figure 4-7B; see Experimental Procedures). Peptide synthesis was
monitored by electrophoretic thin-layer chromatography (TLC) 183,216.
Synthesis of MF, MFF, and MFFF peptides progressed well in the absence and presence
of eIF5A (Figures 4-6B and 4-7D), with less than 2-fold stimulation in both the observed rate
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Figure 4-6. eIF5A Stimulates Synthesis of Polyproline Peptides. (A) Scheme for in vitro reconstituted translation
elongation assay. (B) Fractions of MF, MFF, MFFF (left column) or MPK, MPPK, and MPPPK (right) synthesis
in elongation assays (Fig. 4-7D and 4E) performed in the absence (open symbols) or presence of eIF5A (closed
symbols) were plotted and fit to a single exponential equation. (C) Summary of maximum fractions of peptide
synthesis (Ymax, top) and fold stimulation of Ymax by adding eIF5A (bottom) calculated from the data in panel B.
Error bars are (upper) standard deviations from at least three independent experiments and (lower) calculated
propagated errors. (D) Effect of eIF5A hypusine modification on peptide synthesis. Fraction of MPPPK
synthesis (Fig. 4-7F) in reactions lacking eIF5A, containing unmodified eIF5A (no hypusine), or containing
hypusinated eIF5A prepared from E. coli (+5A, see Experimental Procedures) or purified from yeast (+5A,
yeast) was plotted and fit to a single exponential equation.
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Figure 4-7. eIF5A Expression, Modification, and Stimulation of Peptide Synthesis, Related to Figure 4-6. (A)
Schematic of plasmid pC4183, derived from pST39 (240), for coexpression of eIF5A, Dys1 and Lia1 in E. coli.
(B) ElectroSpray-Ionization Quadrupole-Time-of-Flight Mass Spectrometry (ESI QTOF MS) analysis of eIF5A
produced in E. coli (top panel) or produced in cells co-expressing Dys1 and Lia1 (lower panel). (C)
Electrophoretic TLC analysis of MP synthesis in elongation assays lacking or containing eIF5A (left panels), and
fraction of MP synthesis in each reaction was plotted and fit to a single exponential equation (open squares, no
eIF5A; closed squares, + eIF5A). (D-E) Electrophoretic TLC analysis of peptide products from elongation
assays programmed to synthesize MF, MFF, and MFFF (D) or MPK, MPPK, and MPPPK (E). The identities of
spots corresponding to peptide products and free methionine are indicated. (F) Effect of eIF5A hypusine
modification on peptide synthesis. Peptide formation assay for MPPPK synthesis was performed in the absence
of eIF5A, or in the presence of unmodified eIF5A (no hypusine), or hypusinated eIF5A prepared from E. coli
(+5A, see Experimental Procedures), or purified from yeast (+5A, yeast).

constant and the fraction of maximal yield (Ymax) for formation of the peptides in the presence
of eIF5A (Figure 4-6C). These results are consistent with the previously reported ∼
2-fold
stimulation of MFF synthesis upon adding eIF5A to the reconstituted system 204. In preliminary
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experiments, the Pro-containing peptides MP, MPP, and MPPP failed to resolve as discrete spots
on the TLC (see Figures 4-7C, 7E, and 7F). However, incorporation of a Lys residue at the C
terminus of the Pro peptides enabled resolution of the peptides by TLC and facilitated their
quantitation. The fraction of maximum peptide yield for MPK peptide synthesis was stimulated
∼
1.3-fold by adding eIF5A (Ymax = 0.36 in the absence of eIF5A and 0.48 in the presence of
eIF5A) (Figures 4-6B, 6C, and 4-7E, top panels). Thus, the presence of a single Pro residue
conferred a modest eIF5A dependency for peptide synthesis. In contrast, synthesis of the MPPK
peptide containing two Pros was significantly impaired in the absence of eIF5A (Ymax = 0.06 ±
0.03). An 8.3-fold stimulation of Ymax was observed upon adding eIF5A (Ymax = 0.49 ± 0.02)
(Figures 4-6B, 6C, and 4-7E). The large difference in reaction endpoints for the Pro-containing
peptides in the presence versus the absence of eIF5A suggests that competing reactions are likely
occurring (e.g., peptidyl-tRNA drop-off). Since the observed rates reflect both peptide bond
formation and these competing reactions, we have limited our analysis to the reaction endpoint
differences and not to the observed rates. Remarkably, no detectable formation of the MPPPK
peptide containing three consecutive Pro residues occurred in the absence of eIF5A during
the time course of experiments. The addition of eIF5A efficiently restored MPPPK synthesis,
stimulating the Ymax at least 39-fold (Ymax = 0.58 ± 0.1) (Figure 4-6C). Thus, consistent with the
results of the in vivo assays, eIF5A is required for synthesis of peptides containing consecutive
Pro residues.
To assess the importance of the hypusine modification on eIF5A, MPPPK synthesis was
analyzed using different forms of the factor. As shown in Figures 4-6D and 4-7F, no MPPPK
synthesis was detected in the absence of eIF5A and very little synthesis was detected in assays
that included unmodified eIF5A prepared from E. coli (see Experimental Procedures). In
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contrast, hypusine-modified eIF5A, prepared either from yeast or from E. coli coexpressing the
hypusine modification enzymes (see Experimental Procedures), readily stimulated MPPPK
synthesis (Ymax = 0.38 ± 0.02 for yeast eIF5A; Ymax = 0.45 ± 0.02 for recombinant eIF5A). Thus,
the hypusine modification of eIF5A is necessary for efficient polyPro synthesis in vitro.

eIF5A Prevents Ribosome Stalling on Consecutive Pro Codons
The in vitro peptide synthesis assays revealed defects in synthesizing MPPK and
MPPPK, suggesting that ribosomes stall when translating polyPro sequences. To directly detect
ribosome stalling, toeprinting assays were performed to determine the position of the ribosome
on mRNAs encoding MPPPPP and MFFFFF in the reconstituted in vitro translation system
described above. A 32P-labeled primer was annealed to the 3′ end of the mRNA and extended by
reverse transcription. The ribosome blocks reverse transcriptase 15–16 nucleotides downstream
of the first nucleotide of the P site codon. As shown in Figure 4-8 (lanes 3 and 8), toeprinting
confirms that the AUG start codon is positioned in the P site in 80S initiation complexes. When
elongation factors and Phe-tRNAPhe were added to the ribosomal complexes translating the
MFFFFF mRNA, this toeprint was diminished and a different toeprint was observed,
corresponding to the final Phe codon in the P site (Figure 4-8, lanes 4 and 5). The position of this
latter toeprint is consistent with the ribosome translating to the end of the ORF and arresting with
the stop codon in the A site; note that no release factors were included in the translation reaction.
Consistent with the robust synthesis of the MFFF peptide in the presence and absence of eIF5A
(Figures 4-6B, 6C, and 4-7D), production of the MFFFFF complex in the toeprinting assays was
unaffected by the presence or absence of eIF5A (Figure 4-8, lanes 4 and 5).
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Figure 4-8. eIF5A Prevents Ribosome Stalling on Consecutive Proline Codons. Reconstituted peptide synthesis
assays were performed in the absence or presence of eIF5A using mRNAs encoding the peptides MFFFFF (left
panel) or MPPPPP (right panel). The position of the 80S ribosome was determined by reverse transcription of
the mRNA template using a [32P]-labeled primer, and C and T sequencing reactions were run alongside.
Reactions lacking elongation factors were performed to identify 80S initiation complexes (IC) on the AUG
codon (lanes 3 and 8). The identity of the 80S toeprint signals is indicated on the right; and the sequences of the
mRNA and the corresponding amino acids are shown on the left with the sites of ribosome stalls at the 2nd and
3rd proline codons boxed.

Toeprinting analysis of elongation complexes revealed ribosomal stalling on the MPPPPP
mRNA. In reactions lacking eIF5A (Figure 4-8, lane 10), toeprints were observed corresponding
to the ribosome stalling with the second or third Pro codon in the P site. Importantly, addition of
eIF5A diminished the abundance of these stalled complexes and increased the yield of ribosome
complexes with the final Pro codon in the P site and the stop codon in the A site (Figure 4-8, lane
9). These results indicate that, in the absence of eIF5A, the P site tRNA is linked to an MPP or
MPPP peptide and that a Pro codon, and presumably Pro-tRNA, is in the A site. The positions of
the stalled ribosome complexes are consistent with the in vivo assays (Figure 4-4) that showed
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that at least three consecutive Pro residues are necessary to observe an eIF5A dependency and
indicate that peptide bond formation between diPro-tRNA and Pro-tRNA is particularly
dependent on eIF5A. Moreover, these results are consistent with reports of E. coli ribosomes
stalling on triPro motifs with the peptidyl-tRNA linked to consecutive C-terminal Pro residues
and the third Pro codon in the A site of the ribosome 98,172.

eIF5A Binds Near the E and P sites of the 80S Ribosome
Directed hydroxyl radical mapping was used to identify the binding site for eIF5A on the
yeast 80S ribosome. It is notable that EFP, which contains an extra C-terminal domain not found
in eIF5A, binds between the P and E sites and contacts both the large and small subunits of the
bacterial 70S ribosome 189. A Cys-less derivative of yeast eIF5A was generated by mutating the
native C23 and C39 residues to Ala and Thr, respectively. Yeast expressing the eIF5AC23A,C39T mutant (eIF5A-ΔC) as the sole source of eIF5A grew as well as cells expressing the
wild-type protein (Figure 4-9A), indicating that the mutations do not affect eIF5A function.
Next, single Cys residues were introduced at four surface-exposed sites generating eIF5A-ΔCS36C, eIF5A-ΔC-K48C, eIF5A-ΔC-M105C, and eIF5A-ΔC-T126C (Figure 4-10A). All four
mutant proteins supported yeast cell growth at wild-type rates (Figure 4-9A), suggesting that the
mutations did not interfere with either the essential hypusine modification of eIF5A or the
function of the protein on the ribosome. The eIF5A-ΔC and four single Cys mutant proteins were
purified from yeast, derivatized with Fe(II)-1-(p-bromoacetamidobenzyl)-EDTA (Fe[II]-BABE),
which links the ferrous iron to the Cys residue, and then added to assembled 80S complexes
containing 5′ end-labeled Met-[32P]tRNAiMet in the P site (see Figure 4-10B).
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Figure 4-9. Analysis of eIF5A Cys Mutants and Sites of 25S rRNA Cleavage, Related to Figure 4-10. (A) Yeast
growth analysis of eIF5A Cys mutants. Derivatives of yeast strain J697 expressing wild type (WT) eIF5A or the
indicated eIF5A mutants were streaked on YPD medium and incubated at 30°C for 3 days. (B) Ribbon
representation of yeast eIF5A (PDB 3ER0) showing the positions of the C23A and C39T mutations (black dots)
that removed the native Cys residues in eIF5A, and the sites (Spheres representation) of Cys mutations for
tethering Fe(II): Ser36 (green), Lys48 (magenta), Met105 (blue) and Thr126 (red). (C) Sites of directed hydroxyl
radical cleavage by Fe(II)-BABE derivatives of eIF5A are mapped on the secondary structure of yeast 25S
rRNA. Sites of cleavage are color-coded to match the site of Fe(II)-BABE modification on eIF5A (see panel B).
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Figure 4-10. Directed Hydroxyl Radical Probing of eIF5A Binding to 80S Ribosomal Complexes. (A) Ribbon
representation of T. thermophilus EFP (right panel, PDB ID code 3HUW (189)) and yeast eIF5A (left panel,
PDB ID code 3ER0) showing the protein domains (Roman numerals), the positions of the C23A and C39T
mutations (black dots) that removed the native Cys residues in eIF5A, and the sites (Spheres representation) of
Cys mutations for tethering Fe(II): Ser36 (green), Lys48 (magenta), Met105 (blue) and Thr126 (red). (B)
Scheme for directed hydroxyl radical cleavage by Fe(II)-BABE modified forms of eIF5A in 80S complexes. (C)
Directed hydroxyl radical cleavage of Met-[32P]tRNAiMet by Fe(II)-BABE-derivatized eIF5A in 80S complexes.
Cleavage products were resolved on 10% (w/v) denatured polyacrylamide gels, and cleavage sites on
[32P]tRNAiMet were determined by comparing them to samples containing eIF5A-ΔC [WT(Cys∆), lane 8]. The
tRNA ladders were prepared by digesting Met-[32P]tRNAiMet with RNase T1 (cleaves 3′ of G residue) or by base
cleavage (lane 2). The tRNA residue numbers are shown at the left, and cleavage fragments are boxed. (D)
Primer extension analysis of 25S rRNA cleavage fragments produced by Fe(II)-tethered to the indicated
positions in eIF5A. U and C: 25S rRNA sequencing reactions using reverse transcriptase and dideoxynucleotides
ddATP and ddGTP, respectively. 25S rRNA helices and the position of the L1 stalk are indicated on the left. (E)
Sites of eIF5A-Fe(II)-BABE cleavages are shown on the secondary (left) and three-dimensional (PDB ID code
1YFG (218)) structures of tRNAiMet. Cleavage sites are color-coded according to the site where Fe(II) was
tethered on eIF5A (see A). (F) Summary of 25S rRNA cleavages by eIF5A-Fe(II)-BABE derivatives.

Cleavage of Met-[32P]tRNAiMet by hydroxyl radicals generated in the vicinity of the
ferrous iron by the Fenton reaction was monitored by 10% denaturing gel electrophoresis.
Compared to reactions employing eIF5A-ΔC, which, due to the absence of Cys residues, is not
modified by Fe(II)-BABE, hydroxyl radicals generated by Fe(II)-BABE tethered to eIF5A-ΔCK48C yielded cleavages in the tRNAiMet acceptor stem bases G70–U72 (Figure 4-10C [compare
lanes 4 and 8] and Figure 4-10E). As this K48C site of Fe(II)-BABE modification is located only
three residues from the site of hypusine modification (K51) on eIF5A, these results place the
hypusine side chain in the vicinity of the amino acid attached to the 3′-CCA end of the P site
tRNA. In contrast, hydroxyl radicals generated using Fe(II)-modified eIF5A-ΔC-M105C cleaved
bases A54 and U55 in the T stem region of Met-tRNAiMet (Figure 4-10C, lane 7, and Figure 410E), while hydroxyl radicals generated using Fe(II)-modified eIF5A-ΔC-T126C cleaved two
different regions in tRNAiMet: bases U16–A20 in the D stem-loop region and bases A38–C41 in
the anticodon stem region (Figure 4-10C [lane 6] and Figure 4-10E). No noticeable tRNAiMet
cleavages were observed using the iron-modified form of eIF5A-ΔC-S36C (Figure 4-10C, lane
5). From these data, we conclude that the eIF5A binds alongside the P site tRNA on the 80S
ribosome, a position similar to the EFP binding site on the bacterial 70S ribosome 189, with the
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hypusine residue at the top of eIF5A near the aminoacyl end of the tRNA and the eIF5A domain
II residue T126 near the anticodon stem of the tRNA.
In order to further define the eIF5A-binding site on the ribosome, hydroxyl radicals were
generated in 80S complexes containing Fe(II)-BABE-modified forms of eIF5A, and ribosomal
RNA (rRNA) cleavages were analyzed by primer extension using 32P-labeled primers. Whereas
Fe(II)-modified eIF5A-ΔC-S36C did not generate cleavages in tRNAiMet, this eIF5A derivative
yielded cleavages in helices H68, H76, and H88 of 25S rRNA that were not seen with the eIF5AΔC control (Figure 4-10D, compare lanes 1 and 2 and lanes 8 and 9; see summaries of cleavage
sites in Figures 4-10F and 4-9C). These cleavage sites are clustered around the E site tRNA
binding region of the 60S subunit (Figure 4-11A, green color). Primer extension analysis of
rRNA cleavages generated using Fe(II)-BABE-tethered eIF5A-ΔC-K48C revealed enhanced
cleavages in helices H68, H74, and H93 (Figures 4-10D [lanes 3 and 1], 10F, and 4-9C).
Noticeably, these cleavage sites map near the PTC of the 60S subunit (Figure 4-11A, magenta
color), consistent with the idea that the hypusine residue (modified K51 side chain) is close to
the PTC active site of the ribosome.
The rRNA cleavages generated using iron-modified eIF5A-ΔC-M105C mapped to
helices H83 and H88 (Figures 4-10D [lanes 4 and 11] and 6F). Interestingly, these helix H88
cleavages partially overlap with the cleavages generated by eIF5A-ΔC-S36C (Figures 4-10D,
10F, and 4-9C), consistent with the presentation of these two residues on the same surface of
eIF5A. Finally, the Fe(II)-BABE-modified form of eIF5A-ΔC-T126C generated cleavages near
the L1 stalk region of the 60S subunit (Figures 4-10D [lanes 5 and 12], 10F, and 4-9C).
It is interesting to note that all of the eIF5A-generated cleavages map to the 3′ half of 25S
rRNA (Figure 4-9C), and there are no detectable cleavage sites in 18S rRNA (data not shown).
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Thus, in contrast to EFP, which contacts both the small and large ribosomal subunits 189, eIF5A
appears principally to contact the 60S subunit when binding to 80S ribosomal complexes. To
generate a model of eIF5A binding to the ribosome, the hydroxyl radical cleavage data were used
to orient yeast eIF5A (Protein Data Bank [PDB] ID code 3ER0) on the yeast 60S subunit (PDB
ID code 3O58; 217 with tRNAiMet (PDB ID code 1YFG; 218) bound in the P site. To initiate the
docking process, the eIF5A residue K48 was positioned near the PTC and centered among its
25S rRNA and tRNAiMet acceptor stem cleavage sites. Next, the residue T126 was positioned
between the ribosomal L1 stalk and the D loop and anticodon stem of the P site tRNAiMet. After
fixing the K48 and T126 locations in the model, the eIF5A structure was rotated so that residues
S36 and M105 were oriented toward their respective cleavage sites (Figure 4-11A). In the 60StRNAiMet-eIF5A complex model, eIF5A binds between the P site tRNAiMet and the E site such
that the N-terminal domain of eIF5A (residues 1–82) and the C-terminal domain (residues 87–
157) are close to the acceptor stem and D loop region of tRNAiMet, respectively (Figure 4-11B).
This eIF5A binding position, which is based on the hydroxyl radical mapping studies presented
here, overlaps with the position of EFP domains I and II as found in the cocrystal structure of
EFP bound to the bacterial 70S ribosome (Figure 4-11C, 189). It is notable that domain III of EFP,
which is missing from eIF5A (Figure 4-10A), contacts the small ribosomal subunit adjacent to
the anticodon stem region of fMet-tRNAifMet, which is bound in the P site 189. Thus, despite their
structural and functional similarities, the C-terminal truncation of eIF5A relative to EFP
apparently limits eIF5A ribosomal contacts to the large subunit and may confer a functional
distinction between the two factors.
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Figure 4-11. Models of 60S–Met-tRNAiMet–eIF5A Complex and eIF5A Stimulating Polyproline Synthesis. (A)
Docking model of a surface representation of yeast eIF5A (orange, PDB ID code 3ER0) and ribbons
representation of tRNAiMet (cyan, PDB ID code 1YFG (218)) on the ribbons structure of the yeast 60S ribosome
(PDB ID code 3O58 (217) as viewed from the subunit interface. The position of tRNAiMet was modeled by
alignment with P-site tRNA on the bacterial ribosome (PDB ID code 2J00 (see ref. 200)), and eIF5A was docked
on the 60S subunit according to the cleavage data for Met-tRNAiMet and 25S rRNA. Cleavage sites in 25S rRNA
and tRNAiMet are color-coded according to the sites of Fe(II) attachment on eIF5A (see Figure 4-10A). Positions
of L1 stalk, 5S rRNA (black), and GTPase activating center (GAC) Stalk on the 60S subunit are indicated. (B)
Magnified view of docked eIF5A and P-site tRNAiMet structure as shown in panel A (left) and rotated 180°
(right). Lys51, the site of hypusine modification, is colored black. (C) Magnified view of docked eIF5A and Psite tRNAiMet (from A) overlaid on the structure of EFP (blue) from the EFP–70S structure (PDB ID code 3HUW
(189)) oriented as shown in panel A (left) and rotated 90° (right). (D) Model of ribosome stalled on polyproline
sequence with di-proline attached to the P-site tRNA and Pro-tRNAPro in the A site (left). (Right) Binding of
eIF5A near the E site places the hypusine side chain (Lys51, black) adjacent to the peptidyl-tRNA in the peptidyl
transferase center (PTC) of the ribosome where it can help promote peptide bond formation with the amino acid
attached to the A-site tRNA (right).

Discussion
In addition to the universally conserved translation factors, eEF1A/EFTu and eEF2/EFG,
three other factors have been implicated in translation elongation. However, these latter factors
are not universally conserved. The factor eEF3 is proposed to coordinate E site tRNA release
with eEF1A-aminoacyl-tRNA binding to the A site of the ribosome in some fungi including
S. cerevisiae 219,220. Bacterial EF4 (LepA) is proposed to maintain rapid protein synthesis under
stress conditions such as high ionic strength and low temperature 221, and SelB/eEFsec is an
EFTu ortholog required for the delivery of selenocysteinyl-tRNA to the ribosome 222. In this
chapter we demonstrate that eIF5A is required for the translation of polyPro sequences. As our
results concur with the findings of the recent studies on EFP, the bacterial ortholog of eIF5A
184,185

, we conclude that eIF5A/EFP is the third universally conserved translation elongation

factor.
Our data demonstrating that eIF5A promotes the translation of polyPro sequences are
consistent with the recent reports on EFP 184,185. Partial inactivation of eIF5A-S149P in yeast
(Figure 4-1, Figure 4-4 and Figure 4-5), like deletion of the efp gene in E. coli 185, impaired
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expression of reporters or native proteins containing polyPro sequences in vivo. Moreover,
peptide synthesis assays demonstrated that eIF5A (Figure 4-6) and EFP are critical for the
in vitro synthesis of polyPro peptides 184. Finally, toeprinting analyses revealed that, in the
absence of eIF5A, translating ribosomes stall on polyPro motifs with the second or third Pro
codon in the P site (Figure 4-8). Thus, diPro or triPro will be attached to the 3′-CCA end of the
peptidyl-tRNA in the P site, and Pro-tRNA will be bound in the A site. These results suggest that
eIF5A and EFP are required to promote synthesis of the Pro-Pro peptide bonds needed to convert
diPro to triPro and higher-order polyPro sequences.
In addition to amino acid sequence and structural similarities, both eIF5A and EFP are
posttranslationally modified. As described earlier, the ε-amino group of a conserved Lys residue
in eIF5A from all archaea and eukaryotes is modified by deoxyhypusine synthase and
deoxyhypusine hydroxylase to generate hypusine (reviewed in 223). Similarly, the E. coli gene
products YjeA, YjeK, and YfcM attach a β-lysine residue to the ε-amino group of Lys34 in
E. coli EFP and then hydroxylate the side chain 190,191,194,210. Both the hypusine modification of
eIF5A and the β-lysine modification of EFP are required for these factors to stimulate polyPro
synthesis (Figure 4-6D, and 184,185). Loss of β-lysylation in E. coli impairs translation of a
polyPro motif in CadC, the transcriptional activator of the CadBA operon, whereas loss of βlysylation in Salmonella enterica alters the expression of a variety of cellular proteins, impairs
virulence in mice, and alters resistance to antibiotics 190, presumably due to impaired translation
of polyPro sequences. In a similar manner, perhaps the assorted genes identified in suppressor
and synthetic enhancement screens with eIF5A mutants in yeast 224,225, as well as the connections
between eIF5A, hypusine, cancer, and tumorigenesis in humans and other mammals 206,207,
reflect altered expression of proteins containing polyPro motifs.
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eIF5A and EFP were originally identified based on their ability to stimulate Metpuromycin synthesis 186,201–203. Whereas eIF5A was thought to function as a translation initiation
factor, it is notable that puromycin, an aminoacyl analog that reacts well with most peptidyltRNA substrates, reacts poorly with fMet-tRNAfMet and with peptidyl-tRNA substrates with a Cterminal Pro 118. In contrast, these latter substrates react well with authentic aminoacyl-tRNAs
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. The poor reactivity with puromycin has been attributed to poor substrate positioning in the

active site of the ribosome 118,183. Thus, the Met-puromycin synthesis assay is likely not a good
mimic of first peptide bond synthesis. Consistent with this notion, the kobs (data not shown) and
the Ymax for MP or MF synthesis were only modestly affected by adding eIF5A (Figures 4-6 and
4-7C); similarly, recent studies show that EFP does not stimulate dipeptide formation 184,226.
Consistent with a function in translation elongation, inactivation of eIF5A (Figure 4-2B
and204) or of EFP, or its β-lysine modification, mimics the effects of elongation inhibitors and
causes polysome retention 226. It is unclear at present whether the polysome retention upon
inactivation of eIF5A observed in Figure 4-2B reflects impaired translation elongation on the
majority of cellular mRNAs or if it could be due to impaired translation of just the mRNAs
containing polyPro motifs (549 of 5,889 ORFs in S. cerevisiae contain a polyPro tract consisting
of three or more Pro residues). This prevalence of polyPro motifs in yeast (95 proteins with
motifs containing 4 or more consecutive Pro residues) is consistent with eIF5A being essential in
yeast, whereas the efp gene can be deleted in E. coli in which only 9 out of ∼
4,000 proteins
contain motifs of four or more Pro residues 184. Taken together, the puromycin, dipeptide, and
polysome analyses indicate that eIF5A and EFP do not substantially stimulate first peptide bond
formation, consistent with the notion that the primary function of these factors is to promote
peptide bond formation, especially for poor substrates like polyPro.
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Previous studies revealed that peptidyl-Pro-tRNA in the ribosomal P site reacts poorly
with puromycin 117 and that Pro is an inefficient A site substrate for peptide bond formation 165.
Our data, as well as the recent studies with EFP 172,184,185, demonstrate that combining peptidylPro-tRNA in the P site with Pro-tRNA in the A site dramatically impairs protein synthesis and
establishes a dependency on eIF5A/EFP. At present, it is not clear why polyPro is such a poor
substrate for protein synthesis; however, it may reflect the imino acid nature of Pro, the
geometrical or steric constraints of a cyclic side chain, or the unique ability of Pro to readily
sample both cis and trans conformations of peptide bonds 227. Perhaps insertion of the extended
hypusine (or β-lysine) side chain into the PTC (Figure 4-11D) stabilizes the proper conformation
of the PTC or restricts the conformation of Pro in the P site, enabling a favorable geometry for
peptide bond formation with the A site amino acid. While the data reported here and the recent
studies on EFP establish that translation of homopolyPro motifs requires eIF5A/EFP, additional
studies, including genome-wide ribosomal profiling 228 of wild-type and eIF5A mutant cells, will
be needed to define the spectrum of amino acids and motifs that rely on eIF5A for their efficient
translation.

Experimental Procedures.
Dual-Luciferase Assay
Dual-luciferase reporter constructs were obtained from Elizabeth Grayhack 214. Whole
cell extracts from yeast transformants were assayed for firefly and Renilla luciferase activity.
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Peptide Formation and Toeprinting Assays
Initiation complexes were prepared as described previously 229 using [35S]Met-tRNAiMet
and purified translation initiation factors. Limited amounts of initiation complexes were mixed
with purified eEF1A, eEF2, eEF3, Phe (or Pro)-tRNA, guanosine triphosphate (GTP), and ATP
in the presence or absence of eIF5A in buffer containing 30 mM HEPES-KOH (pH 7.4),
100 mM potassium acetate, 1 mM magnesium acetate, 2 mM magnesium chloride, 1 mM
spermidine, and 2 mM dithiothreitol (DTT). All reactions were performed at 26°C. Peptide
formation was monitored by electrophoretic TLC (as described previously; 216), and the
fractional yields of the peptides and free [35S]Met in each reaction at different times were
quantified and fit to the single exponential equation y = Ymax (1−exp [−kobs × t]), where Ymax is
the maximum fraction of peptide formed and kobs is the observed rate constant. Toeprinting
assays were performed as described 230 with minor variations.

Preparation of Initiation and Elongation Factors
Recombinant initiation factors eIF1, eIF1A, and eIF5 were purified as described
previously 231. Initiation factor eIF5B 232, native elongation factor eEF1A 216, and polyHis-tagged
versions of elongation factors eEF2 and eEF3 233,234 were purified from yeast using published
protocols with some modifications. Recombinant, hypusinated eIF5A was prepared by
coexpressing His6-eIF5A, Dys1, and Lia1 in E. coli, and the hypusine modification was analyzed
by MS. Cys mutants of eIF5A used for hydroxyl radical cleavage studies were purified from
yeast as previously described 204.
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Preparation of mRNA, tRNA, and Ribosomes
Unstructured model mRNAs based on the template 5′-GGAA(UC)7U-peptide-codingsequence-(CU)10C-3′ with codons Met(AUG), Pro(CCA), Phe(UUC), and stop(UAA) were
prepared by T7 in vitro transcription or purchased. The UGG isoacceptor of tRNAPro was
purified from bulk S. cerevisiae tRNA using a biotinylated oligonucleotide 198, and tRNAPhe
(Chemical Block) and tRNALys (tRNA Probes) were purchased. The tRNAs were aminoacylated
using S. cerevisiae His6-tagged ProRS or yeast postribosomal supernatant (S100). Ribosomal
subunits were prepared from the yeast strain YRP840 as described previously 235.

Directed Hydroxyl Radical Cleavage Analysis
Following addition of Fe(II)-BABE-modified eIF5A to 80S initiation complexes,
hydroxyl radicals were generated by the Fenton reaction, and primer extension analyses were
used to monitor rRNA cleavage sites as described previously 235.

Yeast Strains Used
Yeast Strains
Strain

Description

H1511

MAT ura3-52 leu2-3 leu2-112 trp1-∆63

J697

MATα trp1-∆63 ura3-52 leu2-3 leu2-112 gcn2Δ

236
204

tif51b::NAT tif51a::KANMX4 p[TIF51A, LEU2]
J699

MATα trp1-∆63 ura3-52 leu2-3 leu2-112 gcn2Δ

204

tif51b::NAT tif51a::KANMX4 p[tif51a-S149P, LEU2]
J828

MAT trp1-∆63 ura3-52 leu2-3 leu2-112 GAL2+

This study

gcn2∆ tif51a::KanMX4 tif51b::NAT p[LEU2, TIF51A]
J832

MAT trp1-∆63 ura3-52 leu2-3 leu2-112 GAL2+
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This study

Source

gcn2∆ tif51a::KanMX4 tif51b::NAT
p[LEU2, tif51a-∆C(C23A,C39T)]
J836

MAT trp1-∆63 ura3-52 leu2-3 leu2-112 GAL2+

This study

gcn2∆ tif51a::KanMX4 tif51b::NAT
p[LEU2, tif51a-∆C-M105C]
J838

MAT trp1-∆63 ura3-52 leu2-3 leu2-112 GAL2+

This study

gcn2∆ tif51a::KanMX4 tif51b::NAT
p[LEU2, tif51a-∆C-T126C]
J917

MAT trp1-∆63 ura3-52 leu2-3 leu2-112 GAL2+

This study

gcn2∆ tif51a::KanMX4 tif51b::NAT
p[LEU2, tif51a-∆C-S36C]
J920

MAT trp1-∆63 ura3-52 leu2-3 leu2-112 GAL2+

This study

gcn2∆ tif51a::KanMX4 tif51b::NAT
p[LEU2, tif51a-∆C-K48C]
TKY597 MATα leu2-3 leu2-112 ura3-52 trp1-7 yef3::LEU2

(Anand et al., 2003)

lys2 his4-713 met2-1 p[YEF3, TRP1]
TKY599 MATα leu2-3 leu2-112 ura3-52 trp1-7 yef3::LEU2

(Anand et al., 2003)

lys2 his4-713 met2-1 p[yef3-F650S, TRP1]
TKY675 MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3

237

eft2::TRP1 p[EFT2-6xHis, LEU2]
TKY702 MATα leu2-3 leu2-112 ura3-52 trp1-7 yef3::LEU2

(Anand et al., 2003)

lys2 his4-713 met2-1 p[YEF3-6xHis, TRP1]
TKY742 MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3 eft2::TRP1

234

p[eft2-6xHis-H699N, LEU2]
TKY825 MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3 eft2::TRP1

234

p[eft2-6xHis-H696A, LEU2]
YRP840 MATa leu2-3 leu2-112 his4-539 trp1 ura3-52

238
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cup1::LEU2/PGK1pG/MFA2pG

Dual Luciferase Assay
Dual luciferase reporter constructs containing 10 codon repeats at amino acid 314
between the in-frame Renilla and firefly luciferase open reading frames (ORFs) were obtained
from Elizabeth Grayhack

214

. Constructs with insertions of variable numbers of Pro or Phe

codons between the two luciferase ORFs were generated by cloning PCR products between the
unique SalI and PstI restriction sites of the parental dual-luciferase plasmid pDL202. Individual
yeast transformants were grown in SD medium containing required nutrients to OD600 = 0.8–1.0,
harvested, and the cell pellets were resuspended in 300 µl Breaking Buffer L (20 mM Tris-HCl
[pH 7.5], 100 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, Complete Protease Inhibitor cocktail
[Roche]), and vigorously mixed with 1 vol glass beads on a vortex for 1 min at 4°C. Lysates
were cleared by centrifugation at 9,400 x g for 5 min at 4°C, and aliquots of the supernatant were
assayed for firefly luciferase activity using a microplate luminometer (Berthold) and the Dual
Luciferase Reporter 1000 Assay System (Promega). Next, Renilla luciferase activity was
measured following addition of Stop and Glo reagent (Promega).

Peptide Formation Assay
Initiation complexes were prepared in 1X Recon Buffer A (30 mM HEPES-KOH [pH
7.4], 100 mM potassium acetate, 2.5 mM magnesium acetate, 2 mM DTT) based on the protocol
described by Acker et al. 229 and contained the following components: 4 nM [35S]Met-tRNAiMet,
0.4 μM eIF2, 1 μM eIF1, μM eIF1A, 0.4 μM 40S, 1 μM mRNA, 1 μM eIF5 and 0.5 μM eIF5B.
All reactions were performed at 26°C. Following assembly of initiation complexes, reactions
were layered on 0.8 ml 1M sucrose cushion in 1X Recon Buffer A and then pelleted by
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centrifugation at 260,000 x g for 1 h. Ribosomal pellets were dissolved in 1X Recon Buffer B
(30 mM HEPES-KOH [pH 7.4], 100 mM potassium acetate, 1 mM magnesium acetate, 2 mM
magnesium chloride, 1 mM spermidine, 2 mM DTT), and aliquots were stored at -80°C.
Peptide formation assays contained 2 nM initiation complex, 2 μM eEF1A, 1 μM eEF2, 1
μM eEF3, 5 μM eIF5A, 1 μM Phe- (or Pro) tRNA, 1 mM GTP and 1 mM ATP in 1X Recon
Buffer B. The elongation assay components were pre-incubated for 15 min on ice before adding
the initiation complex, and then reactions were incubated at 26°C. Progress of peptide formation
was examined by electrophoretic TLC as described previously 216. Briefly, elongation reactions
were quenched at different times by mixing with an equivalent vol of 0.2 N KOH, and then 0.5
μl was spotted on a cellulose TLC plate (EMD Chemicals). The spot was dried using a heat gun,
then the TLC plate was briefly equilibrated with pyridine acetate buffer (200 ml glacial acetic
acid and 5 ml pyridine in 1 l, pH 2.8) before electrophoresis at 1,000 V for 30 min in the same
pyridine acetate buffer. Following electrophoresis, the TLC plate was dried using a heat gun, and
peptide spots were detected by phosphorimage analysis. The fractional yield of the peptides and
free [35S]Met in each reaction at different times were quantified and fit using Kaleidagraph
(Synergy Software) to the single exponential equation: y = Ymax (1-exp (-kobst)), where Ymax is
the maximum fraction of peptide formed and kobs is observed rate constant.

Preparation of Initiation and Elongation Factors
Initiation factors eIF1, eIF1A and eIF5 were expressed in E. coli BL21 CodonPlus
(DE3)-RIL cells (Agilent Technologies) and purified using the IMPACT Protein Purification
System (New England Biolabs) as described previously 231. Initiation factor eIF5B was purified
from yeast strain using Glutathione Sepharose 4B affinity chromatography as described
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previously 232 with minor modification. Briefly, yeast strain H1511 harboring the expression
vector pEG-KT-eIF5B397-1002 232,239 was grown in S-raffinose medium (0.145% yeast nitrogen
base, 0.5% ammonium sulfate, and 2% raffinose plus required supplements) until A600 = 0.5, and
GST-eIF5B397-1002 expression was induced by adding galactose to final 2% (v/v) and incubating
the culture with shaking at 30°C for 14 h. Cells were harvested and the cell pellet was suspended
in an equivalent volume of Lysis Buffer A (1X phosphate buffered saline [PBS] solution
containing Complete Protease Inhibitor cocktail [EDTA-free, Roche], 0.5 mM 4-[2-Aminoethyl]
benzenesulfonyl fluoride hydrochloride [AEBSF], 5 µg/ml pepstatin). Cells were broken by
adding 50% (v/v) glass beads to the cell suspension and then mixing vigorously on a vortex for 5
min at 4°C. Following removal of the glass beads and unbroken cells by centrifugation at 1,900 x
g for 10 min, the extract was clarified by centrifugation at 27,000 x g for 30 min, and then mixed
with 1 ml of a 50% slurry of Glutathione Sepharose 4B (GE Healthcare) at 4°C for 2 h. The resin
was then washed extensively with 20-fold excess volume of 1× PBS buffer, and eIF5B was
eluted by adding 40 U/ml thrombin in 1× PBS buffer and incubating at room temperature for 2 h
and then overnight at 4°C. The supernatant containing released eIF5B was dialyzed against
Storage Buffer (20 mM HEPES-KOH [pH 7.5], 100 mM potassium acetate, 2.5 mM magnesium
acetate, 2 mM DTT, and 10% glycerol) and stored at -80°C.
Elongation factor eEF1A was purified from yeast strain YRP840 238. Cells were grown in
2 l YPD to A600 = 3.0, harvested and broken in 50 ml Lysis Buffer B (60 mM Tris–HCl [pH 7.5],
50 mM KCl, 5 mM MgCl2, 0.1 M EDTA [pH 8.0], 10% glycerol, 1 mM DTT, 0.2 M AEBSF)
using glass beads as described above. After removal of unbroken cells by centrifugation at 7,600
x g for 10 min, the supernatant was clarified by centrifugation at 150,000 x g for 3 h, and then
mixed gently with 10 ml DE52 resin (Whatman, pre-equilibrated with Lysis Buffer B) for 1 h at
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4°C. The unbound fraction containing eEF1A was isolated by pouring the mixture into a column
and collecting the elute, which was then applied to a HiTrap CM Sepharose column (GE
Healthcare), and eEF1A was eluted with a linear gradient to 300 mM KCl. Fractions containing
eEF1A were identified by SDS-PAGE, pooled, dialyzed against Storage Buffer and store at 80°C.
Poly-histidine tagged versions of elongation factors eEF2 and eEF3 were purified from
yeast strains TKY675 and TKY702, respectively, using published protocols 233,234 with some
modifications. Cells were grown in 2.5 l YPD to A600 = 1.5, harvested, and then suspended in
Lysis Buffer C (50 mM Tris-HCl [pH 8.0], 300 mM KCl, 1 mM 2-mercaptoethanol, 1 mM
AEBSF, 10 mM imidazole, and 1X Complete protease inhibitor EDTA-free). After the cells
were broken with glass beads as described above, the lysate was cleared of unbroken cells by
centrifugation at 17,000 x g for 30 min, clarified by centrifugation at 180,000 x g for 80 min, and
then gently mixed with 1 ml Ni-NTA resin for 2 h at 4°C. The resin was then washed with 5 vol
of the Lysis Buffer C containing 20 mM imidazole, and the His-tagged proteins were eluted in
Buffer C containing 250 mM imidazole. The eluted proteins were mixed with a 6-fold excess of
Dilution Buffer (20 mM Tris-HCl [pH 7.5], 2 mM DTT and 10% [v/v] glycerol), loaded on a
HiTrapQ HP column (GE Healthcare), and then eluted by a linear KCl gradient to 1 M. Fractions
containing eEF2 or eEF3 were identified by SDS-PAGE, pooled, dialyzed against Storage
Buffer, and then stored at -80°C.

Preparation of eIF5A
The polycistronic expression system developed by Song Tan 240 was used to produce
hypusinated eIF5A in E. coli (Figure S4A). First, an N-terminally His6-tagged version of the
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eIF5A open reading frame was cloned between the NdeI and BamHI sites of the vector pET3a
Trm, and then moved as an XbaI-BamHI fragment to the expression vector pST39 generating the
plasmid pC4181. The Dys1 and Lia1 open reading frames were cloned into pET3a Trm using
NdeI-HindIII and NdeI-MluI sites, respectively, and then sequentially transferred to pST39 using
EcoRI-HindIII and BspEI-MluI sites, respectively, to make the plasmid pC4183.
To purify eIF5A, E. coli strain BL21 CodonPlus (DE3)-RIL (Agilent) was transformed
with pC4181 (for unmodified eIF5A) or pC4183 (for hypusinated eIF5A) and cells were grown
in 1 l LB medium containing 100 μg/ml ampicillin at 37°C to A600 = 0.5. Then, 0.5 mM IPTG
was added and the culture was incubated at 25°C for 14 h. Following harvesting, the cell pellet
was suspended in 40 ml Lysis Buffer D (50 mM Tris-HCl [pH 7.5], 300 mM KCl, 10 mM
imidazole, 0.5 mM AEBSF) and cells were broken by sonication using a microtip (5 cycles of 30
sec pulse followed by 30 sec cooling at 4°C). The cell lysate was cleared by centrifugation at
27,000 x g for 30 min and then mixed gently with 1 ml Ni-NTA resin (Qiagen) at 4°C for 2 h.
The resin was transferred to a disposable column (Qiagen), washed sequentially with 10 ml Lysis
Buffer D and then 10 ml Lysis Buffer D containing 20 mM imidazole, and then protein was
eluted in 10 ml Lysis Buffer D containing 0.5 M imidazole. The elute was diluted five times with
Dilution Buffer (20 mM Tris-HCl [pH 7.5], 10% glycerol, 2 mM DTT), loaded on a HiTrapQ
FPLC column, and the bound proteins were eluted in a 100 mM to 1M KCl gradient in Dilution
Buffer. Fractions containing eIF5A (eluting near 0.3 M KCl) were identified by SDS-PAGE,
pooled, and then dialyzed against 30 mM Hepes-KOH (pH 7.5), 150 mM potassium chloride, 2
mM DTT and 10% glycerol.
Hypusine modification of eIF5A was analyzed by ElectroSpray-Ionization QuadrupoleTime-of-Flight Mass Spectrometry (ESI QTOF MS, Agilent). As shown in Figure S4B, analysis

133

of unmodified eIF5A purified from E. coli showed a single major peak with a calculated
molecular weight of 17,805.94, consistent with the predicted mass of eIF5A with the first
methionine removed. Analysis of the eIF5A purified from E. coli co-expressing Dys1 and Lia1
revealed a major peak with molecular weight of 17892.79. The 87 Da increase in mass is
consistent with the mass of the hypusine modification and indicates that the majority of eIF5A
was hypusinated.
Cys mutants of eIF5A used for hydroxyl radical cleavage studies were purified from
yeast (Table 1), according to Saini et al. 204 with minor modification. Cells were grown in 2.5 l
YPD to A600 = ~3.0, harvested, and then the cell pellet was washed in 1X TBS (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl), suspended in 4 pellet vol 1X TBS containing 1X Complete Protease
Inhibitor and 1mM AEBSF, mixed with 50% vol glass beads, and broken by vigorous mixing on
a vortex for 5 min at 4°C. Lysates were cleared by centrifugation at 27,000 x g for 30 min, and
then gently mixed for 2 h at 4°C with 1 ml anti-flag-M2 affinity gel (Sigma, pre-equilibrated
with 1X TBS). The resin was transferred to a 1 ml disposable column, washed with 10 ml 1X
TBS, and bound proteins were eluted in 1 ml 1X TBS containing 200 μg/ml FLAG peptide
(Sigma). Eluted proteins were dialyzed against eIF5A Storage Buffer (30 mM HEPES-KOH [pH
7.5], 150 mM KCl, 2 mM DTT, 10% glycerol), and stored at -80°C. Fe(II)-BABE derivatization
of purified eIF5A was performed as described previously 231.

Preparation of mRNA, tRNA, and Ribosomes
Unstructured model mRNAs based on the template: 5′-GGAA(UC)7U-peptide-codingsequence-(CU)10C-3′ were prepared by T7 in vitro transcription or purchased (Integrated DNA
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Technologies) and used for preparation of elongation complexes. The following codons were
used to encode: Met(AUG), Pro(CCA), Phe(UUC), and Stop (UAA).
The UGG isoacceptor of tRNAPro was purified from bulk S. cerevisiae tRNA (Roche)
using the biotinylated oligo 5’-CCAAAGCGAG AATCATACCA CTAGAC-3’ (BioTEG) as
follows 198: 400 µl streptavidin beads (Pierce) were washed three times with 400 µl 10 mM TrisHCl (pH 7.5), bound to 8 nmol biotinylated oligonucleotide at 25°C for 30 min, and then washed
twice with 10 mM Tris-HCl (pH 7.5). The beads were pelleted by centrifugation for 30 sec at
1000 x g after each wash to remove the supernatant. Bulk tRNA (180 nmol in 300 µl) was mixed
with an equal volume of 2 M TMA buffer (20 mM Tris-HCl [pH 7.5], 1.8 M
tetramethylammonium chloride, 0.2 mM EDTA), incubated with the streptavidin beads at 65°C
for 10 min to denature the tRNA, then the mixture was slowly cooled to 25°C over ~10 min to
allow annealing. The beads were then washed eight times with 400 µl 10 mM Tris-HCl (pH 7.5)
to remove unbound tRNA. The tRNAUGG was melted off the beads by heating to 65°C for 5 min
and then eluted by centrifugation of the beads in a new tube pre-loaded with 2 µl 1M magnesium
acetate. After repeating this melting and elution process, the two eluted fractions were combined
and precipitated with ethanol. The tRNA was then resuspended in 50 µl water and quantified by
measuring the A260. The purified tRNAPro was further treated with CCA-adding enzyme to
increase the proline charging efficiency. For the CCA-adding reaction, 20 μM tRNAPro was
mixed with 10 mM ATP, 10 mM CTP, and 6 μM nucleotidyl transferase (CCA-adding enzyme)
in 1X CCA Buffer (50 mM Tris-HCl [pH 7.5], 20 mM magnesium chloride, 0.5 mM DTT), and
then incubated at 37°C for 30 min. For aminoacylation of tRNAPro, 5 μM tRNAPro was mixed
with 2 mM ATP-Mg2+, 0.3 mM proline, and 2.5% reaction vol ProRS in 1X Reaction Buffer (40
mM Tris-HCl [pH 7.6], 10 mM magnesium acetate, 1 mM DTT), and then incubated at 30°C for

135

30 min. Typical charging efficiency of tRNAPro with yeast ProRS was ~20%, as determined
using [3H]proline (Perkin-Elmer). The S. cerevisiae His6-tagged ProRS was purified as described
241

.
tRNAPhe (Chemical Block) and tRNALys (tRNA Probes, College Station, TX) were

aminoacylated using a post-ribosomal supernatant (S100) as the source of PheRS and LysRS.
The S100 was prepared by growing strain BY4741 in 10 l YPD to A600=1.0 and then lysing cells
with glass beads as described above in 10 mM potassium phosphate buffer (pH 7.2) containing
EDTA-free Complete Protease Inhibitor cocktail (Roche). Lysates were cleared by centrifugation
at 27,000 x g for 30 min, and the S100 was obtained following centrifugation at 100,000 x g for
3 h. The S100 was mixed with DE52 resin for 1 h at 4°C, then the mixture was poured into a
column, washed with 5 column vol 10 mM potassium phosphate buffer (pH 7.2), and bound
proteins were eluted with 250 mM potassium phosphate (pH 6.5). Following addition of glycerol
(5%) and DTT (2 mM) to the eluate, aliquots were stored at -80°C.
Ribosomal subunits were prepared from the yeast strain YRP840 (also known as
YAS2488) as described previously 235.

Polysome Analysis
Yeast cultures were either treated with 50 µg/ml CHX for 5 min before collection or left
untreated, transferred to a 500-ml centrifuge bottle containing shaved ice, pelleted, and washed
with 10 ml Buffer P (20 mM Tris-HCl [pH 7.5], 50 mM KCl, 10 mM MgCl2, 1 mM DTT,
Complete Protease Inhibitor cocktail [Roche]). In all subsequent steps, the CHX-treated cells
were treated with 50 µg/ml CHX. Cell pellets were suspended in 300–500 µl Buffer P, mixed
with an equal volume of glass beads, and then cells were broken by 5 cycles of vigorous mixing
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on a vortex for 1 min followed by 1 min on ice. Following clarification, ten A260 units of the
whole cell extracts (WCEs) were layered on 4.5–45% sucrose gradients prepared in 20 mM TrisHCl [pH 7.5], 50 mM KCl, 10 mM MgCl2 and 1 mM DTT, and then subjected to centrifugation
in a Beckman SW41 rotor for 2.5 h at 260,000 x g. Gradients were fractionated while monitoring
absorbance at A254.

Toeprinting Assay
Toeprinting was performed as described 230 with minor variations. Initiation complexes
were prepared as described above except that 0.4 µM Met-tRNAiMet was used in place of 4 nM
[35S]Met-tRNAiMet, and the mRNAs coded for MPPPPP (5’-GGAA[UC]7UAAAAAUGCCACCACCACCACCAUAA[UC]22GUUAAUAAGCAAAAUUCAUUAUAACC-3’) or
MFFFFF (5’-GGAA[UC]7UAAAAAUGUUCUUCUUCUUCUUCUAA[UC]22
GUUAAUAAGCAAAAUUCAUUAUAACC-3’). Initiation complexes were reacted with
elongation factors and tRNA as described in the peptide formation assay in a final vol of 15 µl
and incubated at 26°C for 5 min. Following addition of 0.3 μl 1 M MgCl2, two pmol 32P-labeled
toeprinting primer (5′-GGTTATAATGAATTTTGCTTATTAAC-3′) 96 and 0.1 μl SUPERase-In
(Ambion) were added to each reaction mixture. Samples were diluted with 3 vol Primer
Extension Mix (10 mM Tris-HCl [pH 7.5], 10 mM MgCl2, 60 mM NH4Cl, 6 mM 2mercaptoethanol, 360 μM each dNTP and 0.5 U/μl AMV Reverse Transcriptase [Roche]) and
then incubated for 30 min at 30°C to allow primer extension. Products were diluted with 2 vol
formamide/EDTA loading buffer (1x TBE, 17 mM EDTA [pH 8.0], 90% formamide, 0.001%
bromophenol blue, 0.001% xylene cyanol) and then resolved on a sequencing gel (8%
polyacrylamide, 7 M Urea).
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Directed Hydroxyl Radical Cleavage Analysis
80S initiation complexes were assembled in 1X Recon Buffer A as schemed in Figure
6B, and then Fe(II)-BABE-modified eIF5A was added to the reaction. Following incubation on
ice for 5 min, hydroxyl radicals were generated by the Fenton reaction as described in Shin et al.
231

. Final concentrations for each component in the reaction were: 0.4 μM eIF2, 0.4 μM Met-

tRNAiMet, 1 μM eIF1, 1 μM eIF1A, 1 μM mRNA, 0.2 μM 40S, 0.8 μM eIF5, 0.4 μM eIF5B, 0.2
μM 60S and 0.2 μM Fe(II)-BABE-modified eIF5A. To analyze cleavage of tRNAiMet, 0.1 μM
Met-[32P]tRNAiMet was used in place of unlabeled Met-tRNAiMet and the concentration of 40S
and 60S subunits was increased to 0.4 µM. Primer extension analysis of rRNA cleavage sites
were performed as described previously 231 using the previously described seven primers for 18S
rRNA 231 and 13 primers for 25S rRNA:
25-1, 5′-CAGACAACAAAGGCTTAATCTC-3′;
25-2, 5′-CTGACTTAGAGGCGTTCAGCC-3′;
25-3, 5′-CTGCCACAAGCCAGTTATCCC-3′;
25-4, 5′-AGCTCCGCTTCATTGAATAAG-3′;
25-5, 5′-TCATAGTTACTCCCGCCGTTTACC-3′;
25-6, 5′-CCAAGCAGTCCACAAGCACGC-3′;
25-7, 5′-GTGATAAGCTGTTAAGAAGAA-3′;
25-8, 5′-GCTACTACCACCAAGATCTGC-3′;
25-9, 5′-GCACCTTAACTCTACGTTCGG-3′;
25-10, 5′-TATACCCAAATTCGACGATCG-3′;
25-11, 5′-GCGGCATATAACCATTATGCC-3′;
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25-12, 5′-TTCCATCACTGTACTTGTTCG-3′;
25-13, 5′-AGGAACATAGACAAGGAACGG-3′.
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